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ABSTRACT
Menorrhagia is a condition which affects a considerable number of women. 
The traditional treatment is hysterectomy, which has significant morbidity 
associated with it. Over recent years more minimally invasive techniques have 
been developed to treat menorrhagia without resorting to hysterectomy.
Photodynamic therapy (PDT) is a non-thermal technique which can be used to 
cause tissue damage. It requires the activation of a photosensitiser with light, 
which in the presence of oxygen produces cytotoxic oxygen species.
5-aminolaevulinic acid (ALA) is a photosensitising agent which has been used 
as a pre-cursor for the photoactive protoporphyrin IX (PPIX) in the past to 
successfully destroy the endometrium in the rat and rabbit model. When the 
technique has been used in humans, the effect has been unsatisfactory and has 
not been reproducible.
This thesis demonstrates that by the addition of an iron chelator CP94 there is 
a significantly increased level of PPIX in the endometrium, as measured with 
fluorescence microscopy after both chemicals are instilled into the uterine 
cavity of the rabbit. We show that pH has little effect on these data. The 
optimum time for PDT was shown to be seven hours after instillation. We 
show a dramatically increased PDT effect when using a combination of ALA 
and CP94 in the rabbit endometrium. In addition this PDT effect remains at 28 
days. These studies showed that it may be possible to improve on the 
previously reported disappointing clinical results using ALA-PDT by the 
addition of the iron chelating agent, CP94.
We performed preclinical trials of light distribution within the human uterine 
cavity using different light delivery systems. This showed that an effective 
light dose could be applied to the irregular shaped endometrial cavity, in order 
to maximise the PDT effect in humans. The technique is now ready to take 
into pilot clinical studies.
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The treatment, which I have described, seems to have 
proved its value, and there is every reason to give it 
the place that it deserves in therapeutics, a place which 
it is at present still far from having obtained, doubtless 
owing to its strangeness and unintelligibility. In reality, 
its scientific basis is much better and more solid than 
that of many other methods of medical treatment.
Niels Rydberg Finsen, 1901.
(The founder of phototherapy: 1860-1904).
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SECTION ONE 
INTRODUCTION
20
CHAPTER 1: MENORRHAGIA
1.1 Introduction.
Menstruation is a normal physiological process in women whereby the 
endometrium is sloughed off if a pregnancy has not been achieved. Its 
monthly appearance commences at the menarche and finishes at the 
menopause. The concept of a monthly cycle is a modem phenomenon, as in 
primitive societies ‘marriage’ occurred at menarche or soon after, followed by 
a succession of pregnancies and periods of amenorrhoea associated with 
lactation. Finally, death often occurred before the menopause (Short 1976). In 
our modem western society with an average of two children per family, a 
short period of breast-feeding and longer life expectancy, women may only 
have a few months in their reproductive life when they do not menstruate. The 
age of menarche is also declining. In the mid-nineteenth century the average 
age was 17; whereas in the mid-twentieth century it was 13 years of age 
(Tanner 1962).
Normal menstrual blood loss (MBL) was defined in the 1960’s in Sweden 
(Hallberg et al 1966). By careful measurement of total menstrual loss, they 
found that the mean loss to be 43 mis and the 90th centile of loss was found to 
be 80mls. They also found that where the loss was more than 60mls, women 
were at risk of developing anaemia. Cole et al found similar results with a 
mean loss of 37.5 mis (Cole et al 1971).
Therefore an average woman today may have 350-400 menses in their life, 
and lose 15-20 litres of blood throughout her menstrual life. However these 
figures are of little value as the quantity of blood loss cannot be easily
21
measured, and it is the woman’s perception of the loss that is of relevance. A 
simpler method of assessing MBL is the presence, or otherwise of clots. The 
commonest objective indicator of heavy menstrual loss is iron deficiency 
anaemia. A low serum ferritin is more sensitive, although the test is rarely 
used (Lewis 1982).
In Hallberg’s study, one quarter of women who had a blood loss in the normal 
range stated that their periods were heavy, and 40% of those with blood loss in 
excess of 80mls described their loss as Tight’. Gath et al reported that almost 
one third of over 500 women surveyed stated that their periods were heavy or 
very heavy. In addition 22% of their survey stated that the blood loss was of 
such an extent as to adversely affect their lifestyle (Gath et al 1987). Similar 
findings were observed in other studies (Haynes et al 1977; Chimbira et al 
1980; Fraser et al 1984). However, with these data it is apparent that the 
perception of menorrhagia within a population is variable, but leads to the 
assumption that a great many women would demand treatment for what they 
perceive as heavy periods. The demand on resources would also be higher 
than population studies suggest.
The duration of bleeding has generated less interest. However, the World 
Health Organisation has a method of assessing the bleeding and spotting 
patterns (Belsey and Farley 1988). Normality is defined as a bleed of 5 days or 
less and total bleeding days less than 20 in every 90 (Datey et al 1995).
The actual extent of the problem in the general population is not known, but 
women presenting to their general practitioners (GPs) with menstrual 
problems is common (Coulter et al 1991). Approximately 5% of women of 
reproductive age will consult their GPs each year because of menstrual
22
abnormalities (Vessey et al 1992; Anonymous 1994). Of all referrals to a 
hospital gynaecologist for abnormal bleeding, approximately 75% are for 
(subjective) excessive MBL; indeed one third of all gynaecology referrals are 
for excessive MBL (Coulter et al 1989; Coulter et al 1991). Once referred they 
have a high chance of a surgical intervention, mainly because they are 
reluctant to retry medical treatments or try different medical treatments 
(Cooper KG et al 1997). Sixty percent of women referred to a gynaecologist 
with menorrhagia will eventually have a hysterectomy (Coulter et al 1991). 
Indeed, 44% of women referred with any gynaecological complaint will 
eventually have a hysterectomy (Coulter et al 1991). Fibroids are the 
commonest reason for hysterectomy in the UK (38%); but menstrual problems 
in the absence of fibroids account for 35% of all hysterectomies (Vessey et al 
1992). In the Netherlands 14.6% of all hysterectomies were performed in 
women under 45 years with menorrhagia with no pathological abnormalities.
Hysterectomy remains one of the commonest operations in the western world 
(Dicker et al 1982; Wingo et al 1985; Loft et al 1991; Coleman et al 1997), 
with rates increasing. Scottish hysterectomy rates have doubled between the 
1960s and 1980s (Anonymous 1995; Roberts et al 1996). In the UK about 
20% of women will have had a hysterectomy by the age of 55 years (Vessey 
et al 1992). The hysterectomy rates in Australia and New Zealand are 25% 
and 20% respectively for women before the menopause (Coleman et al 1997). 
In New Zealand 90% of these hysterectomies are performed for heavy 
menstrual blood loss and fibroids (Coleman et al 1997).
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In the past decade, there has been a huge increase in the number of surgical 
treatments available for women with menorrhagia, without having to resort to 
hysterectomy (Garry 1997; Garry 2002). The aim of all these techniques is to 
improve symptoms with minimal morbidity and mortality, reduced hospital 
stay and a quicker return to normal. However, since the introduction of more 
of these newer techniques to the UK, there seems to have been little impact on 
the overall number of hysterectomies performed (Prentice 1999) (table 1.1). 
There are many reasons put forward for this. The threshold for surgical 
intervention with minimally invasive (and minimal access) procedures is
1989-1990 1990-1991 1991-1992 1992-1993 1993-1994
Abdominal
hysterectomy
60 554 57 747 58 446 59 607 59 376
Vaginal
hysterectomy
12 726 12 928 13 184 13 562 14 141
All
hysterectomies
73 280 70 675 71 630 73 169 73 517
Therapeutic
hysteroscopy
1 699 4 244 7 707 9 982 9 945
All operative 
procedures
74 979 74 899 79 3 77 83 151 83 462
Table 1.1 : Number of operative interventions from 1989-1994 in the UK (from (Prentice A 
1999).
undoubtedly lower, both from the patient’s and clinician’s perspective. 
Hysterectomy is merely delayed rather than prevented in some cases, as 16% 
of women undergo hysterectomy within 12 months of a minimal access 
procedure (Pinion et al 1994).
The majority of these newer minimal access techniques used in the treatment 
of heavy menstrual loss involve a trans-cervical approach to endometrial
24
destruction. Some are well-established techniques whilst other newer methods 
are undergoing assessment. Most appear to offer short-term improvement rates 
of the order of 80-90 %. They are not without complications and generally 
require a little skill. They will be discussed in more detail in later chapters.
1.2 The aetiology of heavy menstrual blood loss.
There are population differences in menstrual blood loss. The range of mean 
blood loss (MBL) in Western Europe is 34.6 ml (in the UK) to 43.4ml (in 
Sweden) (Hallberg et al 1966; Cole et al 1971; Guillebaud et al 1978). There 
are few studies outside Europe. One from Egypt showed a MBL of 25.6 ml 
(Hefnawi et al 1979). One from China showed a MBL of 56.3 ml, with 20% of 
women having menorrhagia (blood losses of greater than 80ml per month) 
(Gao et al 1981). Population differences can be explained by either a genetic 
disposition or an environmental one. Rybo and Hallberg found a greater 
difference in menstrual blood flow in dizygotic twins than in monozygotic 
twins (Rybo and Hallberg 1966). Diet undoubtedly plays a part in the control 
of menstrual blood loss. The composition of the diet can modulate arachidonic 
acid release in the endometrium and thus modulate prostaglandin-controlled 
haemostasis in the endometrium. Onions and garlic have been shown to inhibit 
platelet aggregation and to cause mild bleeding disorders (Makheja et al 
1979).
Age may have an effect on the amount of menstrual blood loss (Barer and 
Fowler 1938; Hallberg et al 1966; Rybo 1966; Janssen et al 1995). Blood loss 
does tend to be lighter at menarche and heavier at the menopause. The age of 
menarche has little effect (Rybo 1966). However in some adolescent (Fraser 
1985) and perimenopausal women (van Look et al 1977) dysfunctional uterine
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bleeding can occur with chronic anovulation. In the majority of women with 
regular but heavy periods, no hormonal abnormalities can be found (Haynes et 
al 1977). The impact of parity and infant birth weights on menstrual loss is 
unclear from the literature (Rybo and Hallberg 1966; Rybo 1966; Cole et al 
1971; Gao 1990).
1.2.1 Dysfunctional uterine bleeding.
In the vast majority of cases, menorrhagia is unexplained and known as 
dysfunctional uterine bleeding (DUB). DUB is best described as abnormal 
bleeding from the uterine cavity in the absence of organic disease of the 
genital tract (Davey 1995). There are several theories to explain the blood loss 
in these women. The main factor is haemostasis in the endometrium
Haemostasis occurs when platelets adhere to the subendothelium of damaged 
blood vessels, followed by further platelet aggregation, degranulation and 
fibrin deposition. In the skin this results in the formation of a platelet plug 
which seals the damaged vessel. However, this normal haemostatic 
mechanism is inhibited in the endometrium. The platelet plug formation in the 
endometrium is much smaller, often failing to completely occlude the vessel, 
and there seems to be little, if any, haemostatic reaction to endothelial 
damage.
Women with menorrhagia (who have no bleeding disorders) have higher 
concentrations of certain clotting factors: factor V and VIII, antithrombin III, 
and alpha 1-antitrypsin (Hahn et al 1975). Levels of albumin caeruloplasmin 
and IgG are also lower (Hahn et al 1976).
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The fibrinolytic activity on the endometrium is higher in the secretory phase 
of the menstrual cycle than in the proliferative phase. The highest 
concentrations of plasminogen activators are found in the late secretory phase 
and during menstruation. The presence of a systemic (Cole and Clarkson 
1972; Hahn et al 1976) or a local (Rybo 1966; Hahn and Rybo 1975; Rees et 
al 1985) fibrinolysis system in women with menorrhagia remains unsolved. 
The evidence that there is a local mechanism that is at least partly responsible 
for DUB is growing (Rees et al 1985). The benefits of antifibrinolytic drugs 
support this hypothesis (Nilsson and Rybo 1971).
1.2.2 Prostaglandins
Prostaglandins have an important role in haemostasis in the endometrium, and 
in menstruation (Baird et al 1996). Cyclo-oxygenase metabolises arachidonic 
acid to unstable endoperoxidases (PGG2 and PGH2). From these precursors, 
thromboxane A2 is formed in platelets, which induces platelet aggregation and 
degranulation. It is a potent vasoconstrictor. In the endothelium and smooth 
muscle PGG2 and PGH2 are transformed into mainly prostacyclin (PGI2). PGI2 
inhibits platelet aggregation and degranulation, and is a potent vasodilator. 
The endoperoxidases can also be transformed into PGD2 , PGE2 and PGF2 . 
PGD2 is an inhibitor of platelet function, whilst PGE2 and PGF2 are weak 
stimulators. PGF2 ; also acts as a weak vasoconstrictor.
All these prostaglandins are present in the human endometrium. Cyclo- 
oxygenase is present in the surface and glandular epithelium of luteal phase 
endometrium. It is not present, however, in the endometrial stroma, the 
myometrium or the blood vessels (Rees et al 1984; Rees et al 1987; Rees
1990). Changes in endometrial prostaglandin metabolism have an important
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role in the regulation of menstruation. This is supported by the fact that 
prostaglandin inhibitors decrease menstrual blood flow (Anderson et al 1976).
Recently the role of nitric oxide (NO) has been investigated. It is present 
throughout the uterus and acts as a potent vasodilator and inhibitor of platelet 
aggregation. It may mediate the vasodilator effects of oestrogen and PGE2 . 
Disturbances in its function have been implicated as a cause of menorrhagia 
(Telfer 1997).
1.3 Causes of menorrhagia.
1.3.1 Organic causes.
Local conditions, which can cause menorrhagia, are adenomyosis, pelvic 
inflammatory disease, endometrial hyperplasia and benign tumours of the 
cervix or endometrium (polyps and fibroids) or malignant tumours (whether 
cervical or endometrial) (Fraser et al 1984). Fibroids are found in 25 - 30% of 
women over the age of 35 years. It is difficult to determine how many women 
with menorrhagia have fibroids as an aetiological factor. It has been shown 
that 30% of women undergoing myomectomy suffered from menorrhagia, but 
the proportion varies from 17 to 62%, (Buttram and Reiter 1981).
Menstrual blood loss in women with endometrial polyps, adenomyosis, pelvic 
inflammatory disease has been measured by Fraser and co-workers (Fraser et 
al 1986). They concluded that these conditions were not always associated 
with menorrhagia.
1.3.2 Intrauterine contraceptive devices.
The insertion of a non-hormonal intrauterine contraceptive device (IUCD) is 
associated with an increase in measured menstrual blood loss (Guillebaud et al
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1976). Ten to twenty percent of women have their IUCD removed within a 
few months of insertion because of excessive menstrual loss (DTB 2002). This 
is the major reason for discontinuing the devices. The incidence of anaemia 
and menorrhagia are four to five times higher in users of IUCD than in women 
using other forms of contraception (Guttorm 1971). The structure of the 
endometrium at the time of menstruation in IUCD users shows specific 
features: the formation of the haemostatic plug is delayed and there is reduced 
rapidity of endometrial shedding (Christiaens et al 1981). Different devices 
have different rates of removal for excessive bleeding. Removal rates at 3 
years were 4.5% with GyneFix a frameless device; 7.5% with FlexiGard; 
8.3% with Cu-Fix and up to 11.5% with TCu 380A (Rosenberg 1996; DTB 
2002).
The Mirena intrauterine system (IUS), is a levonorgestrel-containing device. 
Its structure is very similar to the copper containing IUCDs mentioned above, 
but users have lighter less painful periods (Tang & Lo 1995). The Mirena IUS 
is mentioned later in chapter 3.
1.3.3 Tubal ligation.
The incidence of menorrhagia in women after tubal ligation has ranged from 
2.5-50% (Rioux 1977). Hysterectomy rates after sterilization by tubal ligation 
are higher than in unsterilised women (Treloar et al 1999). Some studies did 
not correct for previous use of the contraceptive pill, nor previous 
dysfunctional uterine bleeding. Two studies revealed that a third of women 
had longer and heavier periods following laparoscopic sterilisation 
(Letchworth and Noble 1977; Jackson and Lander 1980; Goh et al 1981). 
Women using the oral contraceptive pill before surgery had the heaviest and
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longest periods, whilst women using the IUCD had lighter and shorter periods 
after sterilisation (Chamberlain and Foulkes 1976). A recent study has shown 
no difference in MBL after tubal ligation, whichever technique is used (Sahwi 
et al 1989).
Two studies corrected for these factors and found that the incidence of 
menorrhagia after tubal ligation was 5.4% (Rubenstein et al 1976) and 6% 
(Stock 1978), with four percent of all women undergoing further surgery for 
pain or menorrhagia (Stock 1978). The method of sterilisation affects the 
incidence of menorrhagia. After diathermy division, tubal ligation and 
vasectomy, the incidence of menorrhagia resulting in hysterectomy was 9%, 
3% and 1% respectively (Letchworth and Noble 1977). Women followed up 
for ten years after tubal ligation have a 13% incidence of hysterectomy for 
irregular or heavy menstrual blood loss (Muldoon 1972).
1.3.4 Thyroid dysfunction.
Menstrual abnormalities are related to thyroid dysfunction. Menorrhagia is a 
common abnormality in women with hyperthyroidism, myxoedema and in 
those after thyroidectomy (Scott and Mussey 1979). Albright coined the term 
“metropathia haemorrhagica” to describe periods of amenorrhoea interrupted 
randomly with spotting for menstruation in those women with long-standing 
hypothyroidism (Scott and Mussey 1979). Thyroid hormone replacement 
effectively restores normal ovulatory cycles in hypothyroid women (Wilansky 
and Greisman 1989). There is only one case report of a hypothyroid woman 
where menstrual loss was measured. The pre-treatment loss was almost 500ml 
and after treatment reduced to less than 80ml (Higham and Shaw 1992).
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1.3.5 Clotting abnormalities.
Menorrhagia has long been associated with platelet abnormalities, von 
Willebrand’s disease, clotting factor deficiencies and haemophilia (see table 
1.2) (Quick 1966).
Coagulation disorders Platelet defects
Von W illebrand’s Thrombocytopenia
Haemophilia A carriers Glanzmann’s thrombasthenia
Prothrombin Aplastic anaemia
Factors V, VII, IX, X, XI Leukaemia
Deficiencies Bemard-Soulier syndrome
Table 1.2 Disorders of haemostasis presenting as menorrhagia.
There have been few studies actually measuring blood loss in these conditions, 
but subjective analysis has shown that some 70-80% of women with 
thrombocytopenia or thrombopathia and 50% of women with von 
Willebrand’s disease have menorrhagia (Van Eijkeren et al 1989). In addition, 
coagulation disorders have been found in 29% of adolescents admitted to 
hospital with acute menorrhagia where no genital tract abnormality was found 
(Claessens and Cowell 1982). In those women taking anticoagulants, 50% had 
objectively measured menorrhagia (van Eijkeren et al 1990).
1.4 Methods of measuring blood loss.
Menorrhagia is a purely subjective complaint, based on the patient’s 
assessment of her menstrual blood loss. Hallberg and colleagues measured 
menstrual blood loss in Sweden, and found that 40% of women with a 
menstrual loss of greater than 80 ml did not consider them heavy; while 14% 
of those with a blood loss of less than 20 ml did consider their periods heavy
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(Hallberg et al 1966). Several later studies have confirmed these findings; 
more than half of the women complaining of menorrhagia in a study by Fraser 
had a blood loss of less than 80 ml per month, while a fifth had a loss of less 
than 35 ml when measured objectively. A substantial number of the women in 
this latter group will have failed medical management of their menorrhagia 
(Fraser et al 1981). Chimbira and others showed that more than a third of 
women who stated that their periods were light had a blood loss of more than 
80 ml (Chimbira et al 1980).
1.4.1 Pictorial methods.
Women use a pictorial chart of the amount of blood staining on their tampons 
and sanitary towels to score their menstrual blood loss (figure 1.1). There 
appeared to be good correlation between the menstrual score obtained by this
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Figure 1.1: Pictorial chart for assessment o f women’s menstrual blood loss.
method and objective menstrual blood loss (Higham et al 1990). However 
there is a degree of difficulty in standardising the charts based on differing 
absorbencies in sanitary products currently on the market, and a recent study 
was unable to validate Higham’s work (Reid et al 2000).
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1.4.2 Weight measurements.
This technique calculates the blood loss by comparing the weight of sanitary 
towels and tampons before and after use (Pendergrass et al 1984). Although 
this technique is simple to perform, it is inaccurate, as the percentage of blood 
in menstrual fluid varies considerably between individuals (Fraser et al 1985).
1.4.3 Uterine artery Doppler.
If the pulsatility index (PI) of uterine arteries, arcuate arteries, and radial 
arteries is measured by transvaginal colour Doppler, there is a significant 
inverse correlation with the amount of menstrual blood loss, suggesting that 
women with lower uterine flow impedance, bleed more. The association was 
specific and not explained by uterine size, fibroids or any other potential 
confounders (Hurskainen et al 1999). This is an interesting finding, and 
confirmation of the findings are awaited.
1.4.4 Spectrophotometry.
This is the gold standard test for the assessment of menstrual blood loss. The 
technique involves collecting all sanitary products, extracting all the blood and 
then measuring the optical density of resultant solution compared with a 
known aliquot of the patient’s blood. The commonest method is the alkaline 
haematin method (Cheyne and Shepherd 1970). There have been several 
modifications on this technique (van Eijkeren et al 1986; Vasilenko et al 
1988). These methods are extremely time consuming but do obtain the most 
accurate determinant of menstrual blood loss (Hallberg and Nilsson 1964). All 
used sanitary wear is bathed in 5% sodium hydroxide to extract the 
haemoglobin and to convert it to haematin. The resultant solution is then
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measured by a spectrophotometer. The extraction and measurement takes 
approximately 48 hours.
1.4.5 Radiolabelled red blood cells.
The patient is given compatible red blood cells, labelled with radioactive iron 
(59Fe) or chromium (51Cr). The radioactivity of the blood extracted from all 
the used sanitary towels and tampons is then compared with that of the 
patient’s venous blood. This technique is invasive, time consuming and does 
not have the same accuracy of other methods (Baldwin et al 1961).
Method Simple for 
investigator
Simple for 
woman
Accurate Patient
satisfaction
Pictorial Yes Yes Yes / no high
Weight Relatively Relatively poor ?
Doppler Relatively Relatively ? ?
Spectral No No Gold
standard
?
Radio­
labelling
No Invasive Yes/no ?
Subjective
assessment
Yes Yes Very poor high
Figure 1.3: Comparison of different methods o f assessing menstrual
blood loss.
1.5 Conclusion.
The woman’s subjective assessment of her blood loss is the most important 
factor in the management of menorrhagia. Accurately measuring blood loss is 
interesting, but does little to help the woman, or her clinician, in treating her 
complaint. Different methods of assessing blood loss are outlined in table 1.3.
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CHAPTER 2: THE ENDOMETRIUM
2.1 Introduction.
Between the years of the menarche and the menopause, the endometrium of 
the uterus undergoes monthly cyclical changes in its structure under the 
influence of ovarian hormonal stimuli. This cycle is naturally only suspended 
because of pregnancy. Normal menstruation lasts 3 to 5 days, with a cycle of 
24 to 32 days, being most regular between the ages of 20 and 40 years. At the 
menarche and the menopause the cycles tend to be abnormal. The vaginal, 
cervical and tubal epithelium also shows cyclical response to sex hormones, 
but not as pronounced as that shown by the endometrium.
The endometrium undergoes changes in both secretory activity and structure, 
correlated with cyclical growth and maturation of ovarian follicles. The end 
of each cycle is characterised by the partial destruction and softening of the 
endometrium. Bleeding from blood vessels within the mucosa assists this.
The endometrium contains a unique system of blood vessels, which undergo 
developmental changes during the menstrual cycle, in preparation for support 
of a fertilised ovum.
Branches of uterine arteries pass through the myometrium to supply the 
endometrium. These divide into two different arteries: the spiral arteries or 
arterioles which supply the superficial two-thirds of the endometrium; the 
basilar arteries supply the deeper one-third. The spiral arterioles are highly 
sensitive to the hormonal changes of the menstrual cycle.
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The endometrium is divided into three histologically and functionally distinct 
layers. At the end of menstruation (menstrual phase) the endometrium consists 
of a thin band of connective tissue approximately 1 mm thick which contains 
the basal portions of uterine glands and lower portions of the spiral arterioles. 
This is the stratum basalis, lying adjacent to the myometrium. This layer 
undergoes minimal changes during the menstrual cycle. It contains the cells 
for cyclical regeneration of the upper layers. The broad intermediate layer is 
called the stratum spongiosum. The thinner superficial layer is known as the 
stratum compactum. The two superficial layers are jointly referred to as the 
stratum functionalis.
2.2 Endocrine basis of menstruation.
After ovulation the corpus luteum continues producing progesterone and 
oestradiol, for 10 days. If fertilisation does not occur, the levels of these 
hormones decline, as the corpus luteum regresses. Withdrawal of the influence 
of these hormones on the endometrium will result in menstrual bleeding. The 
most important hormone is progesterone. Bleeding may occur with withdrawal 
of oestradiol, but always occurs with progesterone withdrawal, and indeed 
maintaining levels of progesterone will prevent bleeding.
The majority of women presenting to gynaecological clinics with heavy 
menstrual blood loss have regular ovulatory cycles (Cameron 1989). 
Measuring oestradiol and progesterone in these same women with excessive 
menstrual blood loss has failed to demonstrate abnormalities in their hormonal 
status (Haynes et al 1977). In order to understand abnormal menstruation, 
therefore, we must understand normal menstruation.
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2.3 Normal menstruation.
In the first few days after menstruation, under the influence of oestrogen the 
cells in the stratum basalis proliferate. The epithelial cells rapidly cover the 
denuded endometrial surface. It is lined with simple columnar epithelium, 
with a mixture of ciliated cells and secretary cells. The stroma cells 
proliferate, and the spiral arterioles lengthen. This is known as the
proliferative phase. This phase continues until the day after ovulation (which 
in a regular 28-day cycle is approximately on day 14). At the end of this 
phase the endometrial glands are narrow and straight, and the spiral arterioles 
are only slightly coiled and do not extend into the upper third of the 
endometrium.
Under the influence of progesterone produced by the corpus luteum, the 
endometrium becomes oedematous and thickens to 10 to 15 mm thick. The 
glands enlarge becoming tortuous, secreting a mucoid fluid, rich in nutrients, 
in particular glycogen. The spiral arterioles lengthen becoming more coiled, 
extending nearly to the surface of the endometrium. This is known as the 
secretary phase lasting to menstruation. The corpus luteum remains active 
producing oestrogen and progesterone for ten days after ovulation. If 
fertilisation does not occur hormone levels rapidly decline. The reduction of 
progesterone at the end of cycle causes the walls of the spiral arterioles to 
constrict leading to ischaemia in the stratum functionalis. Markee transplanted 
endometrium into the anterior chamber of the eye of rhesus monkeys, and 
demonstrated that before menstruation occurs there is intense vasoconstriction 
of these spiral arterioles. He also noted the increased coiling of the spiral 
arterioles, as well as a degree of endometrial regression (Markee 1940). As the
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spiral arterioles vasoconstrict there is endometrial thinning, which further 
increases ischaemia. Between 4 and 24 hours after this initial constriction, the 
spiral arterioles dilate, blood passes into the ischaemic endometrium, and 
desquamation occurs. Blood, uterine fluid, soft necrotic tissue, (from the 
stratum functionalis) is therefore lost at menstruation. After 4 to 5 days of 
bleeding, when only the strata basalis remains, the blood flow stops.
This menstrual blood loss is 75% arterial and 25% venous. Blood clotting in 
the spiral arterioles is inhibited during the initial blood flow by locally 
produced prostaglandins. Blood flow to the superficial layers (stratum 
functionalis) is solely by the spiral arterioles; the deep stratum basalis is 
served by basilar arterioles unaffected by this process.
Oestrogen and progesterone act via specific endometrial receptors. Two 
receptor subtypes have been identified for both hormones. The number of the 
specific receptors (ERa or ERP) vary in the endometrium throughout the 
cycle. The predominant form is ERa; the expression of which reaches a nadir 
at the time of menstruation (Salamonsen et al 1999). The progesterone 
receptors are known as PRA and PRB. PRA is present in glandular and stomal 
nuclei during the proliferative phase but in only the stromal cells at the end of 
the secretory phase (Wang et al 1998). PRB is present in both glandular and 
stomal nuclei during the proliferative phase, but totally absent in the secretory 
phase (Wang et al 1999). The question that has not been answered is what 
effect these hormones have - whether a direct effect on the endothelial cells, or 
whether it is a cytokine-mediated effect.
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2.4 Control of Blood Loss - Haemostatic 
Mechanisms.
2.4.1 Platelet plug formation.
Menstrual fluid can be kept for several weeks without clotting (Schinkele 
1912). It is free of platelets and fibrin (Salamonsen et al 1999). Fibrin has 
been demonstrated in the haemostatic plugs of the endometrium, but it is very 
rapidly removed (Salamonsen et al 1999). Indeed increased fibrinolysis is 
associated with the onset of menstruation in vivo (Casslen and Astedt 1983; 
Glesson 1994a).
Tissue Factor (TF) generates thrombin, converting fibrinogen to fibrin. It is 
the primary initiator of haemostasis, and is localised within stromal cells 
within the secretory endometrium (Salamonsen et al 1999). TF levels are 
increased under the control of progesterone and decreased with its removal 
(Lockwood et al 1993).
Unusually in the body, the endometrium appears resistant to scar formation. 
After menstruation the two raw basal layers remain in apposition for a number 
of days, yet the body’s normal healing mechanisms cause no adhesions to 
form. This is true after parturition as well as menstruation. The coagulation 
cascade occurs in the endometrium just as in other tissues. Platelets 
accumulate, degranulate and cause the deposition of fibrin sealing the 
endometrial vessels, within hours of the onset of menstruation. In order to 
prevent the formation of a scar and therefore obliteration of the uterine cavity, 
it is important to prevent clot formation. This is done by two main fibrinolytic 
mechanisms. Tissue plasminogen activator, and urokinase plasminogen 
activator initiate fibrinolysis. They are both released by the degrading
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endometrium. Oestradiol stimulates and progesterone inhibits urokinase 
plasminogen activator (Casslen and Astedt 1983; Casslen et al 1986; Casslen 
et al 1995). Progesterone also inhibits tissue plasminogen activator. Thus as 
progesterone levels fall causing the onset of menstruation, and oestradiol 
levels rise, plasminogen activator levels rise and therefore intrauterine 
adhesions are prevented.
One of the few situations in which the endometrium fails to regenerate 
properly was first described by Asherman in 1948: the syndrome of 
‘amenorrhoea traumatica\ This amenorrhoea was described either
postpartum, or post-abortal curettage. The endometrium in these cases appears 
insensitive to hormonal stimulation, and intrauterine adhesions form. It has 
been suggested that vigorous curettage causes adhesion formation, in cases of 
missed abortion, although it may be due to infection (Asherman 1948, Moyer 
1968). These adhesions result from repair by fibrosis instead of endometrial 
regeneration. It is not understood why this should occur.
Other factors are produced by the endometrium, which inhibit scar formation, 
namely prostacyclin, nitric oxide and platelet activating factor (Alecozay et al 
1991, Kelly et al 1984). No derangement in the levels of these factors or in 
fibrinolysis has been noted in women with menorrhagia. However, 
plasminogen activator is important in menorrhagia. Women, who use a 
copper-containing intrauterine contraceptive device, tend to have heavier 
periods. The levels of plasminogen activator are increased in these women 
(Shaw et al 1983). Those women using the combined oral contraceptive pill, 
which can be used in the management of menorrhagia, have lower levels of 
plasminogen activator (Casslen and Astedt 1983).
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2.4.2 Vasoconstriction.
During menstruation, the platelet-fibrin plug seals the damaged blood vessels. 
With the loss of further endometrium, these plugs are lost. The blood loss is 
restricted by the vasoconstriction of the spiral arterioles in the stratum basalis 
(Christiaens et al 1982). The status of the spiral arterioles’ lumen is under the 
control of the vasoconstricting prostaglandin PGF2a and the vasodilating 
PGE2 . During the luteal phase of the cycle, both are increased, under the 
influence of progesterone. It has been shown that an increased PGE2 / PGF2a 
ratio is present in those women suffering from menorrhagia. In these women 
there is an increased PGE2 receptor concentration in the endometrium 
(Adelantado 1988a; Adelantado 1988b; Cameron 1989; Cameron et al 1987; 
Smith et al 1981). Prostaglandins are produced from arachidonic acid by the 
action of cyclo-oxygenase. The activity of the cyclo-oxygenase-2 (COX-2) 
enzyme is induced and regulated by progesterone. COX-2 inhibitors reduce 
menstrual blood flow. The precise link between prostaglandins and 
menstruation is not known (Baird et al 1996).
Another extremely potent family of vasoconstrictors are the endothelins, 
which are found in a variety of tissues including the uterus (O’Reilly et al 
1992). There are three endothelin peptides (ET-1, -2 and -3) that are stored in 
the endometrial glands, and as the endometrium breaks down, are released. 
There are two specific receptors ETA and ETB. ET-1 is the body’s most 
powerful vasoconstrictor. They cause long-lasting vasoconstriction in the 
spiral arterioles (Marsh et al 1997). There is evidence that endothelins may be 
the pressor agents responsible for the intense vasoconstriction seen in the
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spiral arterioles at the start of the process of menstruation (Abberton et al 
1999).
2.5 Endometrial repair.
Endometrial repair commences under the influence of rising levels of 
oestrogen, released by the developing follicle. This repair is mediated by 
epidermal growth factor (EGF), produced by the denuded secretory 
spongiosum (Ishihara et al 1990). EGF contributes to both glandular and 
stromal repair (Haining et al 1991). Oestrogen also stimulates the production 
of vascular endothelial growth factor (VEGF) (Chamock-Jones et al 1993). 
Endometrial repair lasts 48 hours (Ferenczy 1976). This replaces the surface 
epithelium and is derived from the exposed end of basal glands, and persistent 
and intact epithelium within the cornual and isthmic regions of the uterus.
By day 5 the surface epithelium is intact. There is then a rapid change in the 
endometrial components (Ludwig et al 1990). Loss of the functional layer is 
responsible for stimulation of endometrial repair, and the rapid mitosis and 
ciliogenesis only occur after this is complete. If the superficial layers of 
epithelium are not totally lost during menstruation, there will be no nude 
basalis. This might in part be responsible for heavy or prolonged menstrual 
blood loss. Therefore if this overlying tissue is removed from the basal layer, 
as during a dilatation and curettage, epithelial regeneration can occur and 
bleeding will stop (Ludwig et al 1990).
Very little is known of the molecular and cellular basis of endometrial repair. 
Numerous growth factors have been implicated and a great deal of work is 
ongoing. Better treatment modalities for the treatment of menorrhagia may
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result from improved knowledge of the process of endometrial regrowth after 
menstruation.
Various techniques have been employed, over the years, to stop women with 
excessive menstrual blood loss from bleeding. Apart from hysterectomy, 
surgical methods currently used aim to prevent endometrial re-growth, and 
therefore to prevent further menstrual blood loss, by destroying or removing 
the endometrium leaving no glandular elements for subsequent re-growth. 
This is discussed later.
2.6 Methods of assessment of the endometrium 
and uterine cavity.
Abnormal uterine bleeding after the age of 40 years requires further evaluation 
to exclude intrauterine pathology (RCOG 1994; RCOG 1998). Patients under 
40 years old have a very little risk of developing endometrial cancer 
(Mackenzie and Bibby 1978). However, the endometrial cavity and 
endometrium should be assessed in the younger woman if abnormal bleeding 
persists after a trial of medical treatment, or where there are risk factors such 
as obesity and diabetes.
2.6.1 Ultrasound.
Ultrasound can be used to assess the endometrium, the myometrium and 
adnexae. Transvaginal ultrasound scanning (TVS) uses higher frequency 
sound waves than transabdominal scanning, giving better quality images at the 
expense of decreased depth of penetration. The RCOG Guideline 
Development Group has summarised the evidence. It states that TVS is
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superior to transabdominal scanning at visualising the uterine cavity (RCOG 
1999).
There have been few studies examining the accuracy of ultrasound. Two small 
studies demonstrated that endometrial thickness measured by ultrasound 
agreed with histological assessment (Fleischer et al 1986; Saxton et al 1990). 
Echoes of high intensity usually imply the presence of endometrial 
abnormalities (Weigel et al 1995). Endometrial cancer is suspected when 
endometrial thickness is 20 mm or more (Smith-Bidman et al 1998), together 
with the presence of hypo-echoic areas, and a heterogeneous appearance 
(Sheth 1993). Endometrial polyps may appear as cystic spaces and all the 
endometrium may appear hyperechoic (Hulka 1994; Kupfer 1994). 
Endometrial thickness (ET) is used to detect intrauterine pathology. Atrophic 
endometrium is 3mm thick or less. In women with post-menopausal bleeding 
a cut off thickness of 5mm has been shown to have a sensitivity of 100% with 
a specificity of 96% of identifying endometrial cancer (Granberg et al 1991). 
Some cancers have been missed at this level (Bombieri et al 1996). A bigger 
study has suggested a cut-off of 4mm which detected 100% of all cancers 
(Karlsson et al 1995). This level does not detect all pathologies. 5.5% of 
benign pathologies are missed, but this was thought to be acceptable by the 
authors who cited a 6% failure rate for D&C (Karlsson et al 1995).
Ultrasound detection of endometrial polyps is, however, unreliable (Fleischer 
1986, Fleischer et al 1987), due to the normal range of endometrial thickness 
overlapping with that seen in women with polyps (Dijkuizen 1986). Detection 
of polyps by TVS varies between 90% (Indman 1995), and 58% (Cacciatore
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1994). TVS has been reported to detect almost 100% of submucous fibroids 
(Indman 1995; Fedele 1991).
Colour flow doppler scanning may assist the diagnosis of endometrial 
carcinoma due to the increased blood flow in malignancy (Kurjak 1993; 
Campbell et al 1993), but increased blood flow has also been reported in 
benign conditions (Kupesic-Urek 1993).
Saline sonography is when saline is introduced into the uterine cavity through 
a catheter under ultrasound observation. It allows better detection of polyps, 
submucous fibroids and other pathologies, and can distinguish between these 
pathologies (Syrop et al 1992; Goldstein et al 1990; Bourne et al 1994). 
Detection rates for intrauterine pathologies are increased from 23.5% with 
transvaginal ultrasonography to 94.1% with saline sonography (Krampl et al 
2001). However, there is a possible risk using saline sonography, of 
intrauterine infection and spread of malignant cells into the pelvic cavity. 
There is an element of discomfort associated with this.
TVS has been found to be a good, non-invasive method of endometrial 
assessment when compared with hysteroscopy and curettage. It has a 
sensitivity and specificity of 96% and 89% respectively for identifying 
endometrial pathology (Emanuel et al 1995).
2.6.2 Magnetic resonance imaging (MRI).
MRI can be used to obtain measurements of endometrial thickness, diagnose 
intrauterine pathology and identify structural abnormalities of the uterus 
(Dudiak et al 1988; Ascher 1996). Its value however must be tempered
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Fig 2.1: MRI sagittal section through pelvis showing posterior fibroid and menstrual 
blood within the cavity
against the high costs and the timescale involved in obtaining an image, 
compared with other methods of assessing the endometrium (figure 2.1).
2.6.3 Dilatation and curettage.
This procedure was introduced by Recamier in 1843 (Ricci 1949) and until 
recently had been considered the standard investigation for endometrial 
assessment. Certainly the annual rate of this procedure at the end of the 1980s 
was 71.1/10,000 in England (Coulter et al 1991). Dilatation and curettage (D 
and C) has limitations and complications and has been largely replaced with 
hysteroscopy. It is a blind procedure where in the majority of cases less than 
half of the endometrial cavity is sampled, and whereby small polyps and sub
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mucus fibroids may well be missed. Uterine perforation occurs in 
approximately 1% of cases. Haemorrhage rates of 0.4% and infection rates of 
approximately the same occur. Diagnostic curettage may rarely also give rise 
to intrauterine adhesions (Shearman 1995). Cervical damage may also occur 
as a result of forced dilatation of the cervix. Generally this is a procedure that 
is performed under a general anaesthetic.
2.6.4 Hysteroscopy.
The first hysteroscopy was performed in 1869, when polyps were diagnosed in 
a woman with post-menopausal bleeding (Lindemann 1973). With the 
advance in technology, hysteroscopy is now offered as an outpatient ‘office’ 
procedure performed under local anaesthetic, whereby the whole surface of 
the endometrium can be directly visualised (Cicinelli 1994). It allows the 
possibility of directed biopsy of specific areas of the endometrium. Carbon 
dioxide (C 02), saline or glycine are generally used to distend the cavity. 
Carbon dioxide is used rather than air because of a decreased risk of gas 
embolism (Weismann 1996). Hysteroscopy can detect small polyps, 
submucous fibroids and malignancies which would have otherwise have been 
missed by outpatient biopsy, ultrasound or D & C (Gimpleson 1988; Loffer 
1988; Towbin et al 1996). The use of pelvic ultrasound can decrease the need 
for invasive diagnostic hysteroscopy (Jones and Bourne 2001). However 
detection rates for intrauterine pathology using transvaginal ultrasound have 
been quoted as low as 23.5%, although using saline sonography can 
significantly increase this to over 94% (Krampl et al 2001). Hysteroscopes are 
becoming smaller, the optical systems are getting better, and now with 2mm
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diameter flexible hysteroscopes, the need for dilatation of the cervix, and 
therefore local anaesthetic is less (Bradley 1995). Hysteroscopy should not be 
carried out in a pregnant woman, or in women with known acute pelvic 
inflammatory disease (PID), or known endometrial cancer (Lewis 1990) for 
fear of disease spread. In women with a history of PID, or ectopic pregnancy, 
antibiotic prophylaxis should be used for Chlamydial infection.
2.6.5 Endometrial biopsy in the outpatient setting.
Most women in the outpatient setting will tolerate an endometrial biopsy. 
They are simple and safe to perform. There is no need for a general 
anaesthetic, and the biopsy devices are relatively inexpensive. The two most 
commonly used devices are the Pipelle (Unimar, Connecticut, USA), and the 
Vabra aspiration biopsy (Berkley Medevices, Berkley, California, USA).
The Pipelle sampler is a 3.1 mm diameter flexible plastic cannula 23.5 cm 
long. There is a distal aperture in the side of the cannula through which the 
endometrial specimen is aspirated. The device is inserted through the cervix; 
the length of the cavity is measured with centimetre depth markings. Once 
inserted a piston within the device is withdrawn to create a vacuum and the 
whole device is rotated while being withdrawn. An adequate endometrial 
specimen is obtained in 90% of women (Forthergill et al 1992; Kaunitz et al 
1988). There is a 98% detection rate for endometrial cancer using Pipelle 
(Stovall et al 1991). However another study has disputed this (Ferry 1993) 
with only a 67% detection rate. Pipelle only samples 4% of the endometrium 
(Rodrigues 1993).
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The Vabra curette is a stainless steel cannula 24 cm long and 3 mm in 
diameter. It has a chamber for collection of the specimen at one end, 
connected to an electric vacuum pump. The device is inserted into the cavity, 
rotated and withdrawn. The Vabra can detect 95% of malignant intrauterine 
pathology (Grimes 1982). Vabra samples 42% of the endometrium 
(Rodrigues 1993).
Other endometrial biopsy devices (e.g. Explora, Accurette, Z-sampler) have 
similar detection rates and sampling rates (Spencer 1999). However, all these 
devices are ‘blind’ samplers. Not all the endometrial surface will be sampled, 
and polyps or other pathology may be missed.
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CHAPTER 3: TREATMENT OPTIONS OF 
MENORRHAGIA.
3.1 Introduction.
Five per cent of women aged 25 to 44 years will consult the GP about 
excessive menstrual loss every year (Vessey et al 1992). More than one 
quarter of the female population consider menstruation excessive (Gath et al 
1987). In fact 22% of women in this study stated that their menstrual loss was 
sufficient to adversely affect their lifestyle. Nearly 10% of employed women 
take time off work because of excessive menstrual loss (Gath et al 1987).
Treatment options may be medical or surgical. The traditional surgical 
treatment is a hysterectomy. This has a cure rate of 100%, and is the treatment 
of heavy menstruation by which all other treatment modalities should be 
assessed. Sixty percent of women referred to hospital with menorrhagia will 
have a hysterectomy within 5 years (Coulter 1991). There are risks associated 
with hysterectomy, and there is a high morbidity associated with the operation 
which will be discussed later in this chapter. Other more minimal surgical 
techniques will be discussed which improve morbidity. Surgical treatments 
have a major disadvantage in that they are not suitable for women who have 
not completed their family.
Several medical treatments are available which women wishing children, or 
those who do not wish a surgical option can use. The ideal treatment option 
for menorrhagia should be cheap, easy to administer, effective and have no 
side effects. Only 58% of women are offered medical treatment by their GPs 
prior to referral to a gynaecologist in the UK (RCOG 1998).
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3.2 Medical treatments.
3.2.1 Anti-fibrinolytics.
Tranexamic acid acts by inhibiting tissue plasminogen activator, a fibrinolytic 
enzyme found to be raised in women with dysfunctional uterine bleeding 
(DUB). It has been shown to reduce menstrual blood loss by just over 50% 
(Nilsson and Rybo 1971; Andersch et al 1988; Milsom et al 1991).
The most common side effect of tranexamic acid are nausea and diarrhoea. 
There have been reports of an increase in arterial thrombosis associated with 
its use (Agnelli et al 1982). However, tranexamic acid has been used for 
many years in Scandinavia, and analysis of 19 years worth of data showed that 
the incidence of thromboembolic events was the same as the general 
population (Lindoff et al 1993). Preston and co-workers studied 46 women 
with menorrhagia and allocated women to Tranexamic acid or norethisterone 
(Preston et al 1995). They found a reduction in mean menstrual blood loss of 
45% with Tranexamic acid, but a 20% increase with norethisterone. Another 
study comparing Tranexamic acid with mefenamic acid and ethamsylate 
showed a reduction of 58% in menstrual blood loss with Tranexamic acid, a 
25% reduction with mefenamic acid, and no change with ethamsylate (Bonnar 
and Sheppard 1996).
3.2.2 Non-steroidal anti-inflammatory drugs.
The non-steroidal anti-inflammatory drugs (NSAIDs), include aspirin, 
ibuprofen, naproxen and mefenamic acid. These drugs act by inhibiting cyclo- 
oxygenase, and therefore reducing the production of endoperoxidases and
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endometrial prostaglandins. The fenamates (mefenamic acid) also block 
myometrial PGE2 receptors.
There are many randomised trials of mefenamic acid used in menorrhagia. 
Reductions in blood flow of between 20% (Dockeray et al 1989) and 47% 
(Hall et al 1987) are quoted. It appears that women with the most severe 
menorrhagia benefit the most. Other NSAIDs have not been studied to such 
an extent. Hall et al found naproxen to be as effective as mefenamic acid in a 
crossover trial (Hall et al 1987). Ibuprofen reduced MBL by 13% (Makarainen 
and Ylikorkala 1986).
The NSAIDs are effective, well tested and well tolerated drugs side-effects are 
outlined in table 3.1).
3.2.3 Ethamsylate.
The mechanism action of ethamsylate is not well understood. It is thought to 
decrease capillary fragility, and also has effects on prostaglandin synthesis. 
Two small studies have shown it is effective in reducing MBL by 50% in 
women with menorrhagia (Harrison and Cambell 1976; Chamberlain et al
1991). This study used ethamsylate for a total of 15 days per cycle. Other 
studies restricting treatment to the days of the menses have been less 
successful. There was only a 7% reduction in IUCD users (Kasonde and 
Bonnar 1975). In a randomised controlled study comparing ethamsylate with 
mefenamic acid and tranexamic acid, there was no reduction in menses with 
the ethamsylate (Bonnar and Sheppard 1996). Ethamsylate is little used in the 
UK and because of commercial pressures the IV preparation was withdrawn 
from use in the UK in 2000.
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D rug M aximum 
reduction in 
MBL (% )
Side effects
Antifibrinolytics 
(Tranexamic acid)
50% Nausea, vomiting, diarrhoea, colour 
vision disturbances
COCP 50% Headaches, migraine, weight gain, 
nausea, breast tenderness, hypertension, 
thromboembolic events
Progestogens 20% Weight gain, nausea, bloating, oedema, 
headaches, acne, depression, exacerbation 
of epilepsy and migraine, loss o f libido
NSAIDs 
(Mefenamic acid)
50% Nausea, vomiting, gastric upset, 
diarrhoea, headache, bronchospasm, 
thrombocytopenia
Danazol 98% Weight gain, headaches, acne, depression, 
loss of libido, rash, hirsuitism, voice 
changes, diminished breast size, mood 
changes
Ethamsylate 50% Nausea, headache, rashes
GnRHa
(Buserelin
Goserelin)
95% Hot flushes, night sweats, loss o f libido, 
dry vagina, lethargy, headaches, 
osteoporosis.
Table 3.1: Potential side effects with medical treatments
3.2.4 Cyclical Hormonal treatments
3.2.4.1 Progestogens.
Norethisterone is one of the most widely used treatments for menorrhagia, it 
has been used for over 30 years (Bishop and de Almeida 1960). It is probably 
the least effective of all treatment modalities. The change in blood loss in one
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study was of an increase of 20% (Preston et al 1995). However, the use of 
progestogens whether as norethisterone or medroxyprogesterone acetate 
support from day 5-26 in irregular non-ovulatory cycles, reduced blood loss 
by 51% (Fraser 1990). Norethisterone has been shown to be of benefit in the 
minority of women with anovulatory menorrhagia, most especially when the 
treatment is extended to 21 days (Fraser 1990). Side-effects are dose- 
dependant and are outlined in table 3.1.
3.2.4.2 The combined oral contraceptive pill (COCP).
Nilsson and Rybo (Nilsson and Rybo 1971) used various contraceptive pills
and found a mean decrease in blood loss of 53%. An added benefit of the 
COCP is that it can regulate cycles. The quantity of hormones in the 
preparations of almost 30 years ago were much greater than today, but studies 
are awaited investigating menstrual blood loss and the newer COCP. The 
COCP, however, is restricted in its use in older women and those who smoke, 
and those with risk factors for thrombosis. Despite the documented reduction 
in MBL, only 11% of GPs prescribe it for treatment of menorrhagia (Coulter 
et al 1995). A review of trials of oral contraceptive pills for menorrhagia was 
unable to reach conclusions because of the paucity of adequate data (Cochrane 
Database 2000).
Part of the reason why the COCP is not prescribed more frequently despite its 
success in the treatment of menorrhagia is the fear of thromboembolic disease, 
especially in the older age group. In the absence of additional risk factors such 
as smoking, previous thromboembolic episode or family history, the COCP is 
not contra-indicated. However, third-generation COCP have been associated
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with an increased risk of throboembolic disease (Jick et al 1995; Poulter et al
1995) and this should be borne in mind when prescribing.
The mode of action in menorrhagia is by suppression of the endometrium, 
reduction of endometrial prostaglandin synthesis and altered fibrinolysis 
within the uterus (Irvine and Cameron 1999).
3.2.5 Continuous Hormone Treatment.
3.2.5.1 Danazol.
Danazol, a synthetic steroid, inhibits sex steroid synthesis, blocks androgen 
and progesterone receptors, and inhibits pituitary gonadotrophins at higher 
doses. It thereby inhibits endometrial growth. Its use is limited because of 
androgenic side effects.
It was first used in the treatment of menorrhagia in 1979 (Chimbira et al
1979). Three large studies of danazol use have shown significant reduction in 
blood flow. One study used 400 mg, 200 mg, and 100 mg with reductions of 
98%, 8 6 %, and 57% respectively (Chimbira et al 1980). Another used 100 mg 
comparing it with mefenamic acid. This study found a 60% decrease in blood 
loss with danazol compared to 2 0 % with mefenamic acid, however three 
quarters of women had side-effects with 40% stopping treatment because of 
this (Dockeray et al 1989). Higham and Shaw compared danazol with 
norethisterone 5 mg twice daily (Higham and Shaw 1993). Continuous 200 
mg of danazol reduced blood flow by 39%, whereas there was a mean increase 
of 9% in the norethisterone group.
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3.2.5.2 Gestrinone.
This is a synthetic derivative of 19-nortestosterone. It has both anti- 
oestrogenic and antiprogestogenic properties. More than 50% of women will 
be made amenorrhoeic and a further 25% will have significant reduction in 
MBL (Chimbira et al 1980).
3.2.5.3 Gonadotrophin-releasing hormone analogues.
The gonadotrophin-releasing hormone analogues (GnRHa) can be used
continuously. There is pituitary down-regulation and inhibition of the 
production of luteinising hormone and follicle stimulating hormone. The 
hypo-oestrogenic state that they produce is associated with menopause-like 
side effects - such as hot flushes and dry vagina. They are effective in 
producing amenorrhoea (Thomas et al 1991). Their use is limited to six 
months because of the risk of osteoporosis (Dawood et al 1989). Bone loss 
over this period is less than 5%, and is 8 % over a twelve-month period; but 
there is a question as to whether this is reversible (Fogelman 1996; West et al 
1987). GnRHa may be given as a nasal spray several times a day (bruserelin 
and nafarelin); as a subcutaneous injection monthly (leuprorelin and goserelin) 
or as a monthly intramuscular injection (leuprorelin).
3.2.5.4 Tamoxifen.
This is an anti-oestrogen with weak oestrogenic activity, tamoxifen has not 
been used widely in the treatment of menorrhagia. However, when used it 
does reduce menstrual blood loss, but with a risk of endometrial polyps 
(Fraser 1987).
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3.2.6 Local Progestogen Treatment.
3.2.6.1 Levonorgestrel Intrauterine System (LNG-IUS).
The levonorgestrel intrauterine system (LNG-IUS) (Mirena®; Sherring, UK),
is licensed in the UK for contraception and in the treatment of menorrhagia. It 
consists of a plastic T-shaped frame with a steroid reservoir containing 52 mg 
of levonorgestrel. Levonorgestrel is the isomer of norgestrel, a derivative of 
the 19 nor-testosterone progesterones. It is released as a rate of 20pg per day. 
This release is sustained over seven years (Hollingworth & Guillebaud 1994).
The effect on the endometrium is mediated via a decrease in oestrogen 
receptors and an increase in the 170H-oxoreductase activity, which converts 
oestradiol to oestrone. Progestogens inhibit mitotic activity; the LNG-IUS has 
been shown to be effective at controlling endometrial hypertrophy by 
suppressing endometrial growth. After only a few weeks there is glandular 
atrophy, mucosal thinning and the epithelium becomes inactive. There is also 
suppression of the spiral arteriolar growth. The endometrium becomes 
unresponsive to oestrogen with reduced (if any) shedding, due to down- 
regulation of the oestrogen receptors (Luukkainen and Toivonen 1995; 
Luukkainen et al 1990). These endometrial changes are uniform within three 
cycles after insertion (Luukkainen and Toivonen 1995), and after the system is 
removed, the morphology of the endometrium returns to normal, including 
normal menses within 30 days (Nilsson et al 1977). The majority of women 
continue to have normal ovulatory cycles (Luukkainen et al 1990). Uterine 
bleeding has no effect on ovulation. It has been shown that there were no 
differences in oestradiol and progesterone levels between users with 
amenorrhoea or those that were continuing to menstruate (Nilsson et al 1984).
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The LNG-IUS has been shown to be highly effective at reducing menstrual 
blood flow in pre-menopausal women with menorrhagia (RCOG 1998; Tang 
& Lo 1995; Irvine et al 1998). After three months use there was an 85% 
reduction in menstrual blood loss, the number rising to 97% after 12 months, 
with 35% of women amenorrhoeic at one year (Andersson and Rybo 1990; 
Tang & Lo 1995; Irvine et al 1998). In a study of 50 women who were 
awaiting a hysterectomy or endometrial resection for menorrhagia, 82% who 
were fitted with a LNG-IUS were satisfied with their menstrual loss by six 
months and 8 % had amenorrhoea. Fifty-six percent of the women noticed an 
improvement or cure in premenstrual syndrome symptoms and 80% had a 
reduction in dysmenorrhoea. Of interest was the fact that 82% of these women 
asked to be taken off the waiting list, as the treatment was so successful 
(Barrington and Bowen-Simpkins 1997). In a RCT, women on the waiting list 
for hysterectomy were offered an LNG-IUS fitted 6  months prior to their 
operation or to continue their medical treatment. Sixty-four percent of women 
in the LNG-IUS group and 14% in the medical group removed themselves 
from the list as they were so satisfied (Lahteenmaki et al 1998).
As the endometrium takes about three months to atrophy, bleeding within this 
time can be highly erratic, but generally settles by 6  months. Women may 
suffer from regular spotting in the first 3-6 months of use (Datey et al 1995).
Despite the fact that serum levels of levonorgestrel are very low, some women 
seem to have adverse progestogenic side effects associated with the use of the 
LNG-IUS. These may be physical, such as oedema, headache, breast 
tenderness and even hirsuitism and acne. There is also evidence of decreased
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LDL levels (Sturridge and Guillebaud 1996). The physical effects are not 
persistent.
The counselling of women about spotting is important, yet women must also 
be counselled about the reduction in menstrual blood flow and the possibility 
of complete cessation of menses, and that this is not a pathological situation. It 
is important to stress that despite cessation of menses, ovarian function will 
remain normal. Otherwise women may request the IUS is removed 
unnecessarily. In the largest study of removal of the LNG-IUS, involving 
17,360 users in Finland, the one, two, three, four and five year continuation 
rates were 93%, 87%, 81%, 75% and 65% respectively, with spotting and 
excessive bleeding being the primary reasons for removal (Backman et al 
2000).
Insertion of a LNG-IUS prior to endometrial ablation can remove the need in 
approximately 75% of cases (Romer 2000). The 1993 costs of 822,000 
prescriptions for 345,255 women was £7 million (NCRD 1995)
3.3 Surgical management.
3.3.1 Hysterectomy.
Soranus of Ephesus performed the first hysterectomy vaginally over 17 
centuries ago (Ewen and Sutton 1995). Numerous other reports occurred in the 
16th and 17th century. Reports of the first total abdominal hysterectomy 
(TAH) of the modem age occurred in Manchester in the UK in May 1844, by 
Charles Clay. The patient died of torrential haemorrhage. In 1850 in 
Massachusetts, Ellis Bumham performed the first TAH where the patient 
survived. However the mortality rate from his operation remained around
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80%. Overall mortality from TAH still exceeded 70% in 1880, but by 1930 
the mortality rate was less than 3% (Ewen and Sutton 1995).
With the further improvement in anaesthesia and antibiotics, mortality is now 
less than 1 per 1000 cases, but the morbidity is high, with almost 50% of 
patients suffering from one or more complication (Dicker et al 1982). In 1985
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Figure 3.1: Hysterectomy rates from around the world (from Hill 1997).
there were over 60,000 hysterectomies performed in the UK (Last 1989), 
although the rate in the UK is below the rate in other countries (figure 3.1). In 
2000-2001 there were just over 47,000 (NICE 2004), the difference being 
accounted by the increase in MAS techniques and the Mirena IUS.
The mortality rate for hysterectomy, excluding cancer and pregnancy is 6  per 
10,000 (Wingo et al 1985). The Confidential Enquiry into Perioperative
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Deaths in 1996-7 reported 7 deaths due to haemorrhage and / or infection in 
women having a hysterectomy for benign disease (Anonymous 1998).
Some surgeons believe that all hysterectomies should be done vaginally 
(Moen et al 1995). There are several techniques of performing a vaginal 
hysterectomy (VH). Other surgeons are very pro-laparoscopic techniques 
(Reich 1999). These laparoscopic hysterectomy (LH) techniques involve 
hysterectomy without a large abdominal wound. They can vary from a 
diagnostic laparoscopy with VH, through different levels of laparoscopically 
assisted VH (LAVH) to subtotal (LSH) or total laparoscopic hysterectomy 
(TLH). Different operators have different techniques, and dissect to different 
levels (Reich et al 1999).
Complications from hysterectomy are largely minor. However, there are 
potential long-term complications, namely premature ovarian failure (Siddle et 
al 1987), sexual dysfunction (Poad and Arnold 1994), cardiovascular disease, 
bowel function (Parys 1989) and bladder dysfunction (Parys et al 1989; 
Thacker & O’Keeffe 2000). El-Toukhy et al showed in a prospective study 
that there was an improvement in all types of incontinence and dyspareunia 
after hysterectomy by all routes (abdominal total and sub-total, vaginal and 
laparoscopic (El-Toukhy et al 2003).
Dicker et al published the CREST report in 1982 reporting complications after 
hysterectomy. Garry and Phillips (1995) and Deprest et al (1995) have also 
reported. These results are summarised in table 3.2.
Most hysterectomies continue to be performed abdominally in the UK, 
Australia and USA (Prentice 1999). Complication rates are inevitable with any
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surgical procedure. As always, an experienced operator will obtain the lowest 
complication rates. The abdominal approach is easier than the others but has a 
higher overall complication rate, although this may reflect the fact that 
surgeons will choose the abdominal approach for the more difficult 
hysterectomies. The numbers involved in LH are probably too small to 
compare but certainly morbidity tends to be lower, but the sequelae of the 
specific LH complications can be far worse.
Complication rate (%)
Hysterectomy route Abdominal Vaginal Laparoscopic
Unexplained fever 1 0 -2 0 5 - 8 1.4
Operative site infection 1 3 .8 -4 2 7 .8 - 2 0 4.3
Urinary tract infection 1.1 -5 1 .7 -5 <1
Intraoperative haemorrhage 0 .2 -3 .7 0 .5 -3 .5 N /A
Post-operative bleed 0 .2 -2 .3 0 .4 -5 .7 0.8
Transfusion 2 .2 -7 .5 0 .7 -1 3 1.2
Bladder trauma 1 -2 0 .5 -  1.5 1.1
Bowel trauma 0.1 -0 .5 0.1 -0 .8 0.5
Ureteric danage 0.1 -0 .5 0 .0 5 -0 .1 0.3
Urinary retention 4.8 8 0.3
Paralytic ileus 2.2 0.2 0.2
Wound dehiscence 0 .3 -0 .7 N/A 0.3 (port site hernia)
Vessel injury N/Q N/Q 0.4
Atelectasis 6 1 N/Q
Pulmonary embolus 0 0.2 0.2
Myocardial infarction, or 
cardio-pulmonary arrest
0 0.1 N/Q
Disseminated intravascular 
coagulation
0 0.1 N/Q
Death 0.2 0.1 0.03
N/Q = not quoted 
N/A = mot applicable
Table 3.2: Complication rates from hysterectomy (figures from references
quoted in text).
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An adverse psychological reaction has been long associated with 
hysterectomy (Polivy 1974). At the turn of the twentieth century a 
hysterectomy or bilateral oophorectomy were recommended for the treatment 
of personality disorder and psychiatric illness. Of course this treatment often 
led to worse psychological problems in the most vulnerable of women (Anath 
1978). Depression after hysterectomy is more likely to be due to the 
considerable hormonal changes than psychological changes. However a 
considerable amount of the psychological morbidity associated with 
hysterectomy may be due to pre-existing disease.
In women where the uterus is a symbol of femininity because of menstrual 
and reproductive capacity, hysterectomy will lead to a feeling of loss of 
femininity (Hollender 1960; Barglow et al 1965). However, a prospective 
study failed to show any influence of femininity on post-hysterectomy 
depression (Gath et al 1987). Meikle et al (1979) studied three groups of 
women having cholecystectomy, tubal ligation and hysterectomy. They found 
no differences in mood disturbance between the groups. Martin showed no 
difference in psychiatric problems before or after hysterectomy (Martin et al
1980). In an Oxford study women were reviewed before and after 
hysterectomy and a significant reduction was noted at the six-month follow-up 
in psychiatric problems which more than halved (Gath et al 1987). Another 
studied showed a reduction in women undergoing hysterectomy or 
endometrial ablation because of dysfunctional uterine bleeding (Alexander et 
al 1996).
The uterus has been thought of as important to a woman for sexual fulfilment 
(Poad et al 1994). However, prospective data from studies shows that there
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was either no change or improvement in sexual activity. The reasoning behind 
this being that there is now a freedom from the worry of pregnancy, as well as 
treatment of gynaecological symptoms such as dysmenorrhoea, which led to 
the loss of libido in the first instance (Poad & Arnold 1994). Maas et al 
showed that there were a large majority of women who after hysterectomy had 
an improved sexual fulfilment (Maas et al 2003), however there were more in 
the radical hysterectomy group who had a worsening of their fulfilment (Maas 
et al 2004).
The endometrium has a remarkable capacity to regenerate, and any surgical 
procedure to treat excessive uterine bleeding, that excludes a hysterectomy 
must ensure that there is adequate destruction of the basal glands of the 
endometrium. In the past many methods have been tried in order to cause 
scarring and to induce an iatrogenic Asherman’s syndrome, whether with 
cryotherapy, steam, intracavitary radioactive substances or other noxious 
chemicals such as formaldehyde, silicone rubber, quinacrine or oxalic acid 
(Goldrath et al 1981). None were particularly successful. In the 5 years 
following referral to a gynaecologist for management of menorrhagia, 81% of 
women had been admitted to hospital. Forty four percent had had a 
hysterectomy, 48% had a dilatation and curettage, with 12% having received 
only drug therapy, and 5% having had no active treatment (Coulter et al
1991).
3.3.2 Uterine curettage.
Uterine curettage is associated with a reduction in MBL in the first few 
months after the procedure of up to 60% (Mikuta 1970), however the effects 
are short-lived (Haynes et al 1977). It is a relatively simple procedure to carry
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out, but complications include uterine perforation and intrauterine adhesions 
or synechiae.
3.3.3 Hysteroscopic surgery - endometrial ablative techniques.
There are many techniques available for endometrial destruction. Some are 
well-established and well researched. Others are still at the research or 
evaluation stage (Table 3.3). The newer techniques will be discussed in 
chapter 13 in the discussion of the PDT results.
Hysteroscopic techniques
Transcervical resection (TCRE) 
Rollerball ablation 
Endometrial laser ablation (ELA) 
Hydrothermal ablation (HTA) 
Versapoint
Non-hvsteroscopic techniques
Radiofrequency ablation (REA) 
Microwave ablation (MEA) 
Thermal balloon ablation 
Electrode balloon ablation 
Cryoablation 
Photodynamic ablation 
Interstitial hyperthermia
Table 3.3 Techniques of endometrial ablation
3.6 Summary-
Prostaglandin inhibitors and antifibrinolytic agents reduce MBL by 25-50%, 
and are successfully used as a first line treatment in menorrhagia. The LNG- 
IUS produces a marked reduction in MBL and offers a more acceptable 
alternative to both oral treatment and surgery. Most of the transcervical MAS 
techniques for the management of menorrhagia result in an 80% satisfaction
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rate, but 1 in 6  of treated women will still undergo a hysterectomy. 
Complications of these MAS techniques such as uterine perforation and
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Figure 3.2: Operative procedures for m enstrual disorders 1990-99 in women 
under 50 years (Scotland).
extrauterine organ damage are severe. The overall number of procedures being 
carried out on women for menstrual disorders is lower now than 1 0  years ago. 
The reasons for this are the steep fall in the number of D and C operations, 
and the increase in the use of hysteroscopy (figure 3.2).
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The ‘blind’ transcervical procedures have, generally, not been thoroughly 
evaluated. Hysterectomy is the best treatment of menorrhagia, but has a higher 
complication rate.
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CHAPTER 4: LASERS
4.1 Introduction.
The word laser is an acronym for Light Amplification by the Stimulated 
Emission of Radiation. Stimulated emission is a physical phenomenon, which 
occurs in atoms when excited electrons are stimulated by an external energy 
source to move from a high energy level to a lower level, with the emission of 
one photon, identical to the one that stimulated the emission. Einstein (figure 
4.1) first described this concept in 1917, as part of quantum theory (Patel 
1964: World Book 2001). Laser development, however, was dependent upon 
the development of optics and quantum physics, and did not occur for several 
more decades.
Figure 4.1: Albert Einstein, (1879-1955).
4.2 Theory of light.
In the 17th century Newton (figure 4.2) proposed the ‘corpuscular theory’ of 
light considering it to be composed of a stream of particles or corpuscles.
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At the same time Hooke and Huyghens considered light to be wave-like and 
propagated through an all pervading elastic medium called ‘aether’. 
Experimental evidence supported both theories. However in 1802, Young 
used the wave theory of light to explain the phenomena of diffraction,
Figure 4.2: Isaac Newton (1642-1727), English scientist, 
astronomer, and mathematician.
polarisation and interference and so the wave theory became generally 
accepted. In 1867, Maxwell discovered that the speed of propagation of a 
disturbance in an electromagnetic field was exactly equal to the measured 
speed of light (measured by and found to be 300 000 km per second). He 
concluded that light was an electromagnetic wave whose propagation through 
the ‘aether’ was determined solely by the electric and magnetic properties of 
the Aither (World Book 2001).
In 1905, Einstein published his Special Theory of Relativity and showed that 
electromagnetic waves were self-propagating and had no need of an ‘aether’.
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Another phenomenon, which could not be explained by the wave theory of 
light, was the ‘photoelectric effect’. Einstein explained this by treating light as 
being made up of discrete indivisible packets of energy, later to be called 
photons. The energy of each photon was inversely proportional to the 
wavelength of the light; therefore ultraviolet light with its short wavelength 
had high-energy photons. The concept of the photon, in which light is both a 
particle and a wave, formed the basis of an entirely new branch of physics 
called the Quantum Theory of Matter.
Niels Bohr (1885-1962), a noted Danish physicist developed a theory about 
the structure of the atom. Bohr’s theory, published in 1913, was based on an 
earlier one proposed by Ernest Rutherford, a New Zealand-born physicist. 
Bohr used the Quantum Theory to remodel the atom, suggesting that atoms 
consisted of positively charged nuclei surrounded by negatively charged 
electrons in discrete orbits, usually in a low energy state known as the ground 
state (World Book 2001). The emission and absorption of light results from 
changes in the energy of the atom, which the quantum theory showed to be 
restricted to only certain allowable values, each of which could be represented 
by a particular configuration of the extra-nuclear electrons. A change from one 
energy state to another was instantaneous and accompanied by the absorption 
or emission of a packet of energy (or photon) equal to the difference in energy 
between the two states, the transition energy. If a photon of an appropriate 
wavelength collides with an atom it is absorbed, the energy is transferred to 
one of the orbiting electrons, which will move into a higher more energetic 
orbit. The excited electron, and therefore the atom, is now in an unstable, 
excited state and its tendency is to return back to the ground state by re-
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emitting the excess energy as a photon. If enough energy is added to the atom 
the electron becomes detached and the atom is ionised. Quantum Theory will 
only allow photon absorption to happen if the absorbed photon has exactly the 
same energy as that required to move the electron between permitted energy 
levels. Similarly, the photon emitted following a return to the ground state 
possesses the same energy.
Einstein called the first process, absorption and the second, spontaneous 
emission. He also suggested a third process: if an already excited atom is 
struck by a photon of the correct wavelength this will stimulate the emission 
of a second photon of identical wavelength, in phase, and with a parallel path 
to the incident photon. This process is called stimulated emission and results 
in an amplification of the original photon by a factor of two.
4.3 Early laser development.
The practical significance of Einstein’s theory was not realised until after the 
Second World War, when it was found that conventional electronic devices 
were unable to amplify the very high frequency microwaves used for radar. 
Basov, Prokharov and Townes realised that the intensity of the original 
electromagnetic wave could be amplified by the phenomenon of stimulated 
emission. For this to occur there must be a situation whereby more than 50% 
of the atoms have electrons occupying a higher energy level called a 
‘population inversion’. These excited atoms are ‘prepared’ to release their 
energy as photons. Without such a high number of atoms in the excited state, 
photons would be absorbed by the lower level atoms rather than stimulate 
emission of further photons from the upper level (Gordon et al 1955). In 1953 
Charles Townes produced such a population inversion and constructed the
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first ‘MASER’: an acronym for Microwave Amplification by Stimulated 
Emission of Radiation. Shortly after this in 1958 Townes and Arthur 
Schawlow described the conditions necessary for Light Amplification by 
Stimulated Emission of Radiation (LASER). For his work, Townes shared the 
1964 Nobel Prize in physics with two Soviet scientists who also developed 
and improved masers (World Book 2001).
A laser consists of three basic elements, a power supply, the excitable medium 
and an optical resonator. The atoms or molecules in the medium are raised to a 
higher energy by the power supply. Many substances are suitable for use as 
the lasing medium. They may be solids, liquids, gases or metal vapours 
(Thearruth and McKenzie 1986).
4.4 The ruby laser.
Theodore H. Maiman a physicist at the Hughes Research Laboratories in the 
United States constructed the first laser in 1960. His laser used a ruby rod as 
its active medium. He demonstrated lasing action using a small rod of 
synthetic ruby crystal as the laser medium on May 16, 1960 (Maiman 1960). 
Ruby is predominantly aluminium oxide (AI2 O3) with a small percentage of 
chromium oxide (0 3 0 4 ) held within the crystal lattice. Its pale pink colour is 
caused by absorption of light in the green and violet parts of the spectrum by 
the chromium (Cr3+) ions. The rod shaped ruby crystal was silvered at both 
ends so that light travelling parallel to the longitudinal axis would be reflected 
back and forth through the ruby rod. To allow some light to escape one face 
was only partially silvered. The energy needed to excite Cr3+ ions and produce 
the population inversion necessary for laser action was produced by a xenon 
flash discharge lamp.
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Cr3+ ions are excited to high energy levels by the absorption of green and 
violet light emitted by the flash lamp. The absorption bands are very short 
lived and decay almost immediately to a metastable state via non-radiative 
transitions. The transition energy is lost as heat in the crystal lattice. The 
metastable state is relatively long lived and returns to the ground state via 
radiative transitions, which emit red light (wavelength 694nm). Because the 
absorption bands decay very rapidly to a longer lived metastable state, a 
population inversion between metastable and ground state is achieved and 
laser action is therefore possible.
Laser action is initiated by a photon emitted by the spontaneous decay of an 
excited Cr3+ ion and this travels parallel to the longitudinal axis of the rod. 
Along its path, the photon stimulates the production of another photon, which 
propagates in the same direction. The two resultant photons stimulate the 
emission of more identical photons by further interactions with other excited 
ions. The chain reaction, of which these are the first steps, continues as 
photons travel back and forth through the ruby rod and lasts for as long as the 
population inversion remains. The result is an intense pulse of highly 
collimated red light emerging from the partially reflective face of the rod.
Following the invention of the ruby laser, a number of other lasers in the 
visible and infrared spectrum have been designed. The neodymium yttrium 
aluminium garnet laser (Nd:YAG laser) was first demonstrated in 1961 
(Johnson 1961), the argon ion laser in 1962 (Bennet et al 1962) and the carbon 
dioxide laser in 1964 (Patel et al 1964). The first ultraviolet laser, using 
excited molecular xenon was demonstrated in the USSR in 1970 (Basov et al 
1970).
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In 1961 the American physicist Ali Javan constructed the first gas laser. In 
1962, three separate teams of U.S. scientists operated the first semiconductor 
lasers. In 1966, the American physicist Peter Sorokin built the first dye laser. 
The carbon dioxide (CO2) laser was reported in 1964 (Patel 1964) and is still 
widely used in clinical practise as is the neodymium-YAG (solid state laser) 
(Geusic et al 1964) and diode laser (Ripley 1996).
4.5 Properties of laser light.
In summary there are four basic characteristics of light produced by a laser, in 
which it differs from ordinary light. Namely that it is monochromatic, 
coherent, collimated and highly directional. Lasers are also capable of 
producing high powers and power densities.
4.5.1 Monochromaticity.
Laser light is monochromatic consisting of one wavelength. It is one colour 
because all the photons come from one transition between two energy levels.
4.5.2 Coherence.
Ordinary light from a lamp is ‘incoherent’ and consists of a mixture of 
wavelengths radiating in all directions. Laser light is ‘coherent’ and consists of 
one wavelength with all its waves travelling in the same direction and ‘in 
phase’ with each other. Waves are in phase such that all troughs and all the 
peaks are exactly opposite one another.
4.5.3 Collimation.
A collimated beam is one that is parallel and does not diverge. This is unlike
light from a light bulb, which spreads out as it travels further away from its
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source. An important property of a highly collimated laser beam is that 
although the power output of the laser may be low, the irradiance (power per 
unit area) of the beam is very high and can remain so up to very great 
distances. The low divergence of the laser beam allows it to be focused to a 
very small spot size and thus increase irradiances even further. The low beam 
divergence of laser light is caused by its high spatial coherence.
The monochromatic nature of laser light is important for photodynamic 
therapy (PDT) as a specific wavelength of light is required for sensitiser 
activation. All of the light produced shares the same optical properties. This 
improves efficiency, and enables the light to be channelled down an optical 
fibre. The highly directional nature also allows the beam to be focused into a 
very small spot, resulting in a high concentration of energy.
4.6 Lasers suitable for clinical use.
A substance has the potential to become a lasing medium if it can have more 
atoms or molecules in a high-energy state than a lower energy state - 
population inversion. In most lasers, a gas, liquid or crystal is energised 
(pumped) by a suitable energy source (light, electric discharge, radiofreqency 
emitter). The input of pumping energy raises electrons to higher energy levels 
in more atoms, more quickly than spontaneous decay can return them to their 
original level. Once there are more excited atoms (i.e. atoms having an 
electron in a higher energy level), stimulated emission becomes possible.
All lasers consist of a chamber that has mirrors at each end so that light can be 
reflected back and forth within the chamber. One of these mirrors will have 
either a hole at the centre or be only partially reflective so that the laser beam
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can leave the chamber. The light can then be focused by a lens and passed into 
a suitable delivery system. The laser medium determines the range of 
wavelengths and the mirrors determine the specific wavelength of the laser 
light.
4.6.1 Argon laser.
The laser medium of the argon ion laser is argon gas held in a small diameter 
air or water-cooled tube made of glass, graphite or beryllium oxide. An 
electric current ionises the argon gas and excites the ions to high-energy 
states. The laser produces blue-green light and this output is made up of a 
number of wavelengths lying between 437-529nm (80% of the power is 
equally divided between 488 and 514.5nm). The argon ion laser is very 
inefficient; it needs a three-phase electrical power source and a supply of 
cooling water. The blue-green light from the argon ion laser passes through 
skin with minimal absorption and is preferentially absorbed by certain tissue 
pigments such as melanin and haemoglobin. This laser is used much less now 
because of the use of semi-conductor lasers which are more reliable and 
efficient.
4.6.2 Carbon dioxide laser.
The carbon dioxide (CO2) laser is one of the most commonly used surgical 
lasers. It emits energy in the non-visible portion of the light spectrum (far 
infrared) with a wavelength of 10,600nm. This light is strongly absorbed by 
water and all conventional optical fibres. The laser medium of the CO2 laser is 
a mixture of carbon dioxide, nitrogen and helium gas, held in an air or water- 
cooled discharge tube. The CO2 laser has a high efficiency of 15% and can be
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powered by a single-phase electrical source and does not need an external 
supply of cooling water. As the laser beam is invisible, it is used with a second 
laser, a visible coaxial (red) helium-neon aiming beam. It is used in 
gynaecology in the treatment of cervical intraepithelial neoplasia and at 
laparoscopy.
The output of the CO2 laser is strongly absorbed by all conventional optical 
fibres and the only flexible fibres currently available to transmit the CO2 beam 
are toxic, expensive and relatively inefficient. This limits the use of the CO2 
laser to rigid instruments, which are manoeuvred, with a series of articulated 
arms.
4.6.3 Neodymium Yttrium Aluminium Garnet laser.
The laser medium of the neodymium yttrium aluminium garnet (Nd-YAG) 
laser is a synthetic crystal of yttrium aluminium garnet which has been 
‘doped’ with a small concentration of neodymium atoms. Light from a 
krypton lamp pumps the neodymium atoms into a broad band of high-energy 
states which rapidly decay via non-radiative transitions to long lived 
metastable states. Lasing occurs at the near infra-red 1,064nm wavelength.
One way of achieving population inversion is to use materials in which the 
laser transition is not between a pumped and the ground state but between two 
other energy levels. This is the case with the Nd-YAG laser, which is a four 
level laser system. The pumping energy raises some of the Neodymium into a 
higher (E3) energy level. This decays rapidly to the E2 level and the laser 
action occurs between the E2 and El levels with the latter decaying rapidly to 
the ground (EO) state. Because the laser transition is slower than the others,
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population inversion between the laser levels (E2 and El) can occur with the 
vast majority of particles still in the ground state (Geusic et al 1964).
The Nd-YAG laser is usually run as a continuous wave system. However 
using a Q-switch can produce very short, high-powered pulses. This is a 
shutter, which is placed inside the laser cavity preventing the normal 
movement of light, and thus inhibiting stimulated emission. The laser medium 
in a switched laser can be pumped to an energy level far greater than one 
which would normally induce a population inversion and thus stimulated 
emission. Therefore when the shutter is opened, the energy stored within the 
laser medium is released as a single optical pulse with duration of about 1 0  
nanoseconds and a peak power of a gigaWatt (109 Watt).
The efficiency of the Nd-YAG laser compared to other lasers is relatively low. 
Most Nd-YAG lasers require a three-phase electrical power source and a 
supply of cooling water, although newer designs can run on single-phase 
electricity without external cooling water. To enable visualisation of the path 
of the invisible infrared beam, a coaxial visible red beam of a low power 
helium-neon laser is used. Both the visible red and near infrared beams can be 
transmitted by small diameter optical fibres.
4.6.4 Potassium-titanyl-phosphate laser.
The potassium-titanyl-phosphate (KTP) laser produces green light of 
wavelength 532nm, which can be transmitted along flexible fibres. This laser 
is simply an Nd-YAG laser whose beam is passed through a KTP crystal, 
which doubles the frequency and so halves the wavelength. It is used 
laparoscopically in the treatment of polycystic ovarian disease and for ovarian
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endometriomas. Like the argon laser it produces more tissue coagulation than 
the CO2 laser but less than the Nd-YAG.
4.6.5 Dye lasers.
Dye lasers have the advantage of producing light with a large range of 
tuneable wavelengths. The laser medium is a dye, such as coumarin or 
rhodamine, in a solvent like ethanol. A typical dye is able to lase at any 
wavelength within a continuous range of about 70 nm and different dyes 
produce different ranges. The efficiency of a dye laser is relatively high at 
25% but it needs to be driven by another laser (e.g. argon or copper vapour 
laser). These lasers are used in photodynamic therapy.
4.6.6 Metal vapour lasers.
A number of metals can be made to lase when in their vapour phase. They 
include copper, which lases at 511 nm (green) and 578 nm (yellow), and gold, 
which lases at 628 nm (red). Metal vapour lasers can only operate in a pulsed 
mode with a high repetition rate. These lasers are used in photodynamic 
therapy.
4.6.7 Excimer lasers.
Excimer is a contraction of ‘excited dimer’ and these lasers provide a source 
of ultraviolet light. The laser medium of an excimer laser is a volume of gas in 
which the atoms will only form dimers when in an excited state. These excited 
molecules will immediately dissociate and release high-energy ultraviolet light 
on returning to the ground state. The first excimer laser used excited dimers of 
xenon (Xe2 ). More modem lasers use a rare gas atom (argon, krypton, and 
xenon) combined in the excited state with a halogen atom (fluorine, chlorine,
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bromine). Examples of rare gas-halide excimer lasers are argon fluoride with a 
wavelength of 193nm and krypton chloride with a wavelength of 222nm. 
Excimer lasers can be pumped either by an electron beam or by an electrical 
discharge. The output is pulsed and the length of each pulse is about 10-20 
nanoseconds. The beam can be transmitted along a fibreoptic system only at 
wavelengths above about 300nm. These lasers are still in the experimental 
stages, in certain cases such as in angioplasty. In ophthalmology they are 
becoming established for reshaping the cornea for the correction of short- 
sight.
4.6.8 Diode Laser.
The diode laser is formed from a tiny chip of gallium arsenide semiconductor 
material. This converts electricity to laser light with a high efficiency of 30% 
thus reducing power demands and heat generation. The tissue effects of a 
805nm diode laser are similar to those produced by a Nd-YAG laser at 1064 
nm. Its main advantages, however over the Nd-YAG laser are that it is easily 
portable, maintenance and service free and needs no special electrical or 
plumbing requirements. It has been claimed that the diode laser can be used in 
all techniques, which previously required a Nd-YAG laser (Wyman et al
1992).
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4.7 Laser Light and Living Tissue.
4.7.1 Light Tissue Interactions.
When a photon of light hits a tissue surface, four interactions can occur and 
are summarised as follows:
1. Reflection at the tissue surface - due to the difference in the optical
properties (refractive index) of air and tissue.
2. Transmission through the tissue (no interaction).
3. Scattering within the tissue- by small particles such as mitochondria in
cells and at cell interfaces.
4. Absorption by the tissue.
This latter effect can lead to the production of heat. By the appropriate 
adjustment of laser wavelength, certain chromophores (light absorbing 
molecules within the tissues) can be targeted for clinical use e.g. intracellular 
water is highly absorbing for CO2 radiation and therefore can be used for 
cutting or vaporisation and is the mechanism seen with thermal surgical lasers 
(Carruth 1984). Alternatively, the wavelength can be used to target 
photosensitisers and cause a photosensitised change to the cell (photodynamic 
therapy). If it is reflected from or transmitted through the tissue no effect will 
occur. If the light is scattered, it will be absorbed over a larger volume so that 
its effects will be more diffuse (Parrish et al 1985). Only absorbed light can 
produce a biological effect.
However unlike ordinary light, laser light has several special qualities. It is 
highly collimated so the laser beam can be focused to a very small spot size 
and very high irradiances can be achieved and large amounts of energy can be
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deposited very precisely in the tissue. It is also monochromatic light, which 
can penetrate varying distances into tissue according to its wavelength. 
Ultraviolet light (193-400 nm) is very strongly absorbed. Visible light (400 - 
700 nm) becomes more weakly absorbed as its colour chances from blue to 
red and in the near infrared (around 1000 nm) tissue becomes relatively 
transparent. Further into the infrared spectrum, absorption again increases 
above 1300 nm. The CO2 laser has a wavelength of 10,600 nm and is very 
strongly absorbed in water.
4.7.2 Light penetration into tissue.
The depth of light penetration in tissue is a very important feature in 
photodynamic therapy, as the action of light on the photosensitiser is crucial to 
the destruction of tumours. The depth of light penetration through different 
tissues is a function of the optical properties of that tissue, specifically 
absorption and scattering coefficients and the scattering angular distribution. 
These factors are related to the tissue chromophores in addition to the 
wavelength of the laser light itself.
The opacity of a tissue is defined as the attenuation coefficient whilst its 
inverse is the penetration depth of light, which is the depth when the incident 
light intensity drops to approximately 37% of the initial value (1/e). 
Penetration depths into tissue typically range from l-2mm to nearly 5mm at a 
wavelength of 630nm used for sensitiser activation with Photofrin and PPIX 
(Dougherty & Marcus 1992), while the penetration depth is almost doubled at 
700-850nm (Wilson et al 1986). This improved penetration depth at longer 
wavelengths has prompted the development of sensitisers that absorb in this 
region. Examples of such sensitisers include, benzoporphyrin derivative which
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absorbs at 690nm, the chlorins (652-660nm) and the naphthalocyanines which 
absorb strongly at 760nm (Dougherty & Marcus 1992). However, absorption 
of light by the photosensitiser itself can limit tissue penetration and is 
particularly pronounced with high concentrations of sensitisers, which act as 
very strongly absorbing chromophores at the treatment wavelength, (Wilson et 
al 1986).
4.7.3 Thermal effects of laserlight.
Lasers deliver energy to tissue that is absorbed as heat, so their most common 
clinical effects are thermal. Regardless of the laser system, laser light that has 
been absorbed by tissue may cause hyperthermia, coagulation and 
vaporisation, effects which are temperature dependent (Welch 1984).
4.7.3.1 Hyperthermia.
This process involves gentle heating of the tissues to produce cell death 
without major alterations in tissue architecture (Matthewson et al 1987). 
Tissue temperatures usually remain within the subcoagulation range, which is 
less than 60°C.
4.7.3.2 Coagulation.
Temperatures below boiling point can be used to treat large volumes of tissue, 
the Nd-YAG laser is particularly effective because it has a greater ability to 
penetrate tissue than other lasers such as the CO2 .
4.7.3.3 Vaporisation.
If the tissue is allowed to heat to greater than 100°C, boiling takes place within 
the intracellular water. The rapid rise in intracellular temperature and pressure 
causes cellular explosion creating steam and cellular debris. This steam and
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debris is seen as the laser plume. The plume remains in the path of the laser 
beam and the particle fragments flash white-hot as they are carbonised.
Three types of thermal laser are in widespread clinical use: the CO2 laser, the 
Nd-YAG laser and the KTP laser. The CO2 laser light is strongly absorbed in 
water, whereas the other two are absorbed more in pigmented cells (Fenech et 
al 1985). Any laser of sufficient energy to be absorbed at the tissue surface 
results in the superficial cells being destroyed and further application of the 
beam will bore a hole in the tissue (Garrison and Srinivasan 1985). However 
beneath the area of vaporisation there is a zone of coagulation which varies in 
depth depending on the laser used. The CO2 and Nd-YAG lasers cause 
coagulation to a depth of 0.1mm and 5mm respectively (Litwin and Earle 
1965).
Initially, heating of soft tissue causes thermal contraction of the treated area 
and as tissue shrinks, small vessels are sealed, which can stop haemorrhage. 
Thrombosis in occluded vessels only occurs as a secondary effect. The Nd- 
YAG laser can heat large volumes of tissue and can therefore seal vessels with 
a diameter up to 1mm in suitable supporting tissue. The volume heated by the 
CO2 laser outside the area of vaporised tissue is so small that it has little effect 
on major haemorrhage, although it can seal capillary oozing particularly when 
a large defocused spot is used. The CO2 laser has a highly localised effect on 
tissue and therefore acts as a laser knife with the cells immediately under the 
beam becoming vaporised with minimal damage to adjacent areas.
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4.7.4 Non-thermal effects of laser.
Light can produce non-thermal effects in tissue, which include photoablation 
and the activation of photochemical reactions in photosensitive dyes (the basis 
of photodynamic therapy). Photoablation occurs when using light with a short 
wavelength (ultraviolet) because the photon energy may be great enough to 
directly disrupt molecular bonds within tissue. The excimer laser is said to 
exert its effect by means of photoablation.
4.7.5 Photodynamic therapy.
Photodynamic therapy (PDT) involves the pre-treatment of target tissues with 
photosensitising agents which enable light within the visible or infrared region 
up to about 1 OOOnm to produce a severe cytotoxic effect. It has been observed 
that certain tissues, particularly tumours, selectively retain the photosensitiser 
while adjacent tissue areas contain very little (Gomer & Dougherty 1979), 
although this selectivity has often been over emphasised (Bown 1990). Light 
at a specific wavelength corresponding to an absorption peak of the 
photosensitiser is then used to activate this drug to produce local necrosis in 
the required area and leave adjacent tissue undamaged.
4.8 Laser and light delivery systems.
Delivery of light allowing optimal irradiation of the whole target tissue is 
essential to the success of photodynamic therapy. The distribution of light 
must not only match the geometric but also the optical characteristics of the 
target tissue, in order to optimise tumour kill and minimise damage to the 
normal surrounding tissue (Wilson & Patterson, 1986). The light source used 
for PDT must be capable of providing the appropriate wavelength of light
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matched to the sensitiser to be used, of an adequate intensity to allow 
treatment to be carried out in a reasonable length of time and be coupled to an 
appropriate light delivery system (which can be selected for different 
geometries).
4.8.1 Light sources.
Various types of light sources are available for photodynamic therapy as lasers 
are not essential. Historically sunlight has been used (von Tappeiner and 
Jesionek 1903), whilst wavelength filtered lamps have been used in the past 
with a recent revival of interest due to low cost production, running cost and 
size (Dougherty et al 1975; Morton et al 1995)
Before the development of diode lasers, the most commonly used lasers for 
PDT were tuneable dye lasers, which are wavelength conversion devices. The 
dye laser is ‘pumped’ by another laser and converts the energy from the pump 
laser by the use of fluorescent dyes such as rhodamine. This results in a 
tuneable output over a range of 30-50 nm (620-650 nm), and such devices 
have been used extensively in PDT related research. The advantage of dye 
lasers is their tunability over parts of the visible spectrum. Copper vapour and 
argon ion lasers are frequently used as the ‘pump laser’ due to strong 
absorption by rhodamine dyes at the green wavelength. The dye can be 
changed to provide different range of wavelength.
The copper and gold vapour lasers are bulky and too expensive for most 
hospitals to purchase specifically for PDT. However, many surgical units 
already have a potassium titanyl phosphate (KTP) Nd:YAG laser that can also 
be used to pump a dye module. The ultimate ‘black box’ laser for clinical use
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must be the diode lasers which make use of semiconductor technology to emit 
light with high power output and are currently available at, for example, 630, 
652 and 675nm for use with ALA, mTHPC and phthalocyanines. These 
compact size lasers are not only portable but significantly cheaper and more 
user friendly than the other laser systems making them particularly attractive 
for PDT use in non specialised units who do not have easy access to technical 
support. The disadvantage of the diode lasers is their lack of tunability, which 
means that extra systems would need to be acquired if using more than one 
sensitiser at different wavelengths.
There has also been renewed interest in non-laser sources particularly for 
dermatological applications. A lamp incorporating a 300W xenon short arc 
plasma discharge with a bandwidth filter of 30nm has been developed 
(Whitehurst et al 1993; Whitehurst et al 1995). Such light devices may further 
complicate light dosimetry, as a percentage of the incident light may not be of 
an appropriate wavelength to activate the sensitisers especially with sensitisers 
that have very narrow absorption bands. Consequently more energy may be 
required than with laser light to achieve the same PDT effect, the presence of 
infrared light will further complicate matters.
4.9 Lasers used in gynaecology.
Lasers have been used quite extensively in the past for various conditions. 
They are now virtually never used, except at laparoscopy.
The CO2 laser was first used in 1973 for the treatment of cervical lesions by 
vaporisation (Kaplan et al 1973). Unlike diathermy or cryosurgery there was 
little post-operative pain. Treatment of cervical intraepithelial neoplasia (CIN)
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has cure rates of more than 90% (Berget 1987). Laser treatment has the 
advantage of destroying or removing less tissue, with more than 95% success 
rates (Anderson 1982). The main disadvantage of laser is the lack of a 
histological specimen.
The CO2 laser has also been used for vaginal intraepithelial neoplasia (VAIN) 
(Graham & Meigs 1952). It was also used with great effect for vulval 
intraepithelial neoplasia (VIN) (Baggish and Dorsey 1981). The depth of VIN 
removal with the laser is 1mm in non-hairy skin and 2mm in hairy skin (Shatz 
et al 1989). Success rates of 90% are quoted.
4.10 Laser safety.
All lasers on the University College Hospitals sites are used under the 
supervision of a physicist and a Laser Protection Adviser (who may be the 
same person). The responsibilities of these persons are several. These include 
drawing up local rules on laser use, certification of laser operators, planning 
new areas for laser use or modifying existing areas, recording use of laser and 
serving as a contact for any questions.
Lasers are dangerous for two main reasons, the output from the laser and the 
power source used to created the output.
4.10.1 Optical safety.
The Bureau of Radiological Health (1975) classifies lasers based on the 
potential hazards. A laser using visible light will be a hazard because if shone 
into the eye, the beam will be focused on the retina by the lens and coagulate 
it if of sufficient energy. Ultraviolet lasers are heavily absorbed by the cornea
causing damage. Class I lasers are virtually harmless whereas Class IV are 
damaging at all exposures.
4.10.2 Skin safety.
Exposure of the skin to high-power lasers will cause burning. In a conscious 
surgeon this results in rapid withdrawl of the affected part. However, if the 
optical fibre is damaged the patient may be at risk.
4.10.3 Electrical safety.
High voltages are required to energise the laser. This is often facilitated with 
capacitors within the device. The capacitors may store the voltage for days; 
they remain dangerous unless the electricity is discharged.
The BRH classifies all therapeutic lasers as Class IV and dangerous. Their use 
is restricted to a designated Laser Controlled area. To protect the eye, different 
goggles are worn to protect against different wavelengths.
All safety rules were rigorously applied and observed during experimentation 
in this thesis.
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CHAPTER 5: PHOTODYNAMIC
THERAPY.
5.1 Introduction.
Light is electromagnetic radiation in the 250-900 nm wavelength. Ultraviolet 
light is 200-400 nm, visible light is in the region 400-750 nm, and infrared 
beyond 750 nm. Light may originate from many different sources, from the 
sun to lasers of specific wavelength.
Phototherapy is the use of light in the treatment of disease. Phototherapy 
involves a light-activated chemical process. An example is the treatment of 
neonatal hyperbilirubinaemia with ultraviolet (UV) and visible light, where no 
drug is used.
Photochemotherapy is a subdivision of phototherapy and involves the 
absorption of light energy by an exogenous molecule, which enters a higher 
energy state. This activated molecule then imparts its energy to tissues and 
causes the desired therapeutic action (Epstein 1990). An example of this is the 
use of a psoralen in combination with ultraviolet light (UV-A) in the treatment 
of psoriasis.
Photodynamic therapy (PDT) is a type of photochemotherapy. PDT is a 
technique based on the interaction of a drug (photosensitiser) with incident 
light of an appropriate wavelength, in the presence of tissue oxygen (Foote 
1984). This results in a photochemical reaction, resulting in the formation of 
singlet oxygen or other high energy oxygen radicals, which react with tissue 
components to cause cellular damage (Bonnet 1999). This damage can be by 
either direct cell killing or indirect effects (for example by direct effects on the
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blood vessels). The photosensitiser is administered either systemically or 
topically. After a delay (the drug-light interval) the target tissue is irradiated 
with light, and a maximal destructive effect is obtained in the target tissue 
with less effect on adjacent tissues.
5.2 History of photodynamic therapy.
Light has been used as a therapeutic tool for centuries, dating back to the 
ancient civilisations in Egypt, India and China. Light from the sun was used to 
treat such conditions as vitiligo, rickets, psoriasis, cancers and even 
psychiatric conditions (Spikes 1985; Epstein 1990).
In the sacred Indian book Atharva Veda dating from 1400 BC, the ‘cure’ for 
leprosy and vitiligo was the ingestion of certain black seeds (now thought to 
be from the plant Bavachee, a species known to contain psoralen), together 
with Bringaraga (Ecclipta prostata), Indravaruni (Colocynth) and tumeric 
(Curcuma longa) then to expose the affected area to the sun (Fitzpatrick et al 
1958, Daniell and Hill 1991). Herodotus first documented the healing 
properties of light and developed heliotherapy (Daniell and Hill 1991). 
Hippocrates in the fourth century BC advocated the use of the solarium for 
building up wasted muscles (Bonnett 1999).
Modem heliotherapy reappeared in Switzerland at the start of the twentieth 
century. It was used by Bernhard and Rollier for the treatent of the skin 
manifestations of tuberculosis (Rollier 1927).
Phototherapy is used in the treatment of jaundice in the newborn, and was 
introduced in the late 1950s (Cremer et al 1958). Bilirubin is a neural toxin 
and the only treatment available prior to this discovery was for an exchange
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transfusion. There are actually two mechanisms involved; photosolubilisation, 
whereby bilirubin is converted to soluble photoisomers, and 
photofragmentation in which the bilirubin is photo-oxidised to soluble by­
products which are then excreted (McDonagh and Lightener 1985).
Niels Finsen, a native of the Faroe Islands, trained and worked in 
Copenhagen. He advocated the use of light devoid of ultraviolet radiation (ie 
red light) to reduce the scarring from smallpox. He also showed that light from 
a carbon arc light could be used to treat lupus vulgaris - the skin manifestation 
of tuberculosis. This condition was almost endemic in Scandinavian countries 
and he was acclaimed. The Finsen Medical Light Institute was set up and he 
was awarded the Nobel Prize in 1903 for his work on phototherapy. Queen 
Alexandra brought the idea to London from Denmark and as President of the 
London Hospital set up the Light Department in the early 1900s. This 
department was still functioning in the late 1920s.
The modem history of Photodynamic therapy can be traced back to the turn of 
the century. A German medical student, Oscar Rabb, working under von 
Tappeiner, was able to photo sensitise paramecia with acridine dye and kill 
them with light (Rabb 1900). His experiments were initially to record the 
behaviour of the paramecia, however, he noticed that on normal days the 
paramecia were all killed, yet on overcast days they were not. By setting up a 
series of experiments he showed, in a seminal piece of work, that it required 
the presence of both light and the acridine to cause death in the paramecia. 
von Tappeiner recognised that oxygen was also an essential requirement and 
coined the term ‘photodynamische Wirkung’ - photodynamic effect (or 
action). Later, in 1903 von Tappeiner and Jesionek, a dermatologist, published
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the first clinical study using PDT. They used topically applied eosin activated 
by an arc lamp to treat skin cancer successfully (von Tappeiner and Jesionek 
1903). However, it was almost 60 years before PDT was used to treat cancer 
again.
Extensive research on psoralens began in 1941 by Fahmy in Egypt. He 
isolated several furocoumarins from a powder called ‘Atrillal’, derived from 
the fruits of Ammi magus a weed growing along the Nile used by herb 
doctors. This was used to treat vitiligo. The results of a clinical trial were 
encouraging (El Mofty 1952), and soon after two of the compounds were 
identified as 8-methoxypsoralen and 8-isoamylene-oxypsoralen were 
marketed by an Egyptian firm. Confirmation of these results followed in 
France (Sidi and Bourgeois-Gavardin 1952), and the USA (Lemer et al 1952).
Lipson used haematoporphyrin derivative (HpD) as a photosensitiser for PDT 
in a case of recurrent breast cancer on the chest wall. HpD is a complex 
mixture of blood derived porphyrins. The chest lesion showed some response 
but was not cured (Lipson 1966). Apart from another case report of PDT 
being used, this time in bladder cancer (Kelly et al 1975), it was not until 1976 
that the first studies were carried out using PDT by Dougherty and co-workers 
(Dougherty et al 1978). Parrish et al (1974) showed that taking oral 
methoxypsoralen and then using UV-A exposure to the affected skin could 
treat psoriasis; this is now known as PUVA (psoralen-UVA).
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5.3 Mechanisms Of Photosensitisation.
On absorbing light of the appropriate wavelength, the sensitiser is converted 
from a stable electronic structure (S°, the electronic ground state) to an excited 
state known as the singlet state (S1*).
S1* is short lived, being consumed by other processes, and may undergo 
conversion to a longer-lived excited state known as the triplet state (T1*), 
which is the photoactive state responsible for the photochemical generation of 
cytotoxic species.
S1* can convert back to the ground state, decaying and giving off light -  
known as fluorescence, or by giving off the energy as heat.
The lifetime of the singlet state is generally less than 1 microsecond (Ds) and 
the main role of this state in the photosensitisation mechanism is to act as a 
precursor of the metastable triplet state. The excitation efficiency is defined as 
the triplet state quantum yield (DT), which for photosensitisers should ideally 
approach unity, i.e. one triplet state formation per absorbed photon. Interaction 
of the metastable triplet state (which in oxygen deplete solutions has a lifetime 
extending to the millisecond range) with tissue components may proceed via 
either a type I or II mechanism (or a combination). A type I process can 
involve hydrogen abstraction from the sensitiser to produce free radical.
The type II mechanism, in contrast, exclusively involves interaction between 
molecular oxygen and the triplet state to form an electronically excited state of 
O2 known as singlet oxygen (’C^*), which is highly reactive in biological 
systems. It is widely thought that the type II mechanism underlies the oxygen- 
dependent photocytotoxicity of sensitisers used for photodynamic therapy.
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A number of the biomolecules in cell membranes react rapidly with singlet 
oxygen. Cell membranes - and mitochondrial membranes in particular - are 
prime targets for PDT damage and cell death (Gomer et al 1988).
When the sensitiser transfers electronic energy to O2 it returns to its ground 
state. Thus the cytotoxic singlet oxygen species is produced without chemical 
transformation of the photosensitiser. It is then free to absorb another photon 
and repeat the cycle. A single photosensitiser molecule is capable of 
generating many singlet oxygen molecules, provided the oxygen supply is 
adequate.
However, there are two thresholds, which must be exceeded before a PDT 
effect can be produced. A minimum tissue concentration of photosensitiser is 
needed, as below this threshold level the photosensitiser may be inactivated by 
photodegradation before sufficient singlet oxygen is produced to cause any 
biological damage. Photosensitisers generally possess long-lived triplet states 
with high triplet-state and singlet oxygen yields; yet these same chemicals are 
prone to photodegradation caused by ‘auto-oxidation’ by the singlet oxygen.
Finally, the product of the total light energy absorbed at each point and the 
tissue concentration of photosensitiser at the time of light exposure is 
important. If the concentrations of photosensitiser in a specific tissue layer is 
too low there will be no PDT damage, whatever the light dose.
Photosensitisers tend to have selective uptake by proliferative and therefore 
neoplastic tissues. This allows targeting of these tissues for successful PDT, 
for example in tumours and in the regenerating endometrium. In general all 
photosensitisers have a strong affinity for tissues with a high reticulo-
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Figure 5.1: Mechanism of photodynamic therapy
endothelial component (Henderson and Dougherty 1992). A simplified 
mechanism of PDT is outlined in figure 5.1.
Different photosensitisers have different time intervals between administration 
and peak tissue levels. Indeed, this may also vary between tissues. The time 
for metabolism or excretion is also highly variable, lasting from hours to some 
weeks.
5.4 Mechanisms of tissue destruction.
5.4.1 Cellular targets of PDT.
Subcellular sites of tissue damage caused by PDT include the plasma 
membrane, many organelle membranes and in particular the mitochondria
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(Gomer et al 1980). There is evidence of direct DNA damage, but this is not a 
determinant of cytotoxicity (Fisher et al 1995). Apoptosis is also induced by 
PDT and is probably induced via the cell membrane. However the significance 
of apoptosis compared with necrotic cell death in the PDT effect is not clear 
(Fisher et al 1995).
5.4.2 Vascular destruction versus direct cell death.
van Geel et al (1996a) showed that vascular injury was a major factor in the 
efficacy of PDT in mouse tumour destruction. Endothelial cells and 
macrophages are known to be highly sensitive to photosensitisation. 
Irradiation of these sensitised cells will cause the release of various vasoactive 
and inflammatory agents, which affect the microvasculature in a target organ 
(Henderson and Donovan 1989).
5.5 Photodegradation (photobleaching) of the 
photosensitiser.
Photosensitisers are generally stable, but will tend to degrade in response to 
light irradiation. Thus, during PDT, the concentration of active photosensitiser 
decreases (Wyss et al 1995). The efficiency of PDT is, therefore, maximal at 
the beginning of light exposure. Photobleaching occurs maximally at the 
surface where the fluence rate is higher. There is therefore a finite amount of 
singlet oxygen that a given amount of photosensitiser can produce.
5.6 The development of photosensitisers.
In the early part of the twentieth century, Oscar Raab had used acridine dye in 
his seminal work with paramecia. von Tappeiner had conducted the first 
clinical trials with eosin. This work was extended to include other sensitisers
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with similar results. Policard in 1924 noticed that there was a (presumed) 
porphyrin fluorescence seen in experimental tumours. This association 
between porphyrins and cancers was shown by experimental tumour 
photonecrosis by Auler and Banzer in 1942 in Berlin. In the late 1940s Figge 
and co-workers showed that haematoporphyrin selectively localised in 
experimental tumours. It was not until Lipson et al introduced 
haematoporphyrin derivative (HpD) that PDT started to have an impact on the 
scientific and medical community (Lipson 1964). Lipson and his colleagues 
used HpD not for treatment but more for diagnosis (Lipson et al 1964; 
Kyriazis et al 1973). This led to the development of fluorescence endoscopy, 
and photodiagnosis.
Diamond et al demonstrated photonecrosis of a tumour in a rat in 1972. They 
showed that PDT was of possible therapeutic importance. Diamond was the 
one who reintroduced the term photodynamic therapy into use.
Several centres then started to investigate HpD and other photosensitisers. 
Dougherty et al made the biggest breakthrough in 1975. They showed a 48% 
cure rate in transplanted animal tumours treated with HpD-induced PDT. 
Dougherty followed this up with a study looking at PDT for tumours in 25 
patients at several sites including breast, prostate, colon and skin. He stated 
that ‘no [cancer] type has been found to be unresponsive’ (Dougherty et al 
1978).
The commercialisation of HpD and its derivatives has proceeded in various 
countries. The most significant development has been with Photofrin 
(QuadraLogic Technologies Inc, Vancouver, Canada), which was approved 
for the treatment of bladder cancer in Canada in 1993. This was followed by
98
approvals in Japan, the USA, France and the Netherlands for a variety of 
cancers (e.g. lung, oesophagus, stomach, cervix, bladder).
HpD and its derivatives were termed ‘first generation’ photosensitisers, as 
newer ‘improved’ drugs became available. However, only ALA is approved 
by the FDA in topical use for actinic keratosis. Foscan is approved for use in 
palliation of advanced oral cancers.
Most of the second-generation photosensitisers belong to the tetrapyrrole 
class. The advantages of this is that these substances are usually completely 
inert in the absence of light, they are stable and generally have intense 
absorption peaks in the red part of the visible spectrum which is where tissue 
transmission is most efficient and they are efficient generators of singlet 
oxygen.
5.6.1 Porphyrins.
Several porpyrins have been examined. For example, 5,10,15,20-tetrakis(m- 
hydroxy-phenyl)porphyrin (m-THPP) was found to be 25-30 times more 
potent than HpD (Berenbaum et al 1986).
An exciting development has been to administer a pro-drug to generate 
endogenous porphyrin. 5-aminolaevulinic acid (ALA) (Deprenyl-USA - 
DUS A, Toronto, Canada) is a pro-drug, which can be given orally, 
intravenously or topically. It forms part of the haem biosynthetic pathway and 
is converted to the active photosensitiser protoporphyrin IX (Kennedy and 
Pottier 1992). The absorption of the porpyrins is, however, weak in the red 
range with a small peak at 630 nm. ALA is gaining an increasingly important 
role in PDT and is the sensitiser used in the experimental work of this thesis.
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5.6.2 Chlorins.
Chlorins have a strong absorption in the red region. m-THPC (Scotia 
QuantaNova pic, Guildford, UK) is at an advanced stage of clinical trial 
directed at advanced oral cancers. These compounds tend to have peak 
absorption spectra in the range 650-700 nm (Bonnett 1995). The chlorins and 
bacteriochlorins are produced by progressive reduction of the porphyrins.
5.6.3 Phthalocyanines.
These compounds, again, have a strong absorption in the red region. The zinc 
derivative is biologically active (Novartis (Ciba-Geigy), Basel, Switzerland), 
but because of the extreme hydrophobic nature of these compounds, a 
liposomal delivery agent is required. A peak absorption spectra for these 
compounds is in the range 670-750 nm. The aluminium derivative is soluble 
in water and has considerable potential as a photosensitiser.
5.7 Light delivery.
The peak absorption of the porphyrins is in the blue range, however 
endogenous substances such as haemoglobin also absorb strongly in this part 
of the spectrum. This results in very little light penetration in this range. At 
wavelengths above 600nm the haemoglobin absorption spectrum falls 
considerably, and although the absorption of most photosensitisers is not 
maximal, it is this range that is generally chosen for PDT. PPIX, the active 
metabolite of ALA has a red absorption maxima at 635nm which is almost 35 
times less than the blue absorption maxima at 405nm (Kimel et al 1989). Also 
the longer the wavelength the better the tissue penetration.
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At a wavelength between 600 and 800 nm, and dependant on the tissue, 
approximately 30% of incident light is reflected in the surface layers 
(Svaasand et al 1989). The photons that are propagated are then multiply 
scattered before being absorbed. After a distance of 1-2 mm these multiple 
scattering events produce near isotropic light distributions in most tisuues 
(Wyss et al 1995).
5.8 Light penetration in tissues.
Light penetration in tissues decreases exponentially with distance because of 
scattering and absorption. The penetration depth (mm) is defined as the 
distance corresponding to a decrease in the optical fluence rate by a factor of 
1/e (where e = 2.718) (Svaasand 1984).
The fluence rate is the quantity of photons that pass through a defined area per 
second (mW/cm2).
The average light penetration in tissues is about 1-3 mm at a light wavelength 
of 630 nm and 2-6 mm at 800 nm. Therefore if the optical penetration of a 
tissue is 3mm, the fluence rate at a depth of 3mm will be 37% of its rate at the 
surface. If the distance is doubled to 6mm the fluence rate will be 1/e2 or about 
10%. The optical penetration depth of a tissue is a unique parameter of that 
tissue.
In a hollow organ such as the uterus where a light delivery system is placed 
within the uterine cavity, the fluence rate may be increased by a factor of 5 or 
6 due to the additional internal reflection of light by the surrounding tissue 
walls (Wyss et al 1995).
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5.9 The optical dose.
This is defined as the irradiation (W/cm2) multiplied by the exposure time 
(seconds). The optical dose (J/cm2) decreases with depth into the tissue in a 
similar way to the fluence rate. Altering the incident power or altering the 
exposure time can alter the optical dose.
Previous work has shown that endometrial destruction using ALA-PDT, in 
rabbits, is extremely successful. When the technique is transferred to humans 
it is much less successful. This is mainly due to the fact that the human 
endometrium is much thicker than the animal model.
5.10 Summary.
Studies to date have shown that ALA is a safe drug to use. Peak PPIX 
fluorescence levels appear to be seen between 3 and 6 hours after the 
administration of ALA with a degree of variability between species. Certainly 
the variability of PPIX levels is dependant on oestrogen (and therefore 
menstrual cycle).
ALA-induced PDT destruction of the endometrium using light at 630nm is 
very effective in a small animal model. The success of this modality for 
human endometrial ablation has not been forthcoming (Gannon 1998). So 
little data has been published in humans that is difficult to know how to alter 
parameters to enable a more consistent effect. Several variables may be 
apparent in the human. First the endometrium is much thicker than the animal 
model. Light distribution in the triangular-shaped cavity may be a problem.
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SECTION TWO 
EXPERIMENTATION.
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CHAPTER 6: AIMS AND OBJECTIVES
The review of non-hysterectomy treatments for menorrhagia has shown that 
none is entirely satisfactory. The use of ALA-induced PDT for the treatment 
of menorrhagia in women is particularly attractive because the principle is 
simple and the drug has been shown to be safe. The administration of the drug 
and the treatment itself has the potential to be performed without the need for 
a general anaesthetic and can therefore be thought of as an “ambulatory 
treatment”. Previous animal work has been very encouraging with ALA- 
induced PDT. The human, clinical, work has so far been disappointing with 
very poor success (Gannon et al 1998).
We have a technique for enhancing ALA-PDT of the endometrium in women 
that has not been tried previously, using the iron-chelator CP94.
The objectives of this thesis, therefore, are:
i. to assess whether using topical CP94 in combination with ALA 
can maximise levels of PPIX in the endometrium;
ii. to assess different preparations of ALA, using different solute 
mediums and different levels of pH;
iii. to treat normal rabbit endometrium with PDT using ALA either 
alone or in combination with CP94 to find the conditions under 
which endometrial ablation is most complete and most long- 
lasting;
iv. to assess the distribution of light in the human uterine 
specimens from hysterectomies with a range of light delivery
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devices to find which gives the most even distribution of light 
to all areas of the endometrium, and
v. to propose how these results might be taken forward in clinical 
studies.
vi. to put PDT in context with other modalities for the treatment of 
menorrhagia.
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CHAPTER 7: MATERIALS AND
METHODS.
7.1 Introduction.
The endometrium has a phenomenal regenerating capacity in both humans and 
other mammals (Ferenezy 1977; McLennan and Rydell 1965; Schenker et al 
1971). To prevent regeneration, endometrial destruction by photodynamic 
therapy (PDT) must extend within the endometrium to include the deep 
glandular tissue. To perform successful PDT to the endometrium resulting in 
lasting endometrial destruction, drug concentrations should be as high as 
possible throughout the endometrium. Higher drug concentrations will then 
result in an increased PDT effect, assuming that the light dose is above the 
threshold value. Systemic administration limits the endometrial drug 
concentration because of side effects. As a result topical administration with 
an enhancer would appear to be the best strategy.
We were interested in optimising human endometrial destruction, yet had to 
show the improvements in the animal model. Several other workers had 
shown PDT in the animal model to be highly effective (Wyss et al 1992; Yang 
et al 1993; Fehr et al 1996; Wyss et al 1996). Showing a difference in the 
PDT effect was, therefore, potentially difficult. Rather fortuitously the laser 
that we used for ALA-PDT was a commercially available Diode Laser 
(Diomed Ltd, Cambridge, UK). It was supplied with a quoted output of 
630nm by the company. When we tested this output we measured it at 628nm 
(+/- 1 nm) (figure 7.1).
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Figure 7.1: Measured wavelength of LASER output.
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Figure 7.2: Area of necrosis produced by different 
lasers after PDT to the bowel mucosa.
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We know from Cumow’s work that there is nearly a three times increase in 
tissue damage when the laser wavelength is changed from 628nm to 635nm 
(figure 7.2). This meant that the differences in tissue destruction that we were 
to observe would be maximal with the sub-optimal laser.
7.2 Materials
7.2.1 Aminolaevulinic acid (ALA).
The administration of ALA to metabolising tissues results in the biosynthesis 
of protoporphyrin IX (PPIX). These tissues where there is an accumulation of 
PPIX will fluoresce at 670nm (red) when exposed to and excited by light at 
635nm.
PPIX is the direct precursor of haem in the haem biosynthetic pathway (figure 
7.3). All nucleated cells are able to synthesise haem. Also a number of haem- 
containing enzymes are crucial in energy metabolism. By adding excess ALA 
to a tissue, an accumulation of PPIX will occur; as the metabolism of PPIX to 
haem with the chelation of iron by ferrochelatase is the rate-limiting step, and 
therefore by definition is slow. Thus PPIX synthesised in vivo is used for PDT 
by the tissues (Kennedy and Pottier 1992). ALA is, therefore, a pro-drug used 
for PDT. In certain tissues, most notably certain tumours, the haem 
biosynthetic pathway is disrupted which results in a naturally occurring 
accumulation of PPIX. This results in selective PDT destruction, with relative 
sparing of adjacent tissues (Peng et al 1997). This may also be utilised for 
photodiagnosis.
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Figure 7.3: Schematic diagram of the haem biosynthesis 
pathway.
The committed step in the synthesis of haem is the condensation of glycine 
and succinyl-CoA. The enzyme responsible for this is ALA synthase. It is 
located within the mitochondria, and ALA is exported from the mitochondrion 
to the cytosol. Exogenous ALA, which rapidly enters cells is therefore easily 
converted in the cytosol to coproporphyrinogen III which is then transported 
into the mitochondrion, to form PPIX (Jordan 1991). An increase in the haem 
concentration within the mitochondrion has a negative feedback effect on 
ALA synthase, thus reducing further production of haem. However, by the
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exogenous administration of ALA, this first major control point in the cycle is 
bypassed; there is then a build up of substrate causing a maximal rate of 
operation of all enzymes in the cycle. PPIX accumulates as the enzyme 
ferrochelatase is working relatively slowly. PPIX itself is poorly soluble and 
therefore it is not practical to simply administer this to tissues. The 
administration of other precursors is also limited by solubility and costs 
(Kennedy and Pottier 1992).
ALA is highly water-soluble and can be administered systemically, orally, 
topically or intravenously. ALA in aqueous solution is extremely acidic (pH 1 
- 1.5), but when buffered to a physiological pH (pH 6  - 7) is highly unstable. 
When buffered to pH 4 - 5 it is reasonably stable (Elfsson et al 1998).
ALA is thought to enter cells by active transport, but passive diffusion may 
also occur. Once inside cells, the primary sites of damage on administration of 
light are those where PPIX is produced - i.e. the mitochondria. It may also be 
that damage occurs without light as extremely high levels of ALA and PPIX 
may disrupt respiration and normal cell function (Peng et al 1997).
Unlike other photosensitisers, the PDT effect is maximum within a few hours 
of administration of ALA. Photofrin, by contrast is administered 48 hours 
before PDT (Stewart et al 1998). Side-effects with ALA are also much less. 
The most notable is skin sensitivity, lasting 24-48 hours or so. This is also 
reduced by topical administration.
ALA esters are currently being investigated as a way of improving treatment. 
The esters are more lipophilic and therefore enter cells more rapidly (Peng et
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al 1997). Other methods are used to improve penetration either with azone 
(Steiner et al 1996), or DMSO (Peng et al 1997).
7.2.2 l,2-diethyl-3-hydroxypyridin-4-one (CP94).
The hydroxypyridinones are a relatively new group of iron chelators. They are 
active orally and enter the intracellular iron pools rapidly, being of a low 
molecular weight and of neutral charge (Hoyes et al 1993). These were 
designed to supercede desferrioxamine for the treatment of iron overload 
states. They are well suited to enhancing ALA-induced PDT, as they are of a 
lower molecular weight and have greater lipophilicity than desferrioxamine 
(Brittenham 1992).
CP94 has been used orally in patients with little toxicity, providing effective 
iron mobilisation (Brittenham 1992). It is rapidly absorbed orally, and enters 
all cells by simple diffusion (Hoyes et al 1993). It is excreted in the urine after 
glucoronidation, something that cannot happen in rats, but can in rabbits 
(Porter 1993). It is bidentate compared to desferrioxamine, which is 
hexadentate, and has a much higher affinity for iron, binding in the ratio of 3 : 1  
compared with 1:1 with desferrioxamine (Hershko et al 1991).
Little work has been carried out on CP94 and ALA-induced PDT. It has been 
shown to double the PPIX fluorescence in the urothelium of the rat bladder 
when used in combination with ALA (Chang et al 1997). It has also been used 
in rat colon to increase the PDT effect (Cumow et al 1998). Previous work 
with ALA-induced PDT has used CP94 intravenously.
CP94 will inhibit the final pathway in the conversion of PPIX to haem by 
removing iron (Fe2+) from the pathway. There is thus more PPIX available for
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PDT. Desferrioxamine, and ethylenediamine tetraacetic acid (EDTA) have 
been investigated as enhancers of ALA PDT (Chang et al 1997). EDTA has 
poor penetration into cells. Desferrioxamine is therefore a better enhancer of 
ALA-induced PDT (Berg 1996). CP94 was developed to supercede 
desferrioxamine in the management of iron overload states (Porter 1996).
7.3 Endometrial photosensitisation.
We undertook an initial series of experiments to investigate the 
pharmacokinetics of ALA in the normal rabbit uterus, used alone and in 
combination with l,2-diethyl-3-hydroxypyridin-4-one (CP94). These 
experiments were to investigate whether the topical co-administration of CP94 
would have any effect on the absorption of ALA. There is considerable 
experience using the rabbit model with a number of different photosensitisers 
and ALA especially (Yang et al 1993; Wyss et al 1994; Fehr et al 1996; Wyss 
et al 1996). The pharmacokinetics of the hydroxypyridinone l,2-diethyl-3- 
hydroxypyridin-4-one (CP94) has not been studied in this animal model.
The inherent fluorescent properties of PPIX were used to identify, localise, 
and quantify the levels of photosensitiser within the different layers of the 
rabbit uterus, using the fluorescence microscope. The similar structure of 
PPIX and haem are noted in figure 7.4. It was necessary to confirm other 
workers’ findings about time of peak fluorescence in order to determine 
optimal treatment parameters prior to commencing the photodynamic therapy 
studies.
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Figure 7.4: Chemically similar structures of PPIX and Haem
ALA absorption has not been studied at different pH. We undertook a study to 
compare the pharmacokinetics of buffered and unbuffered solutions of ALA 
used alone and in combination with CP94.
Once the optimal conditions were identified, we performed PDT with both 
ALA alone and in combination to investigate whether there is a difference in 
PDT effect by the addition of CP94. In order to prevent regeneration we also 
undertook long-term studies after PDT to assess the permanency of the 
treatment.
Within the study period several interesting observations were made, and so 
new experiments were undertaken. An example is the photobleaching 
experiment, which was not in our initial planned series of experiments. To 
ease the experimental progression it will be dealt with first, and not in 
chronological order.
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7.4 Animal model.
In women the majority of the genital tract develops from the Mullerian or 
paramesonephric ducts, extending from the genital ridge where the gonads
develop, to the urogenital sinus. The lower ends of the two ducts fuse in the
fallopian tubes, in close proximity to the ovaries. There is thus a single uterus 
with a midline cavity and two fallopian tubes (figure 7.5).
The thickness of the endometrium is 10-20 mm depending on the cycle. The 
only mammals with a similar uterine structure are primates. Primarily because 
of ethical reasons, as well as the number of animals that we would require and 
therefore the cost, it is inappropriate to use primates. The rat model was also 
deemed inappropriate because the rat uterus is made of two uterine horns, 
measuring 1-1.5 cm in length with an extremely thin wall. Instrumentation 
would therefore be difficult, and as cannulation of the structure was required, 
trauma may have had a profound influence on the experimental validity.
Figure 7.5: Human uterus
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Figure 7.6: Rabbit uterus exposed at laparotomy
The rabbit uterus is similar to the rat, in that it has a duplex structure 
consisting of two cervices and two uterine horns of 7 - 10 cm in length (figure 
7.6). The thickness of the endometrium by contrast is 2 - 6  mm with a 
myometrial thickness of 1 - 3 mm. This is less than one tenth that of the 
human uterus. This does mean that the potential for collateral damage to 
adjacent organs would be high, unlike the human where the thick myometrium 
offers a considerable safety buffer. The tubular structure of the rabbit uterine 
horns also allows us to use standard laser fibres for illumination.
7.4.1 Endometrial repair in the rabbit.
There is no menstrual cycle in rabbits. They are reflex ovulators; ovulating 
after copulation or an artificially-induced LH surge. Menstruation can be 
induced by curettage of the cavity (Schenker et al 1971). The regeneration 
seen after curettage (Schenker et al 1971) or cryotherapy (Schenker and
115
Polishuk 1972) has been studied. There is more extensive damage with 
cryotherapy. Early regeneration occurs from the basal crypts of the 
endometrium and is seen within 3 and 12 hours respectively. The primary 
cells are flattened and thus have an extensive coverage within a short period of 
time. Full coverage of the denuded endometrium occurred in the curettage 
group within 48 hours. With maturation of these cells, they became more 
cuboidal and eventually columnar. Internally the rabbit endometrium is 
arranged with finger-like projections (villi) - similar to that found within the 
fallopian tubes of the human. This poses a problem of how to adequately 
illuminate the cavity with PDT. In order to adequately illuminate the deep 
crypts, distension should be employed. High-pressure distension would flatten 
the villi allowing complete illumination. However this pressure would reduce 
the blood supply and therefore the oxygenation, hence reducing the 
photodynamic effect. It was therefore decided to use the standard diffuser 
fibre, to keep the experimentation identical, but with the risk of inadequate 
illumination to the crypts.
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7.5 Methods.
7.5.1 Chemicals.
The Aminolaevulinic acid (ALA) powder (ALA HC1, 99% purity, DUSA 
Pharmaceuticals Inc., New York) was dissolved in saline. It was administered 
into the uterine horns of the rabbits with a concentration of 400mg/ml. The 
l,2-diethyl-3-hydroxypyridi-4-one (CP94) was synthesised and donated in 
powder form from the Pharmacy department at Kings College London (95% 
purity). This was dissolved with the ALA using saline. The resultant solution 
was ALA 400 mg/mi and CP94 lOOmg/ml.
The buffered ALA solution was prepared by dissolving lOOOmg of the ALA 
powder in saline (0.9%). This was buffered by the addition of phosphate 
solution made of 143mg of disodium hydrogen phosphate and 11.4mg of 
potassium dihydrogen phosphate in 10ml of water (23% disodium hydrogen 
orthophosphate; 1.9% potassium dihydrogen orthophosphate), making a 
solution with a pH of 4.5-5.0. The solution was made up with additional saline 
to 2.5 ml. The resultant solution was of 400mg / ml ALA. The ALA and CP94 
combined buffered solution was prepared by adding 250 mg of CP94 powder 
with 1000 mg of the ALA powder, the resultant solution was buffered as 
above. Saline was added to make the solution up to 2.5 ml. The resultant 
solution was of 400mg / ml ALA and 100 mg/ml CP94.
The unbuffered solutions were made up to the same concentrations using 
saline only but no buffer was used. The pH of the resultant solution was 1.5- 
2 .0 .
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Solutions were made up immediately prior to use, as buffered ALA solutions 
are known to be unstable (Chang et al 1997). Commercially available 
phosphate buffer (PBS) has insufficient buffering capacity for the ALA 
solutions described. Separate syringes and needles were used for each solution 
during the experiment.
7.5.2 Laser.
The laser we used was a commercially available Diode Laser (Diomed Ltd, 
Cambridge, UK) (figure 7.7). The laser output was measured at 628 nm (+/- 1 
nm) as described earlier in this chapter.
7.5.3 Laser diffuser fibres.
The laser diffuser fibres were radially emitting plastic fibres (cylindrical 
diffusers) which can be used for intraluminal PDT. The fibre has an external 
diameter of 0.94 mm, is highly flexible with a minimum bend radius of 20 
mm. The core diameter is 0.5mm.
Figure 7.7: Diomed diode laser, with diffuser fibres and beam splitting 
box
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The light emitted is homogeneous all along the diffuser’s tip, and not forward 
pitched, allowing a more controlled light dose in a hollow organ. The diffuser 
tip length was 40 mm.
7.5.4 Animal handling.
The New Zealand white rabbit was used. It is albino and has prominent ear 
veins, which are easily identified and cannulated, with little discomfort for the 
animal. Sexually mature females of around eight months of age were used 
with a body weight of 2.9 - 4.0 kg. Animals were supplied by Charles River 
UK Ltd, (Margate, Kent). They are resistant to disease when held in sanitary 
conditions, and are an unlikely vector to man. Proper handling of the animals 
is necessary to prevent animal or human injury. The animals were housed in 
specially designed cages and kept in a controlled environment and given free 
access to food and water, for at least seven days prior to experimentation All 
experiments were approved by the Home Office (UK) and were carried out 
under licence.
7.5.5 Anaesthesia and drug administration.
Anaesthesia was used to render the animals immobile, insensitive to pain and 
to allow the surgery to occur. The rabbits were given a general anaesthetic by 
a single, trained, operator. Adequate analgesia was also required post- 
operatively. Advice and assistance was given by the department of Biological 
Sciences at University College London.
Animals were given a pre-medication of Hypnorm (Fentanyl Citrate and 
Fluanazone) (Jannsen Pharmaceuticals Ltd., Oxford, UK) 15 minutes before 
induction of anaesthesia. Anaesthesia was induced with Diazepam (Phoenix
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Pharmaceuticals Ltd., Gloucester, UK) and maintained with additional 
diazepam as required. Buprenorphine hydrochloride (Reckitt and Coleman 
Ltd., Hull, UK) was used for post-operative analgesia.
Regular observations of the rabbits’ pulse were made. An estimation of 
oxygen saturation was made using a pulse oximeter.
7.5.6 Surgical procedures.
Post-mortem examination was made of animals used and killed in experiments 
carried out by other workers at the University in order to become familiar with 
the anatomy of the rabbit. All instruments were cleaned and sterilised by 
autoclave. Animals were anaesthetised and shaved using a small electric 
shearer. The shaved area was cleaned with alcoholic chlorhexadine and 
allowed to dry for two minutes. Sterile drapes were used to minimise 
contamination from adjacent fur (figure 7.8).
Figure 7.8: Rabbit anaesthetised in theatre.
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Fine instruments were used, a scalpel and disposable blades, a needle holder, 
toothed forceps, fine scissors and suture scissors. A 3 - 4 cm low midline 
incision was made in the skin. The peritoneal cavity was entered by careful 
elevation and cutting with scissors to prevent bowel injury. The uterine horns 
were identified behind the bladder and with minimal handling, exteriorised. 
Silk ties were applied to both the proximal and the distal ends of the uterine 
horns to prevent spill from one horn to the other, an extra suture was placed on 
the horn with the CP94 to confirm identity of the two horns later. The bladder 
was emptied if required using a fine gauge needle and syringe.
7.5.7 Drug instillation.
The solution containing ALA alone was given to the left horn by injection 
through the ante mesenteric border approximately 0.5cm distal to the 
bifurcation, using 25G needles (figure 7.9). The total volume instilled was 
0.5ml (200mg ALA). The ALA / CP94 combination was given to the other
Figure 7.9: Drug instillation into the rabbit uterine horns.
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horn in a similar manner, the total volume being 0.5ml (200mg ALA, 50mg 
CP94). Separate syringes and needles were used for the two solutions. The 
abdomen was closed in two layers using continuous silk sutures.
7.5.8 Laser illumination.
In order to illuminate the uterine horns, a laparotomy was performed under 
general anaesthetic so that a 4cm diffuser fibre could be inserted into each 
exteriorised horn.
Figure 7.10: Laser fibre being inserted into uterine horn.
They were carefully placed through the distal end of the uterine horn and fed 
through the proximal horn and partially through the cervix (figure 7.10). A
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beam splitter facilitated the use of two fibres simultaneously (figure 7.7). A 
total light dose of lOOJ/cm fibre (output power lOOmW/cm fibre) was 
delivered to each using a 628nm diode laser (Diomed, Cambridge, UK). The 
animals were then recovered.
7.5.9 Tissue retrieval.
The animals were killed using high doses of intravenous phenobarbitone.
Tissue specimens removed for fluorescence studies were immediately frozen 
by submerging in isopentane (2 -methylbutane) pre-cooled in liquid nitrogen. 
These snap frozen specimens were stored in liquid nitrogen until sectioned. 
Tissue specimens for histological analysis were submerged in formalin.
7.5.10Fluorescence microscopy studies.
Tissue blocks were mounted on OCT medium (Tissue trek II embedding 
compound, BDH) and ten pm thick sections were cut from each block using a 
Cryocut E microtome (Reichert-Jung). One section was left frozen and 
unstained. An adjacent section was stained with haematoxylin and eosin (H & 
E). The frozen slides were kept in the dark at -20°C. These were allowed to 
thaw just before fluorescence microscopy studies were undertaken.
Structures were identified with phase contrast microscopy. Fluorescence 
images were taken with a slow-scan cooled charged-coupled device (CCD) 
camera (Wright Instruments, Enfield, London, UK) with a 400 x 600 pixel 
resolution. Fluorescence was excited using an 8  mW helium-neon laser (632.8 
nm). It was decided to use the helium-neon laser as an excitation source for 
two reasons. First the laser is cheap, easy to use and maintain and gives a 
predictable output. Second, when exciting at this wavelength tissue
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auto fluorescence is low. Fluorescence was detected between 665 and 710 nm 
using bandpass and longpass filters.
Quantitative microfluorimetry was carried out in a dark room. An inverted 
microscope (Olympus IMT-2) with epifluorescence and phase-contrast 
attachments was used (figure 7.11).
Figure 7.11: Fluorescence microscope and detection and assimilation 
hardware.
An 8  mW HeNe laser was used to excite fluorescence. The beam was 
delivered through a liquid light guide, through a 1 0  nm band-pass filter 
centred at 633 nm to remove extraneous light, and onto the dichroic mirror 
(Omega Optical Inc.) for epifluorescence studies. The fluorescence detection 
range was from 665 nm to 700 nm centred at 675 nm by band-pass and long-
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pass filters. The long-pass filter (>665 nm) removed scattered excitation light. 
The low fluorescence yield from the HeNe excitation was circumvented by 
using a highly sensitive slow scan CCD camera. The camera is normally used 
for astronomy. Because of the nature of the sensitivity, it had to be pre-cooled 
with liquid nitrogen prior to use. This cooling lowered the electronic ‘noise’ 
picked up by the camera. The camera was attached to a personal computer 
which could alter the settings on the camera. The sections once thawed were 
examined with phase contrast microscopy and when a representative section 
was identified, background lights were extinguished, and the laser and CCD 
camera activated.
The recorded signal was processed on a PC and a false colour-coded image 
projected depicting the mean fluorescence signal counts per pixel ( 2 0  photons 
per count; quantum efficiency = 0.5 at this wavelength). A false colour-coded 
image of the fluorescence signal was therefore produced and the fluorescence 
intensity in the superficial endometrium, deep endometrial glands and 
myometrium was quantified digitally, by averaging over specified areas. All 
measurements were corrected for background autofluorescence.
Fluorescence emission spectra were also recorded from separate representative 
frozen sections to confirm that the fluorescence obtained was produced by 
PPIX and no other fluorescent compound. This was carried out by connecting 
a spectrograph (Multispec 1/8 m, Oriel Instruments, Connecticut, USA) with a 
slow-scan cooled CCD camera (Wright Instruments) via a fibre-optic bundle 
positioned directly above the opened specimen (endometrium uppermost) to 
an inverted microscope. Fluorescence was excited using a lmW helium-neon 
laser at 543nm, and the emission spectra were recorded over 615-735nm with
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a lnm resolution. Scattered excitation light was suppressed with a RG590 
filter. The epifluorescence excitation was confined to a 100 Dm spot, aligned 
to the area of interest with a phase contrast microscope. There were no 
photobleaching effects noted; integration times were 1 0  seconds.
7.5.11 Histological studies.
Histological assessments were carried out with the assistance of a consultant 
histopathologist from University College London Hospitals. She specialised in 
(human) gynaecological pathology. Measurements were made using a light 
microscope at magnifications of x l 6  and x32 using 0.1mm graticules. The 
thicknesses of the endometrium, including the maximal and minimal thickness 
of the endometrial folds were measured, and a ratio obtained. The stromal and 
the myometrial thickness were measured. The number of glands in the 
superficial and deep endometrium was noted. For each specimen four separate 
measurements were made. All the measurements were averaged and a score 
given of zero, one, two or three.
7.5.12 Scoring system.
Previous studies assessing damage to the endometrium have used very 
subjective measurements or merely descriptive terms (Wyss et al 1994; Wyss 
et al 1996). In order to measure destruction more objectively we developed a 
scoring system based on the measurements made from the thickness of the 
uterine wall, endometrium and stroma. We included the number of superficial 
glands seen in a particular length of endometrium and also the number of deep 
glands seen per unit area. These measurements were tabulated and a score 
obtained. The scoring system was modified slightly and tested with three
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CHAPTER 8: PHARMACOKINETIC 
STUDIES
8.1 Experiment 1: Light bleaching
8.1.1 Introduction.
This small experiment was undertaken after seeing the methods used to obtain 
the cryosections. We were exceptionally careful to avoid light exposure of the 
harvested uterine specimens, and once we obtained the cryosections, again we 
were careful to avoid light exposure prior to measuring fluorescence. 
However, the technicians who kindly cut the sections used high illumination 
during the preparation of the uterine specimens and cutting the cryosections. 
This was of concern and so a simple experiment was undertaken to investigate 
the effect of photobleaching on the fluorescence of the specimens.
8.1.2 Methodology.
Samples were taken from the uterine horns of four rabbits that had undergone 
the initial pharmacokinetics experiment. The ALA instilled was buffered to 
pH 4.5 - 5.0. The samples used were taken at four hours after administration 
of ALA. Two samples were used from each of the four animals. Eight slides 
were, therefore, were used to analyse fluorescence as outlined above. The 
slides were deliberately prepared by one of the senior technicians using very 
low light conditions.
The slides were viewed and a suitable area identified. Two fluorescence 
measurements were made on each side of this area at the ‘9 o’clock’ and ‘3 
o’clock’ positions, from each slide. The slides were then placed under an 
angle-poise table light as used by the technicians cutting the sections. Every 5
minutes each slide had fluorescence measured from the same section of the 
specimen, and were replaced under the lamp. The experiment was concluded 
after 1 2 0  minutes.
There were therefore 48 readings from each slide. All the results at each time 
point were averaged and the medians calculated and the interquartile range. 
Statistical analysis was performed using the Mann-Witney U test. Significance 
was deemed to be reached with a p value <0.05.
8.1.3 Results.
The median fluorescence levels at each time point are plotted on the graph 
(figure 8.1.1). There was no significant difference between any of the times. 
Full results are displayed in appendix 3.
l a s
1 15
1 2 3  4 5  6 7 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Time (minutes)
Figure 8.1.1 : Median fluorescence
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8.2 Experiment 2: Pharmacokinetics in the 
rabbit uterus of topically applied ALA and CP94.
8.2.1 Introduction.
Although there is considerable experience of ALA absorption in the rabbit 
uterus (Wyss et al 1992; Yang et al 1993; Fehr et al 1996; Wyss et al 1996) 
there are no data regarding ALA and CP94 absorption. The first part of these 
series of experiments was using buffered solutions as used by other workers 
(Wyss et al 1992; Fehr et al 1996; Wyss et al 1996). The second set of 
experiments in this series used unbuffered solutions.
All these solutions have the same viscosity as water and therefore have the 
potential to simply spill out of the uterus unless prevented from doing so with 
some form of physical barrier. In our experiments the uterine horns were 
simply tied. For clinical practice we are trying to develop a highly user- 
friendly method of endometrial destruction. For this reason we concluded this 
series of experiments by using more viscous mediums as a method of reducing 
spillage.
As with all experiments the Home Office restricted us as to the number of 
animals used.
8.2.2 Animal model.
Normal, mature, female, New Zealand white rabbits were used as outlined in 
chapter 7. All experiments were approved by the Home Office and were 
carried out under licence.
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8.2.3 Chemicals.
ALA and CP94 were supplied and used as outlined in chapter 7.
8.2.4 Procedures.
Animals were prepared as described earlier. The uterine horns were identified 
and with minimal handling, exteriorised. Silk ties were applied to both the 
proximal and the distal ends of the uterine horns to prevent spill from one horn 
to the other, and to identify the two horns later. The solution containing ALA 
alone was given to the left horn by injecting 0.5 ml through the antemesenteric 
border approximately 0.5cm distal to the bifurcation, using 25G needles. The 
solution containing the ALA / CP94 combination was given to the other horn 
in a similar manner, the total volume being 0.5ml (figure 8.2.1).
Figure 8.2.1: Solution being injected into rabbit uterine horn.
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The animals were recovered and then killed at various times after the dosage 
(2-12 hours). Each uterine horn was excised and snap frozen in liquid 
nitrogen. Ten-micrometer thick cryosections were then prepared, with 
adjacent haematoxylin and eosin (H and E) staining. For the buffered solution 
experiment two animals were used at each time; 2, 3, 4, 5, 6 , 7, 8 , 9, 10, 11 
and 12 hours after administration. For the unbuffered experiment two animals 
were used at each time; 2, 4, 6 , 7, 8 , 10 and 12 hours after administration. 
There were 4 blank control animals.
The frozen sections were analysed by fluorescence microscopy. Fluorescence 
emission spectra were reported to confirm that the fluorescence observed in 
the imaging was produced by PPIX and no other fluorescent substance.
8.2.5 Fluorescence Studies.
Phase contrast microscopy with a slow-scan cooled charged-coupled device 
(CCD) camera was used to image and quantify fluorescence on the frozen 
sections. Fluorescence was excited using a helium-neon laser as described 
previously. Measurements were made from the superficial endometrial glands 
(adjacent to the lumen), the deep glands (adjacent to the junction with the 
myometrium) and from the myometrium of each section. Multiple sections 
were analysed from each horn. Two uterine horns, from different animals 
were used for each set of time parameters.
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8.2.6 Results I: Buffered solutions.
No adverse effects were observed during or after administration of the drugs. 
Full results are outlined in appendix 3.
8.2.6.1 Fluorescence Spectroscopy.
Normalised fluorescence spectra were obtained from the frozen sections from 
animals given ALA alone, the ALA / CP94 combination, and from untreated 
control animals. No differences were observed in the absorption spectra taken 
from each of the two treatment regimens. Maxima were seen at 632nm (+/- 
2nm) in each case and these conform to the standard PPIX absorption spectra 
(figures 8.2.2 and 8.2.3).
8.2.6.2 Tissue fluorescence quantification.
Figure 8.2.4 shows a representative set of photographs of typical false colour-
coded CCD images of the uterus with matched H & E stained histology seven 
hours after installation of ALA and CP94.
Figure 8.2.5 shows a set of photos of the uterus with matched H & E histology 
seven hours after instillation with ALA alone.
Figure 8.2.6 shows a representative photo of the fluorescence in the 
myometrium with an adjacent H & E.
Even to an untrained observer the fluorescence images show higher 
fluorescence using the ALA/CP94 combination that ALA alone. It is quite 
gratifying to see that even the deeper glands have high levels of fluorescence 
in both examples.
The low levels in the myometrium appear to confirm our hypothesis that there 
will be a good safety margin preventing extra-uterine damage.
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Figure 8.2.2: Fluorescence spectra from a normal untreated uterine horn.
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Figure 8.2.3: Fluorescence spectra from a normal uterine horn treated with ALA and 
CP94 with a peak at the correct wavelength for PPIX.
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Figure 8.2.4: A set of photos showing the endometrial fluorescence with matched H 
& E histology seven hours after instillation with ALA and CP94.
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Figure 8.2.5: A set of photos showing the endometrial fluorescence with matched H 
& E histology seven hours after instillation with ALA alone.
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Figure 8.2.6 A set of photos of the myometrial fluorescence with matched H & E 
histology seven hours after instillation with ALA and CP94.
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Figure 8.2.7: Fluorescence in the superficial endometrium
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Figure 8.2.8: Fluorescence in the deep endometrial glands.
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Figure 8.2.9: F luorescence in the myometrium
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Figure 8.2.10: Comparison of superficial endometrium
myometrium using ALA and CP94.
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Figure 8.2.7 compares the fluorescence levels using ALA alone and the 
combination of ALA and CP94 in the superficial endometrium. Figure 8.2.8 
compares the same in the deep endometrial glands, and figure 8.2.9 compares 
fluorescence in the myometrium, els in the myometrium.
Figure 8.2.10 compares the superficial endometrial fluorescence with the 
myometrium using the combination of ALA and CP94.
Background autofluorescence has been subtracted from all measurements. Full 
results are tabulated in appendix 3.
Figure 8.2.11 shows how the fluorescence in the superficial endometrium, 
deep glands and myometrium varied with both time and drug combination.
Peak Fluorescence (buffered)
BALA
BCP94
Superficial endometrium Deep endometrium Deepest glands Muscle (6 hours)
Figure 8.2.11: Simplified chart comparing ALA alone “ALA”, with ALA + CP94 “CP94”, 
seven hours after administration.
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Peak fluorescence was observed in the superficial endometrium seven hours 
after sensitisation with ALA alone (median 48 arbitrary units - a.u.), or after 
the combination of ALA and CP94 (median 101 a.u.) (p<0.01).
Results from the deep glands at a peak of seven hours after sensitisation 
revealed median peak fluorescence with ALA alone of 18.5 a.u., and with the 
combination, 31.5 a.u. (p<0.01).
Median fluorescence in the myometrium at seven hours was 10 a.u. with ALA 
alone and 3.5 a.u. with the combination. However, the median fluorescence at 
six hours in the myometrium was significantly higher than the seven hour 
measurements at 20.1 a.u. with ALA alone and 13.9 a.u. using the 
combination (p<0.01).
In the superficial endometrium the peak at seven hours was 2.1 times higher 
with the drug combination than with ALA alone (p<0.01). The fluorescence at 
this time was 4.8 times higher than in the myometrium with ALA alone 
(p<0.001); but was 28.9 times higher with the ALA / CP94 combination
(p<0.001).
In the deep endometrial glands the peak seen with the combination was 1.2 
times higher than with ALA alone (p<0.05). The fluorescence measurement in 
the deep glands was 1.9 times higher using ALA alone compared with the 
myometrium (p<0.001); but it was 9 times higher in the deep glands using the 
combination compared with the myometrium (p<0.001).
8.2.7: Results II: Comparison of buffered and unbuffered 
solutions.
No adverse reactions were observed when administering any of the drugs.
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Comparisons of buffered and non-buffered data were made using the buffered 
data obtained in the first experiment (section 8.2.6). We were unable to use 
more animals because of restrictions set by the Home Office on the number of 
animals used. Full results are outlined in appendix 3.
8.2.7.1 Tissue fluorescence quantification.
Figure 8.2.12 shows how the fluorescence in the superficial endometrium
varied with time between giving the ALA/CP94 combination in either saline 
or buffer.
Figure 8.2.13 shows how the fluorescence in the deep endometrial glands 
varied with time between giving the ALA/CP94 combination in either saline 
or buffer.
Figure 8.2.14 shows how the fluorescence in the deepest endometrial glands 
varied with time between giving the ALA/CP94 combination in either saline 
or buffer.
Figure 8.2.15 shows how the fluorescence in the myometrium varied with 
time between giving the ALA/CP94 combination in either saline or buffer.
All results are tabulated in appendix 3.
The median fluorescence in the superficial endometrium with ALA alone has 
a peak at six hours with saline (85 a.u.) and seven hours with buffer (48 a.u.). 
It is 1.8 times higher without buffer (p<0.001). In the deep glands the median 
peak fluorescence is reached at seven hours with buffer (18.5 a.u.) and six 
hours with saline (20 a.u.) (p>0.05). Finally in the myometrium the buffered 
ALA peaks at six hours (20.1 a.u.) and also at six hours with saline (3.5 a.u.) 
(p<0.05).
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F luorescence using ALA/CP94 in combination in the superficial endometrium
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Figure 8.2.12: Fluorescence in the superficial endometrium using the ALA/CP94 
combination.
Fluorescence using ALA/CP94 in combination in deep endometrium
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Figure 8.2.13: Fluorescence in the deep endometrium using the ALA/CP94 
combination.
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Figure 8.2.14: Fluorescence in the deepest endometrial glands using the ALA/CP94 
combination.
Figure 8.2.15: Fluorescence in the muscle the ALA/CP94 combination.
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The fluorescence profile of the ALA-CP94 combination shows that the level 
of fluorescence in the superficial endometrium has a peak at 7 hours with 
buffer (101 a.u.) and at six hours with saline (69 a.u.). This is 1.4 times higher 
with buffer (p>0.05). In the deep endometrium the peak with buffer is at seven 
hours (31.5 a.u.) and six hours with saline (40 a.u.), 1.2 times higher without 
buffer (p>0.05). Finally in the myometrium the peak is at seven hours with 
saline (2.5 a.u.) and six hours with buffer (13.9 a.u.).
8.2.8 Discussion.
The fluorescence microscopy studies of the rabbit uterus show that PPIX 
accumulates preferentially in the endometrium, with low levels in the 
myometrium. This is consistent with other workers findings in the rat, rabbit 
and human (Yang et al 1993; Fehr et al 1996; Gannon 1995). Low levels in 
the myometrium will minimise PDT effects here and therefore help to 
maintain myometrial integrity, reducing risks of laser transmission and uterine 
perforation.
The distribution of PPIX fluorescence in the different levels of the 
endometrium is not uniform with higher levels in the superficial endometrium 
and less in the deep endometrium. This is not an ideal situation as it may 
imply that this will result in less tissue destruction with PDT. It is essential 
that the glands in the deep endometrium are completely destroyed in order to 
prevent endometrial regeneration.
There were significantly higher fluorescence levels in all layers of the 
endometrium with the ALA / CP94 combination compared with ALA alone. 
This suggests that there will be greater PDT damage with the combination.
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It was interesting to note that the levels were lower in the myometrium using 
the combination than with the ALA alone. This may be incidental but may be 
due to less ALA being available because of higher levels absorbed by the 
endometrium. The results of Cumow et al (1998) using ALA and CP94 given 
intravenously (i.v.) showed higher levels in the colon with the combination 
solution.
The highest levels of endometrial fluorescence measured with the ALA / 
CP94 combination was after 7 hours, the peak absorption using ALA alone 
was also 7 hours, this is somewhat at odds with other workers (Wyss et al 
1994; Steiner et al 1995; Fehr et al 1996). Wyss et al (1994) obtained their 
results by performing a similar experiment to us. He did however only 
administer drug at 3, 6, 9 and 12 hours prior to removing the uterine sample. It 
is possible, therefore that they overlooked the peak. Certainly from our results 
the peak would have been overlooked if our time points had been greater than 
two hours apart.
The addition of CP94, therefore, improves both endometrial selectivity of the 
ALA as well as increasing ALA concentrations in the endometrium.Our data 
using buffered solutions was at odds with other workers. We therefore had to 
investigate whether pH would have any effect on the fluorescence.
The Home Office restricts the use of animals and we were therefore limited to 
using the initial data comparing it to data obtained in a different set of 
experiments at a different time. This is far from ideal, but after discussion with 
statisticians at the University and Home Office vets it was deemed acceptable.
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Statistical analysis of the data showed significant peaks at different times with 
different solutions. Comparitive statistics have then been used to analyse these 
data from the peaks. Thus comparison of, for example, the six hour data using 
ALA and CPC94 in saline were compared with data at seven hours using ALA 
and CP94 in buffer.
The non-buffered solutions used in these experiments have a pH of 1.5 to 2. 
This is clearly far from physiological. The assumption is that tissues will 
absorb a more physiological solution better. The other assumption is that a 
very acid solution will cause tissue destruction purely because of the pH. In 
most previous studies of ALA pharmacokinetics or PDT, there is no mention 
of pH, or that the ALA is buffered with (commercially available) phosphate 
buffered saline solution PBS (Wyss et al 1992; Yang et al 1993; Fehr et al 
1996; Wyss et al 1996). As we have shown from our work the quantities of 
phosphate required to buffer 200mg / ml ALA are huge, and there is no 
commercially available PBS that even remotely approaches the concentration 
of buffer required.
At a pH above 5.0, the ALA solution tends to break down forming a brownish 
polymeric product. The pH in the lower female genital tract can be quite 
acidic ranging from pH 3.5 to 4 depending on the menstrual cycle. A very 
acidic solution may cause a local reaction by the endometrium releasing 
prostaglandins and causing pain, thus a more physiological solution would be 
more acceptable.
We hypothesised that using solutions buffered to a more physiological pH 
would improve the absorption of the photosensitisers. Clearly from our data 
this is not borne out. The optimum parameters, therefore, appear to be to use
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ALA and CP94 in combination dissolved in either saline or a buffered 
solution, and to perform PDT at 7 hours. It is more acceptable to use the 
buffered solution because of better patient acceptability.
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8.3 Experiment 3: Pharmacokinetic studies of 
topical ALA and CP94 in the rabbit uterus using 
different transport mediums.
8.3.1 Introduction.
Traditionally ALA is given in a solution dissolved in saline. Several potential 
problems arise from this. First, the resultant solution is extremely acidic. 
However as shown in the last chapter, this appears to be of little relevance to 
the results obtained. Second the solution is a non-viscous liquid, and therefore 
has the potential to spill through either the ends of the fallopian tubes (in 
women) or from the end of the uterine horns in the rabbit model. In our 
experiments this was reduced by gently tying both the proximal and distal 
ends of the uterine horns with a silk suture.
When ALA-PDT is used in dermatological cases, the ALA is mixed in a 
highly viscous cream - Orobase. This allows the drug to be in contact with the 
skin for long periods of time; at the end of treatment it is easily wiped away.
We wanted to test whether there was a difference in the uptake of ALA by the 
endometrium when the ALA was mixed with two different substances, namely 
Orobase and KY jelly. KY jelly is a water-based lubricating gel. We compared 
these with the (buffered) saline solution.
8.3.2 Animal model.
Three rabbits were used for the Orobase study, four for the KY jelly study. As 
indicated earlier, because of ethical and licence restrictions the buffer saline 
results were used from the previous study.
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8.3.3 Chemicals.
ALA and CP94 powder were supplied as described above. For this first 
experiment, the ALA was mixed in a weight to weight manner with the 
Orobase, the mixture was equivalent to 400 mg per gramme (approximately 
400 mg/ml). A second mixture was made up in a similar way using ALA in 
combination with CP94, to a concentration of approximately 400mg per ml 
and lOOmg per ml respectively. The mixtures did not require buffering as the 
salts ALA and CP94 powders were not in solution, and therefore there was no 
dissociation of the salt, and therefore no pH can be recorded.
In the experiment using KY jelly, the ALA or ALA / CP94 powder was mixed 
with KY jelly resulting in a solution of 400 mg/ml ALA and 100 mg/ml CP94, 
buffer was added as described above so that the resultant solution was pH 4- 
4.5.
The mixtures were made up immediately prior to administration. Because of 
the viscosity of the mixtures, no needles were used, merely the syringe. Due to 
the viscosity of Orobase, it was heated in a water bath prior to mixing at 38°C. 
The drug was injected through the ends of the uterine horns, the vaginal ends 
having been closed with a silk tie. After injection the ends were tied with silk 
ties as before. The total volume given to each uterine horn was 0.5 ml; (200 
mg of ALA or a combination of 200 mg of ALA with 50 mg of CP94). 
Separate syringes were used for the different drug combinations.
8.3.4 Procedures.
Animals were given a general anaesthetic and the operation protocols were 
followed as described earlier. This facilitated an easier administration. The
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animals were recovered and then killed at various times after the dosage ( 2 - 5  
hours). Each uterine horn was excised. The horn was then opemed 
longtitudinally, the mixture gently removed, and then the uterine horn was 
snap frozen in liquid nitrogen. Ten-micrometer thick cryosections were then 
prepared, with adjacent haematoxylin and eosin (H and E) staining, as 
described in chapter 7.
The frozen sections were analysed by fluorescence microscopy as described 
earlier.
8.3.5 Fluorescence Studies.
Phase contrast microscopy with a slow-scan cooled charged-coupled device 
(CCD) camera was used to image and quantify fluorescence on the frozen 
sections as previously described. Measurements were made from the 
superficial endometrial glands (adjacent to the lumen), the deep glands 
(adjacent to the junction with the myometrium) and from the myometrium of 
each section. Multiple sections were analysed from each horn.
8.3.6 Statistical analysis.
We discussed the data with our local statistician, and because of the small 
numbers we have used descriptive statistics only in this section.
8.3.7 Results.
No adverse effects were observed during or after administration of the drugs.
8.3.7.1 Procedural results.
Only three animals were used in the Orobase study and were killed at 2, 3 and 
4 hours. Mixing the ALA even with the warmed Orobase proved extremely 
difficult. Administering the resultant mixture into the lumen of the uterine
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homs was next to impossible because of the viscosity. Once the animals were 
killed it also proved very difficult to remove the Orobase from the delicate 
uterine homs. In view of this and the fact that no other similar substance was 
available within the experimental time scale it was decided to abandon any 
further experiments with orobase.
The KY jelly mixture also proved somewhat difficult to administer. When 
administered immediately after mixing, the KY jelly retained its viscosity. Yet 
in a sample made up to see how it reacted over time, there was complete 
breakdown of the KY jelly to its water-based constituents within ten minutes. 
KY jelly made without buffering degraded almost immediately. Again after 
discussion with our pharmacological advisor and the Home Office vet it was 
decided to terminate the experiment after only using four animals.
8.3.7.2 Tissue fluorescence quantification.
This was carried out as previously described.
Figures 8.3.1, 8.3.2 and 8.3.3 shows how the fluorescence induced by ALA 
and the ALA / CP94 combination in the superficial endometrium, deep glands 
and myometrium respectively varied with both time and whether orobase or 
KY jelly were used.
Background autofluorescence has been subtracted from all measurements.
Because of the constraints of numbers and therefore very limited results, we 
can only make observations. Certainly no conclusions can be made about the 
peak fluorescence in any level of tissues. We can merely compare each level 
at different times.
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In the superficial endometrium using ALA alone there was no statistical 
difference between the two preparations in the fluorescence at 2 or 3 hours.
Fluorescence in Superficial Endometrium
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□  ALA + CP94 orobase 
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Figure 8.3.1: Variation in fluorescence in the superficial endometrium using ALA and 
ALA/ CP94 combination with orobase and KY jelly as solvents.
Fluorescence In deep endometrium
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Time (hours) after administration
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Figure 8.3.2: Variation in fluorescence in the deep endometrium using ALA and ALA/ 
CP94 combination with orobase and KY jelly as solvents.
F lu o rescen ce  in m yom etrium
25 0A LA  + CP94 o robase
| □  ALA + C P94 KY 
□  ALAKY20 -
10-
La
Time (hours) after administration
Figure 8.3.3: Variation in fluorescence in the myometrium using ALA and ALAI CP94 
combination with orobase and KY jelly as solvents.
At 4 hours there was a significant difference between orobase (85.5 arbitrary 
units au) and KY jelly (14 au) (p<0.001).
In the deep glands there was a significantly higher fluorescence using orobase 
(21.5 au) compared with the KY (4.5 au) (p<0.01).
In the myometrium there was no significantly detectable fluorescence using 
either solvent.
In the superficial endometrium using ALA and CP94 there was a statistically 
significant difference in fluorescence at 4 hours with values of 71 au with 
orobase, and 12.5 au with KY (p<0.005).
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In the deep glands there was a significantly higher fluorescence at 4 hours 
using orobase (17.5 au) compared with the KY (8 au) (p<0.01).
In the myometrium there was no significantly detectable fluorescence using 
either solvent.
8.3.8 Discussion.
The only conclusions that can be drawn from these limited data is that a highly 
viscous medium similar to orobase warrants further investigation. Certainly 
comparing fluorescence values between orobase, KY and buffered saline at 
2,3 and 4 hours would indicate a favourable result for Orobase. It may be that 
these values reveal a peak for Orobase, or it may be that the eventual peak at 7 
hours would have been considerably higher than the saline. However, a peak 
of over 80 a.u. is of the same order as the maximal peak with saline. The 
advantage of a 4 hour peak is in the time delay between administration and 
treatment that will be discussed in the final chapter.
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CHAPTER 9: PHOTODYNAMIC
THERAPY OF THE RABBIT UTERUS 
USING TOPICAL ALA ALONE AND IN 
COMBINATION WITH CP94.__________
9.1 Introduction.
The previous chapters have established that by administering the 
hydroxypyridinone iron chelator, CP94, it is possible to substantially increase 
the PPIX fluorescence produced in the endometrium. Also that administering 
the drug in buffered solution made little difference. This chapter will 
investigate whether this increased PPIX fluorescence, can be utilised to 
produce enhanced PDT effects in the uterus.
9.2 Chemicals.
The ALA solutions and the ALA/CP94 solutions were prepared as detailed in 
chapter 7.
9.3 Animal model.
Normal female New Zealand White rabbits ( 3 - 4  kg) were used throughout as 
outlined in chapter 7. There were 22 animals used in this experiment (Table 
9.1)
9.4 PDT studies.
The drugs were administered to the uterine homs in the same way as the 
fluorescence studies in chapter 7. In the saline PDT study, irradiation 
occurred at the peak fluorescence of six hours after administration of the
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drugs. In the buffer PDT study, irradiation occurred at the peak fluorescence 
of seven hours after administration of the drugs.
Rabbit number Description Saline or buffer Sacrifice (day)
1 Laser only - 3
2 Laser only - 3
3 Laser only - 10
4 Laser only - 28
5 Drug only Buffer 3
6 Drug only Buffer 10
7 Drug only Buffer 28
8 Drug only Saline 3
9 Drug only Saline 10
10 Drug only Saline 28
11 Control - 3
12 PDT Saline 3
13 PDT Saline 3
14 PDT Buffer 3
15 PDT Buffer 3
16 PDT Saline 10
17 PDT Saline 10
18 PDT Buffer 10
19 PDT Buffer 10
20 PDT Saline 28
21 PDT Saline 28
22 PDT Buffer 28
23 PDT Buffer 28
Table 9.1: Animals used in these experiments
To irradiate the endometrial cavity, a second laparotomy was performed, 
again, under general anaesthetic. Two 4cm long diffuser fibres, coupled to a
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beam splitter were attached to a 628 nm. diode laser, which was used 
throughout the studies (figure 9.1). The laser fibre was passed through the 
ends of the uterine homs. The light dose of 100 J/cm fibre (output was 
lOOmW/cm fibre) was delivered to each uterine hom (figure 9.2). The uterine 
homs were kept moistened with saline throughout the experiment to prevent 
drying. At the end of treatment the abdomen was closed in two layers with 
silk. The animals were then recovered, and killed at three days, and the uterine 
homs removed, fixed in 10% formalin, and sent for histological examination. 
Ten micrometer samples were taken and stained with H & E. These specimens 
were then examined histologically. Twelve animals were used for active PDT 
in these experiments. In addition two laser only, two drug only and two blank 
controls were used.
The method of evaluation of the PDT effect was determined as described 
previously. We wished to have a simple method of testing destruction in a 
reproducible manner.
An initial general description was made of each histological slide, based on 
the macroscopic view.
Histological measurements were made using a phase contrast light microscope 
at a magnification of xl6 and x32 using a 0.1mm graticule fitted to the lens 
piece of the microscope The thicknesses of the endometrium, including the 
maximal and minimal thickness of the endometrial folds were measured, and a 
ratio obtained (figure 9.3). The stromal and the myometrial thickness were 
measured. The number of glands in the superficial and deep endometrium was 
noted. For each specimen four separate measurements were made. All the
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measurements from homs treated in a similar manner were averaged and a 
score given of zero, one, two or three.
The number of endometrial glands per square millimetre ( m m ) was 
specifically measured. For each animal, slides were made up from two 
distinct region of each uterine hom. Five slides were made from each of these 
regions. Four measurements were made from each slide, and these were 
averaged. There were, therefore, ten measurements for each uterine hom from 
each animal. Table 9.2 shows the results from each animal.
9.5 Results.
9.5.1 Macroscopic examination at day three, ten and twenty 
eight.
Examination of the abdominal organs when the control animals uterine homs 
were harvested at day three, day ten and day twenty eight showed no damage 
to adjacent organs. The control uterine homs appeared normal, at all stages. 
In all the treated animals, the abdominal organs showed no damage, but there 
were occasional adhesions formed between uterine homs and adjacent 
structures. In the homs at day three, the uteri were oedematous and 
erythematous. In many animals the uteri were adherent to adjacent tissues 
with fine adhesions. There was no serosal damage seen, and all uteri were 
intact. Examination at later dates showed little or no oedema and the presence 
of occasional adhesions. At all stages the homs remained intact.
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Figure 9.1: Macroscopic damage to the uterine lining at day 3, showing loss of 
folds after PDT using ALA alone.
Figure 9.2: Macroscopic damage to the endometrium at day 3, showing loss of 
folds after PDT using ALA / CP94 combination.
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Figure 9.3: Normal rabbit uterine histology.
9.5.1.1 Control animals.
Figure 9.3 shows the normal histology of a mature rabbit uterus. The laser 
only histology and the drug only controls at all time points had similar 
histology to this. The normal endometrium has folds, with a dense array of 
glands, both in the superficial, as well as in the deeper endometrium. Deep to 
the endometrium is the stroma. This consists of a loose extracellular matrix, 
with fibroblasts and blood vessels of varying size. Deep to the stroma is the 
myometrium. This layer consists of an inner circular and an outer layer of 
longitudinal muscle.
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glands still present
Figure 9.4: Histology at day three after ALA-induced PDT
Myometrium remains unaffected
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Figure 9.5: Histology at day three after ALA/CP94-induced PDT
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9.5.1.2 PDT following drug administration.
The effect of PDT on the macroscopic appearance of the uterine homs can be
seen in figure 9.4 and 9.5. There was obvious thinning of the uterine wall in 
both specimen groups at three days. There were similarly no obvious 
differences between the homs treated with ALA alone or the ALA / CP94 
combination at ten days. The specimens treated with the ALA / CP94 
combination at four weeks was similar to he specimens from ten days. The 
specimens treated with ALA alone were similar in appearance to the untreated 
specimens (controls).
9.5.2 Microscopic examination.
9.5.2.1 Control animals.
Figure 9.3 shows a representative H and E histology slide of a normal rabbit 
utems. The luminal surface of the untreated uterus shows numerous thick 
endometrial folds. These are covered with a columnar epithelium with 
numerous glandular openings. The specimens taken from the light only and 
the drug only specimens are all identical to this appearance at all time points. 
The loose stromal tissue is thick and contains occasional small blood vessels.
9.5.2.2 PDT following drug administration.
There were no differences between the buffer and saline groups at any of the
time points.
Figure 9.6 to figure 9.11 show representative histological sections from each 
of the treatment groups: day three, ALA alone and in combination with CP94; 
day ten, ALA alone and in combination with CP94; day twenty eight, ALA 
alone and in combination with CP94.
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9.5.2.2.1 Day three
There were a few differences between the ALA alone and ALA / CP94 
combination treatment groups at three days. The morphology of the 
endometrium was completely changed following PDT in all specimens, 
compared to the normal. There was extensive haemorrhage in the 
endometrium, with epithelial and blood vessel damage. The myometrium 
showed minimal haemorrhage. There were occasional inflammatory cells 
present in the stroma.
In the ALA treated uterine homs, there was marked endometrial damage, with 
extensive loss of folds, thinning of the endometrium, and a marked reduction 
in the number of superficial endometrial glands. Although in some specimens 
glandular destmction was seen throughout the endometrium, in the majority of 
specimens these deeper glands appeared almost unaffected.
The epithelium was of a cuboidal type, in the majority of the superficial 
endometrium. There was occasional loss of epithelial cover. Although in some 
ALA treated specimens glandular destruction was seen throughout the 
endometrium, in the majority of specimens these deeper glands appeared 
almost unaffected. The columnar epithelium persisted in the majority of the 
residual folds of the endometrium.
In those homs treated with CP94 in combination with ALA, there were 
obvious morphological differences between those treated with ALA alone. 
There was endometrial thinning with quite extensive flattening. Surface 
epithelium where present was cuboidal, but there was extensive loss of 
epithelial cover. Generally there were no endometrial glands seen.
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Figure 9.6 (a) and (b): Representative histology at day three after ALA-induced PDT
Figure 9.7 (a) and (b): Representative histology at day three after the ALA/CP94
combination-induced PDT
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9.5.2.2.2 Day ten
The endometrial morphology was markedly different than normal. There was 
no obvious difference between the histology using the different drug 
combinations comparing saline and buffered solutions.
A large degree of regeneration had occurred in the uteri from the homs treated 
with ALA-induced PDT alone, with a median number of glands of between 0 
and 1 per mm , but also with an increase in the depth of glandular penetration. 
There was also a generalised thickening of the stroma. There was moderate 
endometrial damage, with extensive loss of folds, thinning of the 
endometrium, and a marked reduction in the number of superficial 
endometrial glands, as seen at day three. However, the majority of the 
epithelium was of columnar type. There was generally a reduction in the 
number of endometrial glands, especially in superficial endometrial, but again, 
in the majority of specimens these deeper glands appeared unaffected, or had 
regenerated.
Morphology of the homs treated with the ALA/CP94 combination was similar 
to those treated with the same parameters at day three. The median number of 
glands per animal was between 0 and 0.5 per mm2. There were obvious 
differences when compared to the homs treated with ALA alone, namely gross 
thinning of the endometrium associated flattening of folds. In most specimens 
there was a loss of epithelial covering in the majority of the slide. There was 
no evidence of regeneration.
In no specimen was there evidence of myometrial damage.
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Figure 9.8 (a) and (b): Representative histology at day ten after the ALA-induced 
PDT. There is glandular regrowth.
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Figure 9.9 (a) and (b): Representative histology at day ten after the ALA/CP94 
combination-induced PDT. There is no glandular regrowth
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Figure 9.10 (a) and (b): Representative histology at day twenty eight after 
ALA-induced PDT, showing considerable regrowth of glandular elements
s r
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Figure 9.11 (a) and (b): Representative histology at day twenty eight after the 
ALA/CP94 combination-induced PDT showing a denuded endometrium with no 
regrowth of glandular elements
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Figure 9.11 (c): Representative histology at day twenty eight after the ALA/CP94 
combination-induced PDT, showing some regrowth of glandular elements.
9.5.2.2.3 Endometrial effects four weeks after PDT.
In the ALA treated uterine homs, there was a difference compared with the 
specimens at ten days. There was loss of folds and thinning in the 
endometrium, and a reduction in the number of superficial endometrial glands 
compared with normal. However, the difference between the specimens and 
those at ten days was evident with there being more endometrial glands 
present throughout the endometrium in those treated with ALA alone, there 
was evidence of considerable regeneration (figure 9.10). There was an 
increase in the median number of glands to between 3 and 4.5 per mm2. In 
some of the specimens there was complete regeneration of tissue.
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Endometrium Myometrium
Animal
number
Description Overall
score
Overall 
score ALA 
alone
Overall 
score 
ALA/C P94
Overall
1 Laser only 3 + No damamge
2 Laser only 3 0 No damamge
3 Laser only 10 0 No damamge
4 Laser only 28 0 No damamge
5 DO B 3 0 0 No damamge
6 DO B 10 0 0 No damamge
7 DO B 28 0 0 No damamge
8 DO S 3 0 0 No damamge
9 DO S 10 0 0 No damamge
10 D O S 28 0 0 No damamge
11 CONTROL 0 0 No damamge
12 PDT S3 +++ +++ No damamge
13 PDTS3 ++ +++ No damamge
14 PDT B3 +++ +++ No damamge
1 5 PDT B3 +++ +++ No damamge
1 6 PD TS10 + ++ No damamge
1 7 PDTS10 0 +++ No damamge
18 PDT B10 ++ +++ No damamge
19 PDT B10 + ++ No damamge
20 PDT S28 0 ++ No damamge
21 PDT S28 0 +++ No damamge
22 PDT B28 0 ++ No damamge
23 PDT B28 + +++ No damamge
(number = sacrifice day; DO = drug only; S = saline; B = buffer)
Table 9.2: results of the experiment (with reference to table 7.1).
In contrast, the endometrium of the homs treated with the drug combination 
remained thin, with little regeneration. However, as can be seen in the 
example shown in figure 9.11(c), there were some areas of regeneration. The
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2median number of glands was between 0.5 and 1.5 per mm . There were two 
exceptions. Again, there was no myometrial damage seen in any specimen.
9.6 Discussion.
In order to prevent regeneration, endometrial destruction with photodynamic 
therapy must extend within the endometrium to include the deep glandular 
tissue.
PDT after ALA was administered alone, shows extensive endometrial 
damage. However, there were a greater number of both superficial and deeper 
endometrial glands remaining when compared with the specimens after PDT 
with the drug combination. The current limited and unsustained clinical 
effects of PDT to the human endometrium after topical administration of ALA 
(used alone) may be explained by these findings.
It is known that endometrial regeneration occurs within a few days, from 
residual glands deep within the endometrium, whether after normal 
menstruation, curettage or after endometrial destruction, by means explained 
previously (Ferenczy 1976a; Ferenczy 1976b). In order to prevent 
regeneration glandular elements throughout the thickness of the endometrium 
must be destroyed. Evidence from our histology of the ALA/CP 94 
combination, shows complete endometrial destruction.
Topical application of ALA in the uterus reduces systemic levels and therefore 
may eliminate systemic side effects, notably skin photosensitivity (Roberts et 
al 1989; Dougherty et al 1990). By giving two 0.5 ml doses of the ALA 
solution, the animal will have a total dose of approximately 400 mg. This is 
equivalent to approximately 100 mg / kg. This compares favourably with the
175
i.v. administration used by Yang of up to 400 mg / kg (Yang et al 1996). Wyss 
instilled ALA into the rabbit uterine horns, using 1.2 ml of up to 400mg / ml. 
This is equivalent to a dose of 240 mg / kg (Wyss et al 1994). The doses used 
topically in rats by Wyss were up to 400 mg / kg (Wyss et al 1994). Yang also 
used ALA topically in rats using 0.1 ml per horn at doses of up to 160 mg / 
ml. This is equivalent to doses of up to 640 mg / kg (Yang et al 1993).
The rabbit endometrium is very thin compared to that of the human. Previous 
animal experiments with ALA PDT have shown excellent results using laser 
energy at the optimum wavelength for PPIX of 635 nm, but when the 
technique has been taken into the clinical setting, the results have thus far been 
disappointing. This may be due to insufficient PPIX concentration in the 
deepest endometrial glands resulting in incomplete ablation of these glands 
from which regeneration occurs. This may, therefore, explain the poor clinical 
results obtained with this technique. By combining CP94 with the ALA a 
higher local concentration of PPIX in the endometrium can be obtained than 
has been previously possible. We have demonstrated an improved 
photodynamic effect.
A larger difference was shown in the PDT effects between ALA alone and the 
ALA/CP94 combination in the rabbit model, because the laser used was a 628 
nm laser rather than a 635 nm laser. Previous work in this department has 
shown that photodynamic destruction using a laser is 2.5 times greater at 635 
nm than at 628 nm (p < 0.02) (Cumow 1999).
The rabbit endometrium has numerous deep folds, similar to the fallopian tube 
in humans, and very different from the relatively smooth human endometrium. 
The bare diffusing fibre that we used meant that the endometrium would have
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remained folded, resulting in a reduction of illumination to the glands within 
the deep folds. Better results may have been obtained if we had utilised a laser 
diffuser fibre within a distendable balloon. Despite this, PDT after instillation 
of the drug combination showed good endometrial destruction and the long­
term results are encouraging.
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CHAPTER 10: LIGHT DISTRIBUTION IN 
THE HUMAN ENDOMETRIAL CAVITY.
10.1 Introduction.
In the previous chapters, it has been shown that there is complete and long­
standing damage to the endometrium of the rabbit after photodynamic therapy 
using topical ALA combined with CP94. In these experiments a single 4 cm 
laser diffusing fibre was used. Within the rabbit uterine horn this system 
offers adequate illumination of the entire horn (essentially a hollow cylinder). 
The human uterus, however, has the shape of an inverted flattened pear. The 
endometrial cavity as the shape of an inverted triangle with a narrow cavity 
transversely, being described as a potential cavity (figure 10.1). Placing a 
single diffusing fibre in the endometrial cavity, without distension, would 
therefore fail to adequately illuminate all parts of the endometrium. For PDT 
to be offered as a successful treatment of menorrhagia, not only should 
endometrial destruction be full thickness, but also it must be total.
Figure 10.1: transverse section of human uterus.
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The light delivery device is, therefore, of crucial importance. Tromberg used 
mathematical models to show that sufficient light propagation through the 
uterine cavity is possible with three cylindrical fibres (Tromberg et al 1996). 
Due to the fact that some form of cavity distension is necessary to allow light 
to penetrate all areas, we looked at the possibility of developing an 
intrauterine balloon. The distension pressure within the balloon must not be so 
great as to prevent adequate oxygenation of the tissue, crucial for PDT to 
occur, by restricting the blood supply. In order to fit the human endometrial 
cavity, the balloon must be of a similar shape to the cavity - namely an 
inverted flattened triangle. It was not known whether this non-uniform shape 
would in turn lead to problems with uniformity of light distribution. In 
clinical practice, placement of the balloon and laser fibre in the uterine cavity 
is likely to be performed as a blind procedure. It is also important that 
consistent and accurate placement is easily attained.
The ideal light delivery system should be easy to place within the cavity and 
should allow consistent laser fibre placement within the cavity. If we assume 
that a balloon device is used, there must be uniform light intensity over the 
entire surface.
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10.2 Materials and Method.
10.2.1 Modified Wilson-Cook Uterine balloon stent.
The first device is our own design (Figure 10.2) in which a cylinder diffuser 
fibre is placed within a transparent Balloon Uterine Stent (Cook Ob/Gyn, 
Spencer, Indiana), The Cook balloon is a 60 x 45 mm flattened transparent 
silastic balloon, designed to be used to tamponade the endometrium to reduce 
bleeding. We modified the balloon by the addition of different proximal
Figure 10.2a Unmodified Wilson-Cook balloon
Saline/lntralipid
Injection ChannelWilson-Cook Balloon 
Stent, filled with 
saline or dilute Intralipid
O-ring, seals  fibre
3-way Tap
Cylinder Diffuser 
Fibre (to laser)
Fibre Channel
Active tip of 
Cylinder Diffuser
Fibre
Figure 10.2b Modified Wilson-Cook balloon
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applicators. For normal use the Cook balloon has a one-way valve, which for 
our purposes is removed. We needed to fit a three-way tap to allow the saline 
distension medium to be instilled. We also fitted a modified foley catheter tip 
on one arm of the three-way tap. This was needed to insert the laser diffuser 
fibre. The internal diameters of the channel of the tap used were less than 1 
mm. The increased size was a very simple modification. By using a small 
amount of glycine as a lubricant we were able to insert the laser fibre with 
ease. The glycine also allowed the system to be water-tight with a minimal 
amount of saline loss after instillation. The geometry of the cylinder diffuser 
does not match the uterine cavity, so the primary illumination at the 
endometrium is non-uniform. Light is backscattered and reflected within the 
uterine cavity, which should lead to improved uniformity of illumination of 
the endometrial surface.
The balloon was connected to the three-way tap and the cylinder diffuser fibre 
was partially inserted into the fibre channel and secured in place with an O- 
ring, which also prevented leakage of fluid. The deflated balloon was 
clamped in a Spencer Wells forceps, and wrapped around it. For our 
experiments on hysterectomy specimens, this was then passed transcervically 
into the uterine cavity after cervical dilation to Hegar 8. The balloon was 
inflated using a clear sterile saline solution. The fibre sealing connection was 
loosened and the fibre advanced into the balloon, the required length having 
previously been marked.
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10.2.2 Medlight balloon.
The Medlight balloon (Medlight SA, Eclubens, Switzerland) has a 5.3 mm 
diameter, 150 mm long introducer to pass the folded balloon transcervically.
Figure 10.3: Medlight balloon
The balloon is made of a white transluscent latex in the shape of a ‘typical’ 
uterine cavity (figure 10.3). It is inflated with the recommended 2 ml of saline, 
and attains dimensions of 25 x 25 x 5 mm. The catheter is 100 mm long. The 
design uses a high internal reflectance for the balloon material to improve the 
uniformity of light distribution, based on the same principle as an integrating 
sphere (i.e multiple internal reflections redistribute the light more uniformly 
on the tissue surface). In theory, this should give much improved performance 
over a transparent balloon. The fibre is partially loaded into the device and 
secured in place by tightening the sealing connection. The deflated balloon is 
smeared with a lubricating jelly and passed into the introducer, which can be
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relatively easily inserted via the cervix without dilation. The introducer is 
withdrawn and the balloon inflated using a clear sterile saline solution. The 
fibre sealing connection is loosened and the fibre advanced into the balloon, 
the required length having previously been marked.
10.2.3 Uterine specimens.
A total of 7 premenopausal and 2 postmenopausal patients scheduled for 
hysterectomy for benign conditions such as menorrhagia and prolapse, were 
recruited into the study. Nine intact, fresh uteri were obtained fresh from 
surgery and placed in saline. The uterine vessels were tied to minimise 
leakage of blood from the tissue. During the experiment, the uteri were kept 
moist with saline. The study was approved by the local ethics committee, and 
all women were counselled and consented for their uterus to be used in the 
study.
10.2.4 Methodology.
The specimens were gently held by clamps in the laboratory. The cervix was 
dilated to 6mm and a flexible 5mm hysteroscope with a light source was used 
to view the cavity. The cavity was checked for uniformity, and pathology 
(polyps, significant fibroids or suspicious lesions) (figure 10.4). Five 16G 
cannulae were passed through the myometrium from the outside (figure 10.5). 
The needle inserts were withdrawn when the needles were seen within the 
cavity with the hysteroscope. Detection fibres (500pm) were passed through 
the cannulae under hysteroscopic control.
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Figure 10.4: Checking uterine cavity with a hysteroscope.
*  1
Figure 10.5: Inserting fourth cannula. The placement of the others has 
already been checked with the hysteroscope.
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The positioning of the five cannulae is shown in the diagram (figure 10.6).
Figure 10.6: Approximate positioning of cannulae and isoprobe detectors within
the uterine cavity.
The detection fibres were placed an estimated 1 -2mm within the cavity. Once 
all five had been placed and checked, the hysteroscope was withdrawn. One of 
the balloon devices or the bare fibre was then inserted into the cavity. The 
balloon devices were filled with saline. The amount of saline inserted varied, 
but was between 1.5 to 3 ml for the Medlight balloon and 2 to 8ml for the 
Cook. Light was supplied from a 630 nm diode laser (Diomed, Cambridge 
UK). Power output was 100 mW. A 2 cm long, 400 pm core diameter radially 
diffusing fibre was positioned inside the devices and used to illuminate the 
cavity (RD-20 Medlight SA, Eclubens, Switzerland) (figure 10.7).
Optical fibres with spherical, isotropically diffusing tips were used at the 
locations shown in figure 10.6. Each had an 800pm diameter scattering bulb
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Figure 10.7: Uterine cavity with (a) laser inserted and (b) being 
illuminated with laser light.
(DPI Isoprobe, PDT Systems Inc., Santa Barbara, CA). These detectors 
measure the total power arriving at the bulb from all directions, which is the 
quantity of interest in PDT (light from any direction will activate the 
photosensitiser). The isoprobes were connected to a CCD spectrograph 
(Control Development, South Bend, Indiana) - each individual measurement 
was a spectrum in the range 625 - 635 nm and the power was estimated as the 
integral under the laser peak in this wavelength range. This was done for 
several reasons: the CCD array has high sensitivity and a very wide signal 
range and it allowed compatibility with other studies (including fluorescence 
measurements) undertaken with the same equipment. The isoprobes were 
introduced through the wall of each uterus through the plastic cannulae. 
During the balloon introduction, the isoprobe bulbs were retracted within the 
cannulae, and they were advanced to their locations at the endometrium when
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inflation was complete. This protected the fragile bulbs from damage during 
insertion and inflation of the balloons. The depth of insertion for each 
isoprobe was ascertained using a hyseteroscope before starting the 
measurements so that approximately 2mm were within the cavity, and flags 
were placed on the isoprobe fibres to ensure these depths were maintained 
during the measurements.
10.2.4.1 Data collection.
The raw data were collected using the CCD spectrometer as described. To 
convert these data to power readings, the background was subtracted from 
each spectrum. The power was calculated as the integral under the laser peak 
in the area under this baseline-corrected spectrum between 625 and 635 nm. 
Integration times were 0.01s, 0.025s and 0.05s, this allowed corrections to be 
made, to a standard integration time of 0.05 s. Therefore, readings taken at 
0.01s were multiplied by 5 and readings at 0.025s were doubled. Extraneous 
light is excluded from the CCD as only light at this particular wavelength is 
measured. Cross-calibration of the data were required as we were using five 
isoprobes. This corrected for variations in the light fibre collection properties. 
This was done by the use of an integrating sphere coupled to the laser (figure 
10.8). The individual isoprobes were then placed in the detector and the laser 
fired at specific power settings. A calibration curve was therefore generated 
for each isoprobe. With each fibre this was a straight line. The calibration 
factor was taken as the slope of this curve. The corrected data were then 
obtained.
For each measurement, when the balloon and isoprobe locations had been 
confirmed, the laser was activated and the power measurements were taken.
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The balloon was then deflated and removed. The fibre placement was checked 
with the hysteroscope, and the balloon device re-inserted and the 
measurements repeated to assess reproducibility.
At the end of the experiments the uterus was opened with a longtitudinal 
incision in the lateral wall. The uterine dimensions, macroscopic appearance 
and presence or otherwise of fibroids were noted.
The uterii were transferred to the histopathology department for fixing in 
formalin and histological assessment.
10.3 Results.
Three of the specimens had such significant fibroids that the cavities were 
highly abnormal and they were excluded from the main results, but the results 
are discussed later. The remaining six uteri weighed 420-680 g. The internal 
transverse diameters of the cavities were 24 - 56 mm. The internal 
longitudinal lengths of the cavities from fundus to internal os were 62-104 
mm. There were small fibroids in a further two specimens; one with three 
fibroids of less than 10mm, distorting the cavity, the other with one 11mm 
fibroid and another 4mm fibroid <50% within the cavity. Apart from fibroids 
there were no abnormal pathological findings. The endometrium was little 
disturbed and the gynaecological pathologist was satisfied with her results.
10.3.1 Cook balloon.
Uniformity from the transparent Cook balloon was comparable to the 
MedLight balloon - implying that scattering from the tissue was sufficient to 
redistribute the incident light effectively (figure 10.8). In fact more light 
reaches the uterine horns (40% of maximum, c.f. 20% with MedLight).
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Figure 10.8: Cook balloon data. Laser fibre is placed at fundus and 
withdrawn one and two cms
Throughput is also higher. The larger balloon fits the cavity better, although 
when fully inflated the pressure may reduce blood flow and hence oxygen 
concentration and the PDT effect.
10.3.3 Medlight balloon.
Uniformity is good (figure 10.9), but less light reaches the horns of the uterus 
(20% of maximum). This may be because the balloon is too small to fill the 
whole cavity, reducing the transmission efficiency to the fundus of the uterus. 
The device is very easy to use. Throughput is lower than the transparent
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Figure 10.9: Medlight balloon data. Balloon is placed at fundus.
balloon because the high internal reflectance reduces transmission to the 
tissue.
One postmenopausal uterus which was the smallest in these experiments, and 
had internal diameters less than the Cook balloon, functioned with no 
problems with the Medlight balloon, but split as soon as we attempted to 
inflate the Cook balloon.
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Figure 10.10: Deflated and inflated Medlight balloon.
10.4 Discussion.
Complete and uniform illumination of the endometrial cavity is crucial for 
PDT to deliver complete endometrial ablation with no subsequent 
regeneration. Improvement in light distribution within the bladder has been 
shown with fluid distension (Marynissen et al 1989). Fehr et al showed that 
by using three or four fibres in the cavity, that no distension is required as long 
as the cavity is completely normal; even then, a small volume of fluid can 
improve uniformity of illumination by up to four times. Limitations of filling 
the cavity with fluid are several. Spillage of fluid either through the fallopian 
tubes or through the cervix would result in non-standard distension, unless an 
automated, possibly pressure-driven, distension device was used. Distension 
with high volumes can lead to pain. Unless integrated, a second insufflating 
device would need to be employed. In practical terms a balloon, with a closed 
system would be ideal. This could easily be pressure-monitored. By utilising a 
small balloon device, the uterine cavity can be distended and because of the
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natural reflectiveness of the endometrium can be used as an ‘integrating 
sphere’ which further improves overall light distribution (Tromberg et al 
1995; Wyss et al 1995). This can also lead to a more uniform distribution even 
when there are small fibroids. The ability of the transluscent balloon to 
conform to the cavity is helpful in this regard (figure 10.10).
The Cook balloon was too large and too rigid to be a successful intrauterine 
balloon for PDT. The medlight balloon, despite being smaller than the uterine 
cavity had a broadly similar light distribution characteristics, within each 
uterus. When we removed the Medlight balloon and reinserted and continued 
with the experiment, the results again were similar. This was certainly not the 
case with the Cook balloon, which had highly varied results at each position, 
which altered considerably with re-insertion. Several modifications will be 
required to the Cook balloon if this device is to progress to clinical use. It 
needs an introducer. It needs a stiffer catheter with a larger internal diameter 
but the balloon itself should be thinner and more flexible.
The Medlight Balloon device has been used clinically elsewhere. Although in 
theory its characteristics are inferior to the Cook balloon, it is likely to be used 
for the first clinical applications because of its ease-of-use.
The presence of a submucous fibroid had a significant effect on the results. 
Our aim was to use a balloon to mould to the cavity, to use the inherent 
reflective capabilities of the endometrium and the transluscent nature of the 
balloon to cause a fairly uniform glow within the uterus. Our hope was that 
this would result in illumination of all parts of the cavity.
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By using a single fibre, there are three potential problems. First, there is a 
potential problem of the diffuser fibre being off-centre and thereby part of the 
endometrium furthest from the fibre will have less illumination. Second, 
maximal illumination will be concentrated around the centre of the cavity, in 
order to adequately illuminate all areas of the cavity, a higher power would 
have to be used, this in turn may lead to thermal effects. Third, in order to get 
a maximal PDT effect with a single fibre the treatment time may be 
prohibitively long.
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CHAPTER 11: CONCLUDING 
REMARKS.
11.1 Objectives.
The minimally invasive treatment of menorrhagia has been a goal since 
ancient times. In the Bible abnormal menstrual blood loss required atonement 
by a priest;
‘And if a woman has a discharge of blood for many days .... on the 
eighth day she should take two turtle doves or two young pigeons, 
and bring them to the priest, to the door of the tent of meeting; and 
the priest shall offer one for a sin offering and the other for a burnt 
offering; and the priest shall make atonement for her before the Lord 
for her unclean discharge.’
Leviticus Chapter 15; v: 25-30.
The aim of this study was to cause the selective destruction of the 
endometrium, without causing myometrial damage, by photodynamic therapy 
using topical ALA applied transcervically. We looked specifically at 
increasing the photodynamic effect of ALA using a novel iron-chelating 
agent, CP94. There is a need to improve on the currently available techniques 
for the treatment of menorrhagia.
We will outline currently available minimal access techniques, and then 
discuss the possible future place of PDT.
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11.2 Other minimal access surgical treatments.
The endometrium has a remarkable capacity to regenerate, and any surgical 
procedure to treat excessive uterine bleeding, without a hysterectomy must 
ensure that there is adequate destruction of the basal glands of the 
endometrium. There are many techniques available. Some are well-established 
and well researched. Others are still at the research or evaluation stage. A 
summary of the ‘successes’ of these devices is outlined in table 11.1.
MAS technique Success (%)
(oligomenorrhoea and 
amenorrhoea unless stated 
otherwise)
Patient
satisfaction
Uterine curettage 60 (but short-term)
ELA (endometrial laser ablation) 85-90 60-70
TCRE (Transcervical resection of 
the endometrium)
80-85 60-70
HTA (Hydrothermal ablation) 40 60-75
Thermal balloon 83 80-90
ELITT (endometrial laser interstitial 
thermal therapy)
60-70 (amenorrhoea) 80
MEA (Microwave endometrial 
ablation)
40 (amenorrhoea) 80
Cryoablation 28 (amenorrhoea) 88
Diathermy 40 (amenorrhoea) 60
Table 11.1: Success and satisfaction rates with the newer MAS techniques -  see 
text.
The rates of patient satisfaction are reasonably high, despite low amenorrhoea 
rates, as amenorrhoea is not necessarily the desired outcome. Women often
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want a reduction in MBL, without resorting to hysterectomy. There is a 
correlation between oligomenorrhoea or amenorrhoea rates and satisfaction, 
for all modalities (Garry 2000). Nevertheless, there are drawbacks to most 
methods, particularly in long term efficacy.
11.2.1 Uterine curettage.
Uterine curettage was discussed in chapter 3. There is well documented 
evidence that there is an associated reduction in MBL in the first few months 
after the procedure of up to 60% (Mikuta 1970), however the effects are short­
lived (Haynes et al 1977). It is a relatively simple procedure to carry out, but 
complications include uterine perforation and intrauterine adhesions or 
synechiae. Due to the overuse of this procedure the Royal College of 
Obstetricians and Gynecologists (RCOG) issued guidelines in 1994 (Table
3.2) (RCOG 1994).
11.2.2 Endometrial laser ablation (ELA), rollerball ablation 
and transcervical resection of the endometrium (TCRE).
ELA was first reported by Goldrath in the late 1970s (Goldrath et al 1981).
The first electrosurgical resection was described in 1983 (DeChemey and
Polan 1983). TCRE was made popular in the UK by Magos (Magos et al
1989). A simpler technique than loop resection is rollerball ablation (Vancaille
1989). Since then a great expansion in the use of the technique has occurred,
driven by both gynaecologists wishing to perform these operations and
demand from patients. Numerous publications of uncontrolled series followed
(Garry et al 1991; Magos 1991). These are, therefore, not ‘new’ techniques. A
majority of the new methods employed for endometrial destruction have been
compared with these ‘gold standards’.
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Figure 11.1: Gynaecological resectoscope.
The standards that these techniques have set are high. Most authors use 
“success” to mean patient satisfaction. Goldrath described his ten-year data in 
1989 (Goldrath 1989), reporting a 93% “success rate” from laser ablation. 
Garry et al reported a 97% success rate, although 8% required a second 
procedure (Garry et al 1991); the rate of amenorrhoea was 60%. Erian 
reported on 2342 women with a 93% success rate and 56% amenorrhoea rate 
(Erian 1994).
Outcomes after rollerball ablation for menorrhagia are similar. Short-term data 
are available comparing rollerball to hysterectomy. With follow-up of at least 
18 months, Mousa showed satisfaction rates of 100% with hysterectomy and 
79% with rollerball. He also reported that 100% of the women in the
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hysterectomy group would recommend it to a friend and 91% in the rollerball 
group (Mousa et al 2001).
Endometrial resection using a cutting loop diathermy (figure 11.2) has reports 
of 80% success rates after more than 2 years. The use of medical pre-treatment 
of the endometrium prior to surgery with danazol, medroxyprogesterone 
actetate or GnRHa compared to no pre-treatment failed to improve 
amenorrhoea rates or patient satisfaction (Rai et al 2000; Trivedi et al 1999). 
However, in clinical practice the use of pre-treatment for endometrial 
preparation is widespread.
Figure 11.2: Resectoscope showing loop cutting endometrium.
The choice of whether to use laser ablation or endometrial resection, is really 
the surgeon’s, based on his or her skill as well as the availability of equipment.
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No randomised-controlled studies have been published. A large study by the 
Royal College of Obstetricians and Gynaecologists (RCOG) of the minimally 
invasive surgical techniques, laser, endothermal or endoresection 
(MISTLETOE study Overton et al 1997) - has shown a 60-70% satisfaction 
rate in women undergoing either combined techniques, or resection, or laser or 
rollerball alone. This is coupled with amenorrhoea rates at one year of 
between 68% (for laser alone) and 85% for the combined resection and 
rollerball.
A recent study of women randomised into medical management or 
endometrial resection for menorrhagia showed that women allocated to the 
surgical management arm were in better general health (Cooper 1999). The 
study concluded that early recourse to hysteroscopic surgery will ‘afford these 
women better relief of symptoms and improvements in health related quality 
of life’.
These minimal access techniques were used as an alternative to hysterectomy 
in women with dysfunctional uterine bleeding or menorrhagia, resistant to 
medical treatment. These techniques are, however, not without their risks. 
They require the uterine cavity to be irrigated with fluid. For ELA, saline is 
generally used. For TCRE, an electrolyte-free solution is used, usually 
glycine. Fluid overload is potentially fatal, hence careful attention to fluid 
balance must be paid (figure 11.3).
Hysteroscopic surgery is associated with complications. The most serious, 
common complication is perforation of the uterus (Lewis 1994). It occurs 
either whilst dilating the cervix or with the insertion of the hysteroscope. It 
occurs in approximately 1-2% of cases (Hulka et al 1995; Lewis 1994).
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Approximately 50% of all perforations occur during the operator’s first three 
cases. After a perforation it is usual to perform a laparoscopy to assess 
bleeding, generally nothing more needs to be done. If, however, the 
perforation has occurred after the resection has commenced, there is a serious 
risk of extrauterine organ damage, and a laparoscopy or even laparotomy is 
mandatory.
Figure 11.3: Careful fluid balance during a TCRE
Significant fluid overload occurs in approximately 1-3% of cases. Different 
figures are quoted, and it is in a large way preventable by using a ‘running 
balance’. However, should large vessels be breached deep in the myometrium, 
there will be rapid fluid absorption. Excess absorption leading to fluid 
overload may be minimised by giving frusemide intraoperatively. Excess 
glycine absorption may give rise to life-threatening hyponatraemia, with
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symptoms of hypertension, bradycardia, confusion, seizures, coma and death, 
unless recognised and treated. Death may occur in this acute situation with a 
sodium of 120 mmol/1 (Witz et al 1993). Healthy young women may absorb
I.5 1 of glycine with only minor effects. Close monitoring of fluid inflow and 
outflow should be done during these procedures. Above a deficit of 1000 ml, 
the procedure should be stopped, and serum sodium should be measured to 
detect significant hyponatremia, and the woman should be carefully 
monitored.
Serious haemorrhage after endometrial resection requiring hysterectomy 
occurs in 1% of cases (Overton et al 1997). The bleeding can be controlled 
using a foley-type catheter inflated within the uterus. The tamponade is slowly 
reduced 24 hours later.
II.2.3 Versapoint.
Versapoint (Gynaecare Inc., Menlo Park, California, USA) is a bipolar device 
where the active and return electrodes are consolidated into a single 
instrument. The current is symmetrically distributed through the tissue 
between the two electrodes, the patient is therefore not part of the current 
pathway. The electrosurgical generator determines the power administered 
based on the impedance of the tissue. The device channels current into tissue 
vaporizing it. The devices are 1.6 mm (5 F) in diameter, and fit down the 
operating channel in a standard hysteroscope. There are different electrodes 
designed for variable tissue effects, a ball tip for precise vaporization and 
desiccation, a spring tip for rapid tissue vaporization and desiccation and a 
twizzle tip for vaporization and needle-like cutting (Figure 11.4).
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Figure 11.4: Versapoint tips.
Given the small size and focused tissue effects, this system is aimed at 
outpatient procedures such as hysteroscopic polypectomy, adhesiolysis and 
vaporization of smaller submucous myomata. It is also available as a 
resectoscope to be used as for TCRE. It uses saline as it requires a conducting 
fluid. Saline is a safer medium to use than glycine.
11.2.4Hydrothermal ablation (HTA).
This technique (BEI Medical Systems, Hackensack, New Jersey) requires a 
specialised hysteroscopy. Endometrial destruction is achieved by circulating 
hot saline through the inflow of an 8mm hysteroscope. After the procedure the 
cavity is smooth with little scar tissue formation long-term, unlike TCRE. This 
allows the procedure to be repeated (figure 11.5). The system operates at a 
pressure of 50mmHg. No spillage is seen from the fallopian tubes at this 
pressure (Richart et al 1999). Results of amenorrhoea at 12 months of 40% are 
equivalent to rollerball (51%) (Corson et al 2001).
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Figure 11.5: Uterine cavity after HTA
11.2.5‘Blind’ procedures - non-hysteroscopic surgery.
In recent years there has been a huge expansion of ‘blind’ transcervical 
techniques of endometrial destruction. Device manufacturers are driving much 
of this technology; few have been evaluated thoroughly in randomised trials.
11.2.5.1 Thermal balloon.
There are two thermal balloon devices currently available; Cavatherm and 
Thermachoice. Essentially they are all very similar, consisting of a strong, 
flexible and distendable silicone balloon, at the end of an introducing handle. 
The devices are about 16 cm long and 6-8 mm in diameter. The balloon is 
passed through the cervix, inflated with fluid to a pressure of 150-200 mmHg, 
causing it to conform to the uterine cavity. The systems are disposable and are 
therefore ‘single-use’ systems. Once activated, the irrigating fluid is
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vigorously circulated within a closed system, the temperature of the fluid is 
maintained at 75 - 85 °C. The treatment cycle is 15 minutes (Friberg et al 
1996).
The ThermaChoice uterine balloon therapy system (Gynecare Inc., Menlo 
Park, California, USA) is one such device. It consists of a 16 cm long, 4.5 mm 
diameter catheter with a latex balloon at its distal end which houses a heating 
element.
The controller unit monitors, displays and controls the preset intra-balloon 
pressure, temperature and treatment time. The device automatically 
deactivates if the pressure falls below 45 mmHg or rises above 200 mmHg. 
The cervix is dilated to 5.5 mm. The balloon inserted so as to touch the 
fundus, and then inflated with 5% dextrose in water until the intrauterine 
pressure reaches 150-170 mmHg - this typically requires 10-15 ml of solution. 
The heater is then activated and maintains the intra-balloon temperature at 
87°C (± 5°C). The treatment cycle of 8 minutes results in 4 - 6 mm of tissue 
destruction (Neuwirth et al 1994).
CavaTherm (Wallsten Medical, Morges, Switzerland) is a similar device 
(figure 11.6). Thermachoice has been investigated and published data are 
available on several hundred women (Amso 1998). CavaTherm has had less 
investigation, but a series of almost 50 women has been reported (Friberg 
1998). Patient satisfaction rates of 80 - 90% are reported, but with
amenorrhoea rates of only 15%.
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Figure 11.6: Cavatherm balloon
One randomised trial has compared the thermal balloon with rollerball 
ablation in the USA (Meyer et al 1998). The entry criterion was true 
menorrhagia, based on a pictorial chart; women with fibroids were excluded. 
No endometrial preparation was used, but all women underwent curettage 
immediately prior to treatment. Almost half the women in the balloon arm 
were treated with only local anaesthetic.
Satisfaction rates were equivalent at about 80%. Amenorrhoea rates were 15% 
with the balloon and 27% with the rollerball, but menstrual scores were 
significantly less with rollerball than with the balloon (the main outcome 
measure). Dysmenorrhoea was also significantly reduced with both 
techniques. Gervaise compared ThermaChoice with endometrial resection 
(Gervaise et al 1999). There was no difference between the two groups in 
relation to complications, morbidity or success rates. Success was counted as 
elimination of menses or a ‘significant reduction of flow’. At 24 months 
success for the balloon was 83% and 81% for the resection group. At 36 
months the rates were 83% and 76% respectively (Gervaise et al 1999). 
Loffer’s three year study comparing rollerball and ThermaChoice showed
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little difference between the two groups at treating menorrhagia, avoiding 
hysterectomy, decreasing dysmenorrhoea, decreasing premenstrual symptoms 
and improving quality of life (Loffer 2001).
Due to the lower complication rate with balloon ablation compared with 
resection, authors have suggested that it should be the procedure of choice 
(Loffer 2001; Bongers et al 2000).
11.2.5.2 Thermal Laser Therapy.
The endometrial laser interstitial thermal therapy (ELITT) system (Sharplan 
Laser Ltd., Needham, Massachusetts, USA) consists of three diffuser laser 
fibres, joined distally by semi-rigid plastic arms. Proximally they are attached 
to a hand piece. The system is passed through the cervix, dilated to 8mm, and 
once in the uterine cavity the system is activated by opening the ‘arms’ which 
cause the fibres to lie in contact with the lateral parts of the cavity. A 20 W 
diode laser is activated for 7 minutes. Data from women followed-up for at 
least a year showed 63% - 71% amenorrhoea rates (Donnez et al 1996; 
Donnez et al 2000). The rate of amenorrhoea or severe hypomenorrhoea was 
greater than 90% (Donnez et al 2000).
11.2.5.3 Diathermy.
The Novacept device (Novasure, Palo Alto, California, USA) uses bipolar 
energy and a distendable wire mesh to impart the energy (Cooper 1998). The 
endometrium is drawn into the energy field by suction. The treatment time is 
automatic, based on impedance in the tissues, but usually lasts between one 
and two minutes. There are, however, no published data using this device.
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The Vestablate system (Vesta Medical Inc, Mountail View, California) is a 
multielectrode intrauterine balloon device. The controller regulates energy to 
each of the 12 plates by monitoring the temperature at each electrode. The 
treatment cycle is set at 75°C. Treatment lasts 4 minutes after a one minute 
‘warm-up’. Results compared with TCRE are of amenorrhoea rates of 31% 
compared with 40% at 1 year.
11.2.5.4 Radiofrequency and microwave.
These energy sources are very similar, but must not be confused.
Radiofrequency endometrial ablation (RaFEA) uses a frequency of 27.12 
MHz. Thermal damage is caused by the forced oscillation of charged particles 
in the endometrium caused by the device, passed into the cavity. The 
endometrial surface temperature is raised to approximately 65°C (Phipps et al 
1990a; Phipps et al 1990b). The procedure takes 20 minutes, with the probe
Figure 11.7: Microwave ablation -  handset, 
being rotated to ensure an even destruction.
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Microwave endometrial ablation (MEA) at 9.2 GHz destroys the endometrium 
to a depth of 6 mm (Sharp et al 1995). The commercial system (Microsulis 
Ltd., Waterlooville, UK) requires the cervix to be dilated to 8 mm and by way 
of thermocouples, the temperature of the endometrium is monitored (figure
11.2). The operator maintains a steady ‘back-and-forth’ movement within the 
cavity, slowly withdrawing the device. The system screen records 
temperature. The operating temperature is 70 - 80°C. The system alarms at 
85°C, and shuts off at 90°C. An advantage of this system is that if the initial 
temperature rise fails, suggesting an uterine perforation, the system will also 
shut down. The procedure takes a few minutes only.
With power levels of 30 W, and energies approaching 10 kJ, 5 - 6 mm deep 
necrosis can be achieved. Short-term data comparing this technique with 
TCRE is encouraging giving 80% satisfaction and 57% amenorrhoea at 6 
months (Sharp et al 1995; Cooper et al 1998). Three year results compared 
with TCRE have an amenorrhoea rate of 40% for both modalities with 
satisfaction rates of 77% and 75% respectively (Cooper et al 1999).
The use of Microwave ablation has recently been supported by the National 
Institute for Clinical Excellence (NICE) in guidance published in August 2003 
(NICE 2003).
11.2.5.5 Cryoablation.
The First Option system (CryoGen, San Diego, California) uses carbon 
dioxide, freon gas and nitrous oxide gas under pressure to freeze the tip of a 9 
mm probe. The probe is similar in shape to a hegar dilator. The tip of the
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probe reaches temperatures of -55°C, which causes cell death to a depth of 
3.2-7.2mm when in direct contact with the endometrium (Kremer et al 2000). 
Treatment times last 2 minutes. At 12 month follow-up compared to rollerball, 
there are satisfaction rates of 88% for both treatments; amenorrhoea rates of 
28% and 52% respectively (Dobak et al 2000).
With the other techniques available as discussed, we can consider the 
advantages and disadvantages of photodynamic therapy.
11.2.6 Photodynamic therapy
Unlike other methods of local injury, for example thermal coagulation with a 
laser or diathermy, or ionising radiation, the biological effects on tissues with 
PDT is such that after healing, there is no resultant weakening of the 
underlying strength of the collagen in these tissues (Barr et al 1987; Pope and 
Bown 1991; Pope et al 1991). PDT does not cause necrosis in the underlying 
collagen matrix of the target tissue. This makes PDT a very attractive option 
for endometrial destruction. However it must compete with the “successes and 
patient satisfaction of the other devices and techniques .
Kennedy and Pottier showed that using ALA intravenously (i.v.) in mice 
resulted in high levels of the photosensitiser PPIX in the endometrium. They 
also showed that there were much lower levels in the myometrium (Kennedy 
and Pottier 1992). Judd et al gave ALA i.v. and showed PPIX fluorescence 
nine times higher in the endometrium as the myometrium at 3 hours (Judd et 
al 1992).
Chapman et al gave photofrin either i.v. (7mg/kg), intraperitoeally (i.p.) 
(7mg/kg), or at laparotomy into the uterine horns (i.u.) (0.7mg/kg) of rats. She
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showed that endometrial Photofrin fluorescence was highest in those rats 
given i.u. ALA, despite the lower dose.
Chapman also examined the effects of oestrogen on uptake of photofrin on 
rats after i.u. instillation. The levels were highest in the group given oestrogen 
alone, compared with GnRHa suppression, GnRHa suppression with 
oestrogen or no oestrogen (Chapman 1993).
Photodynamic therapy following topical administration into the uterine horns 
followed. Yang et al showed that there was a difference in pregnancy rates 
between the two horns in rats that underwent uterine PDT 3 hours after pre­
treatment with ALA injected into one uterine horn. There was no difference in 
implantation rates in those rats bred at 10 days using ALA compared to saline 
in the non-PDT group (76% implantation vs. 92%). However in the light- 
treated group there was a difference in implantation rates of 3.8% compared 
with 100%). He also showed that the endometrial destruction caused by ALA- 
induced PDT was lasting. Rats bred at 60 days after PDT had 16.7% 
implantations in the treated horns compared with 100% in the untreated horns 
(Yang et al 1993).
Steiner et al showed that after ALA-induced PDT there was destruction of the 
endometrium and atrophy of the horns in the treated side. Also that 
reproductive performance was significantly worse on the treated side. There 
were a mean of 0.4 sacs on the treated side compared with 8.9 sacs on the 
untreated side). He showed that the peak levels of PPIX were reached 3-6 
hours after topical administration (Steiner et al 1996).
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Pius Wyss from the Beckman Laser Institute in California performed a 
number of experiments. His initial set of experiments was designed to 
determine optimal parameters for PDT of the endometrium. He used rats and 
rabbits to show peak PPIX fluorescence at 3 hours in both animal models with 
uterine instillation of ALA, with much higher levels in the endometrium 
compared with the myometrium. Peak levels were analysed with a variation of 
dose of ALA. This resulted in the highest peak at 200mg/ml. He altered the 
pH of the solution from pH 1.6 - 2.2 (unbuffered); to pH 5.5 and showed no 
significant variations in levels at the different pH (Wyss et al 1994).
After ALA administration into monkey uteri PPIX fluorescence was noted at 
4-5 hours (Yang et al 1996). The monkeys were noted to be able to tolerate 
high doses of ALA with no ill-effects; the only anomaly was a high aspartate 
aminotransferase level in serum samples at 24 hours (Yang et al 1996).
Michael Gannon in Leeds undertook a series of experiments on human uteri in 
vivo and in vitro. In the in vitro study, 4 uterii had the uterine arteries 
cannulated and were perfused with 0.9% saline at 37.5°C, ALA was instilled 
into the cavities. He showed a ten-fold increase in PPIX fluorescence in the 
endometrium compared with the myometrium. The in vivo study involved 8 
women who were undergoing hysterectomy. They had varying amounts of 
ALA instilled into the uterine cavity 2-5 hours before the hysterectomy. 
Again, levels of PPIX fluorescence were some nine times higher in the 
endometrium than the myometrium. In both sets of experiments the 
fluorescence was noted throughout the endometrium including the deep glands 
(Gannon 1995).
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ALA solution has been instilled into the uterine cavities of 27 women by Fehr 
et al (1996). He showed peak fluorescence to occur at between 4 and 8 hours; 
this was 48 times higher than the myometrium, and suggested that selective 
PDT causing endometrial destruction would be possible.
Human PDT using ALA has been performed (Gannon et al 1998). Gannon has 
treated over 30 women but the results are highly variable, although there have 
been no adverse events (Gannon personal communication).
Topical application of ALA in the uterus allows lower doses of drug to be 
used. This in turn results in reduced systemic levels and therefore may 
eliminate systemic side-effects, notably skin photosensitivity (Dougherty et al 
1990; Razum et al 1987; Roberts et al 1995). Current clinical experience of 
PDT induced with topical ALA, has had limited success (Gannon et al 1998) 
we presume, partly due to incomplete illumination of the uterine cavity, and 
partly due to insufficient levels of PPIX being present throughout the 
endometrium. By adding CP94 and therefore chelating iron locally, the 
conversion of the photoactive protoporphyrin IX (PPIX) to haem may be 
reduced, leading to higher and more persistently higher local concentrations of 
PPIX in the endometrium. Our aim was to ascertain the optimal conditions for 
endometrial PDT with ALA prior to embarking on clinical trials.
The two methods of increasing the PDT effect in the human uterus are to 
increase photosensitiser concentration, or increase the amount of light. 
Unfortunately the human endometrial cavity is a non-uniform cavity in the 
shape of a flattened triangle. The light distribution within the cavity is 
therefore non-uniform and somewhat unpredictable. Our study has shown that, 
in the animal model, higher levels of photosensitiser are present in the
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endometrium by using an iron chelator CP94 compared to ALA alone. Topical 
administration of ALA with CP94 led to a dramatic increase in the PPIX 
fluorescence in the endometrium. The increase was more than doubled in the 
superficial endometrium, 1.7 times increased in the deep endometrial glands 
and was three times less in the myometrium. Overall the superficial 
endometrium had levels of PPIX almost 30 times higher than the 
myometrium.
We have shown an improved and long lasting PDT effect in the animal model. 
We can now take these techniques to the clinical setting.
In order to increase the light dose, a balloon device can be utilised. The 
selective destruction is of paramount importance, as the myometrium varies in 
thickness throughout the uterus. The area where regeneration is most likely to 
occur is near the ostia and it is here that the myometrium is at it’s most thin. 
The selectivity of PDT is therefore very desireable.
11.2.6.1 Clinical studies.
The endometrium lends itself to topical administration of photosensitiser. The 
concentrations of drug are much higher than could be achieved by the oral or 
IV route, because of the systemic side-effects.
It has to be stated that there may be no inter-species similarity, and the peak 
photosensitivity will have to be fully investigated in the human uterus. The 
difficulties will not end here, indeed the stage of the menstrual cycle could 
have a very large part to play in the success of treatment.
Light distribution within the uterine cavity has proved to be a more demanding 
problem. The application of a transluscent balloon into a semi-reflective
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slightly distended cavity has resulted in good overall illumination in a normal 
uterus. The results should also have been reproducible. Our results appear 
acceptable in terms of light dosimetry. If the drug can be instilled in an 
acceptable fashion then there could be successful and long lasting endometrial 
destruction in the human.
11.3 Future development.
The problem of low levels of PPIX concentration in the endometrium has been 
overcome by this study, by the coadministration of CP94. Light dosimetry in 
the rabbit has not been an issue, as the rabbit uterine horns are essentially 
cylinders. The human endometrial cavity posed greater problems. This 
appears to have been successfully tackled with our balloon device.
The future development of ALA PDT for endometrial destruction in 
menorrhagia should now be aimed at specific areas.
The pharmacokinetics of ALA absorption within the uterine cavity has to be 
addressed. Although Wyss showed that peak absorption with rats and rabbits 
was around 4 hours (Wyss et al 1996), there can be no such presumption in the 
human. As discussed previously, the oestrogen status of the uterus has an 
impact on drug absorption and PDT effects, therefore a similar investigation 
will have to be performed in women. Garry and others have shown that pre­
treatment of the endometrium prior to endometrial ablation has improved the 
effectiveness, whether this is merely a curretage prior to the procedure, or 
some months treatment with GnRHa analogues (Garry et al 1999).
Distension of the uterine cavity either with a liquid or by a balloon device 
appears the way forward. The limitations of distension causing pain are not
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bome out with the use of the newer endometrial ablation balloons - used under 
local anaesthetic and inflated with more than 15 ml saline to a pressure of over 
diastolic blood pressure with little problem. PDT does depend on oxygen in 
the tissues and therefore any distension should be kept to a minimum to 
prevent hypoxia in the tissues.
Use of devices with multiple diffuser fibres seems an avenue that could also 
be investigated.
Other areas of gynaecology could also benefit from PDT. The treatment of 
endometriosis is promising. The idea of selective uptake of photosensitiser by 
active endometriosis in the peritoneal cavity with subsequent light application 
at laparoscopy causing specific ablation of the endometriosis sparing healthy 
tissue is an exciting concept.
The use of phthalocyanines in endometrial ablation has appeal. The longer 
wavelength needed to activate these drugs, means that the light dose 
penetrates the tissues to a greater degree. This should lead to greater and more 
sustained destruction of the endometrium. However, destruction must be 
limited to the endometrium.
The coupling of photosensitisers to antibodies or viral vectors to target tissues 
very specifically is exciting and could have specific uses in gynaecology 
(Schmidt etal 1992).
11.4 Limitations of PDT in the treatment of 
menorrhagia.
The results of other workers showing peak fluorescence at 3 and 4 hours after 
administration of ALA would have meant that ALA-PDT was quite an
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attractive proposition (Wyss et al 1996). A woman could attend the hospital 
ward in the morning. She could have a small intrauterine catheter placed 
transcervically. A 1 ml balloon would prevent spillage and keep the catheter in 
place. She would then be free for two or three hours, would return and have a 
short treatment in the examination chair, with little or no discomfort.
Unfortunately our results are at odds with most workers. Interestingly Wyss 
found peak fluorescence to be between 4 and 8 hours. He then treated at four 
hours. Our results show a small peak at three to four hours and a second peak 
at seven to eight hours. However we found a much greater 7 hour peak with 
the addition of CP94.
Administration to a woman of the drug 7 hours prior to treatment is much less 
user friendly. The treatment time then necessitates either an overnight stay or 
a long all day stay. Both users and providers find a short ‘one stop’ approach 
much more attractive.
11.5 Summary of the future developments in PDT 
for endometrial destruction.
Work is continuing to further investigation PDT for endometrial destruction in 
the clinical setting.
1. Initially ALA and CP94 will be investigated by giving the drugs 
topically to the uterus of women about to undergo hysterectomy, in a 
similar manner to our animal experiments.
2. When the best drug dose is known a small part of the endometrium 
will be treated at different time scales after drug administration three 
days prior to hysterectomy.
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3. When the correct light dose is known, the whole endometrium will be 
treated three days prior to hysterectomy.
4. The next step would be to investigate long-term success -  measured 
over a few weeks prior to hysterectomy.
5. Then we would investigate long-term success without subsequent 
hysterectomy.
6. Finally the aim is to compare PDT with other MAS treatments for 
menorrhagia in a RCT.
11.6 Conclusion.
Successful photodynamic ablation of the endometrium can be carried out with 
ALA. This thesis has shown that it is possible to substantially increase the 
PPIX levels in the glandular elements of the endometrium and also to increase 
the destruction after PDT by the addition of a novel iron-chelating agent 
CP94. This destruction is not at the expense of myometrial destruction as the 
PPIX levels within the myometrium remain low. This is important from a 
safety point of view as it prevents the possibility of collateral (extra-uterine) 
tissue damage. Selectivity and increased tissue damage is the key to the 
addition of CP94.
There are problems that have been brought up by this thesis. The light 
distribution within the cavity will be of huge importance for successful 
clinical outcomes. Once the light distribution has been sorted out, successful 
PDT of the endometrium could become a reality. However, the simplicity of 
this technique is marred by the potential hindrance of having to pre-treat the 
endometrium -  possibly 7-8 hours prior to treatment. This is of considerable
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inconvenience to the women -  and the clinical staff. It may also be that ALA 
and CP94 compares badly with phthalocyanines with respect to long-term 
endometrial ablation, because of the possibility of deeper destruction with the 
latter. These are exciting areas to study in the future. There may be an 
advantage in pursuing the phthalocyanines, with the longer wavelength 
activation - and therefore deeper light penetration - as photosensitisers.
Work is currently ongoing at our centre, continuing the light distribution work 
and investigating the phthalocyanines.
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APPENDIX 1: CONFERENCE
PRESENTATIONS.
International Meetings.
Invited Session Chairman
XVI FIGO World Congress of Gynaecology and Obstetrics, Washington 
DC. USA.
Conference session chairman
Current thoughts on the management of fibroids. September 2000.
Oral presentations.
XVI FIGO World Congress of Gynaecology and Obstetrics,
Washington, DC (USA).
September 2000.
Does photodynamic therapy have a place in the treatment of 
menorrhagia?
XVI FIGO World Congress of Gynaecology and Obstetrics,
Washington, DC (USA).
September 2000.
Successful treatment of uterine fibroids with interstitial laser 
photocoagulation.
Four Provinces and Juniors in Obstetrics and Gynaecology,
Dublin (Eire).
November 1999.
Successful treatment of uterine leiomyomata using interstitial laser 
photocoagulation.
National Meetings
British Society for Gynaecological Endoscopy,
Leeds.
March 2000.
Photodynamic therapy in the rabbit uterus resulting in endometrial 
destruction using 5-aminolaevulinic acid with the iron chelator CP94.
Conference presentation award.
Royal Society of Medicine,
London.
February 2000.
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Does photodynamic therapy (PDT) have a place in the treatment of 
menorrhagia?
British Society for Gynaecological Endoscopy,
Plymouth.
May 1999.
Interstitial laser photocoagulation; a new, safe and effective treatment 
for small uterine leiomyoma.
British Medical Laser Association,
Liverpool.
May 1999.
A new method of enhancing endometrial destruction in the rabbit 
uterus by photodynamic therapy (PDT) using ALA combined with the 
new iron chelator, CP94.
Conference presentation award.
British Medical Laser Association,
Liverpool.
May 1999.
Using interstitial laser photocoagulation (ILP) to treat small uterine 
fibroids safely and effectively.
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Poster presentations.
British Society for Gynaecological Endoscopy,
Leeds.
March 2000.
Minimal access ablation of uterine leiomyomata using interstitial laser 
photocoagulation.
Royal Society of Medicine,
London.
February 2000.
Resorption of uterine leiomyomata after interstitial laser 
photocoagulation.
Blair Bell Research Society,
London.
December 1999.
Interstitial laser photocoagulation: a new, safe and effective treatment 
for uterine leiomyomata.
Blair Bell Research Society,
London.
December 1999.
Endometrial ablation in the rabbit uterus by photodynamic therapy 
(PDT) using 5-aminolaevulinic acid with the iron chelator CP94.
Four Provinces and Juniors in Obstetrics and Gynaecology,
Dublin (Eire).
November 1999.
Photodynamic therapy in the rabbit uterus resulting in endometrial 
destruction using 5-aminolaevulinic acid with the iron chelator CP94.
British Society for Gynaecological Endoscopy,
Plymouth.
May 1999.
Enhancing endometrial destruction in the rabbit uterus by ALA- 
induced photodynamic therapy (PDT) using the new iron chelator, 
CP94.
British Society for Gynaecological Endoscopy,
Plymouth.
May 1999.
A new method for enhancing topical endometrial photosensitisation of 
the rabbit uterus with ALA - an essential prerequisite for effective 
photodynamic therapy.
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British Medical Laser Association,
Liverpool.
May 1999.
Interstitial laser photocoagulation; a new, safe and effective treatment 
for small uterine leiomyoma.
British Medical Laser Association,
Liverpool.
May 1999.
Enhanced endometrial ablation in the rabbit uterus by photodynamic 
therapy (PDT) using ALA combined with the new iron chelator, CP94.
British Medical Laser Association,
Liverpool.
May 1999.
A new method for enhancing topical endometrial photosensitisation of 
the rabbit uterus with ALA - an essential prerequisite for effective 
photodynamic therapy.
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APPENDIX 2: MANN-WHITNEY U TEST.
An example of the Mann-Whitney U test.
This test is used to analyse results from studies which have compared two 
different unmatched groups of subjects on a task. It compares results from 
each group to see if they differ significantly (Hicks 1995:155).
Comparison of knowledge scores (section 2) between 56 qualified 
midwives (condition 1) and 12 student midwives ( condition 2).
Formula:
V = nin2 + - Tx
2
U = Mann-Whitney
Hf = num ber of subjects in condition 1 (56 qualified midwives)
n2 = num ber of subjects in condition 2 (12 student midwives)
Tx = larger rank total ( i.e. 1790 see  below)
nx = num ber of subjects in condition in the larger rank total
(condition 1 = 56)
1 The total score (2) and means for each condition must be calculated,
i.e. condition 1 2 = 1043 mean score = 18.62
condition 2 2 = 267 mean score = 22.25
2 Taking the whole set of scores together (56 + 12 = 68 scores), they 
must be ranked giving the rank of 1 to the lowest, 2 to the next lowest 
etc. Where there are two or more scores the same, use the tied rank
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procedure. Add up the ranks the scores would have obtained had they 
been different and divide this number by the number of scores that are 
the same. Assign this result to all of these scores that are the same.
Example: A score of 11 occurred twice therefore: had they been 
different they would have been ranked 4 and 5, (4 + 5)/2 = 4.5 This is 
assigned to all the 11 scores see below.
Table A2.1 Frequency distribution of knowledge scores for student and 
qualified midwives obtained in Section 2.
Scores Frequency Ranked
scores
3 1 1
4 1 2
8 1 3
11 2 4.5
12 1 6
13 3 8
14 4 11.5
15 1 14
16 1 15
17 2 16.5
18 11 23
19 7 32
20 8 39.5
21 1 44
22 3 46
23 4 49.5
24 6 54.5
25 3 59
26 6 63.5
27 1 67
29 1 68
Total 68
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3 Add the rank totals for each condition separately;
i.e. rank total of condition 1 = 1790
rank total of condition 2 = 545
4 Using the formula above, select the larger rank total i.e 1790
U = [(56 x 12) + 56 ( 5 6 + 1 ) ] /2 -1790 = 478
5 Because there are unequal numbers in each condition it is necessary to 
repeat the calculations for the smaller rank total.
i.e.
U = [(56 x 12) + 12 (12 +1)] 12 - 545 = 205
6 The smaller U value from the two calculations is used to assess the 
level of significance, by referring to the relevant probability tables.
i.e.
U =205 p = 0.03
(a significant result since the p value is less than 5%).
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